

# UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA"

# Dottorato di ricerca in Scienze Chimiche XXIX ciclo

Reactivity of trifluoromethyl aldimines with active methylene compounds

SUPERVISORI: Dr. Stefania Fioravanti Prof. Lucio Pellacani DOTTORANDO: Dr. Laura Trulli

COORDINATORE: Prof. Osvaldo Lanzalunga

Introduction		5
Chapter 1	Trifluoromethyl aldimines	7
Chapter 2	Mannich-type reaction	17
Chapter 3	Reformatsky reaction	29
Thesis purpose		39
Chapter 4	Purpose and aims	41
Results and discussion		45
Chapter 5	Mannich type reactions of 1,3-dicarbonyl compounds with trifluoromethyl aldimines	47
Chapter 6	Synthesis of trifluoromethyl 2-imidazolines through Mannich-type reactions with isocyano acetates	65
Chapter 7	Aza-Reformatsky reactions on trifluoromethyl aldimines	73
Chapter 8	Work towards the discovery of selective and potent PCAF inhibitors	91
Chapter 9	Conclusions	105
Experimental section		113
	General Experimental Methods	115
Chapter 10	Mannich type reactions of 1,3-dicarbonyl compounds with trifluoromethyl aldimines	117

# CONTENTS

Chapter 11	Synthesis of trifluoromethyl 2-imidazolines through Mannich-type reactions with isocyano acetates	143
Chapter 12	Aza-Reformatsky reactions on trifluoromethyl aldimines	159
Chapter 13	<i>Work towards the discovery of selective and potent PCAF inhibitors</i>	191

Introduction

# Chapter 1

## **Trifluoromethyl aldimines**

After the isolation of elemental fluorine in 1886 by Henri Moissan, the development of fluorination methodologies and synthesis of fluorinated compounds has been an ongoing topic of current interest to the chemical community.<sup>1</sup>

Indeed, fluorinated compounds have opened new opportunities inherent to the physico-chemical properties of fluorine that could be defined a magic element because of strong electronegativity, low polarizability and a small size.

Fluorinated compounds show advantages such as high thermal, light and chemical stability, oil and water repellency, low dielectric constants, and low flammability, as a result of all this they can be used in many different fields such as polymer science,<sup>2</sup> pharmaceutical and molecular biology.<sup>3</sup>

Since fluorine-containing compounds are almost completely absent in nature, an increasing number of synthetic bioactive pharmaceuticals<sup>4</sup> and agrochemicals contain fluorine, in particular, as many as 35% of agrochemicals and 20% of pharmaceuticals.<sup>5</sup> This popularity of organofluorine compounds has been attributed to the influence that the fluorine substituents could have on several properties, such as the acidity or basicity of neighboring groups, dipole moment, and biological

<sup>&</sup>lt;sup>1</sup> Yang, X.; Wu, T.; Phipps, R. J.; Toste, F. D. Chem. Rev. 2015, 115, 826-870.

<sup>&</sup>lt;sup>2</sup> a) Vitale, A.; Bongiovanni, R.; Ameduri, B. *Chem. Rev.* **2015**, *115*, 8835–8866. b) Cametti, M.; Crousse, B.; Metrangolo, P.; Milani, R.; Resnati, G. *Chem. Soc. Rev.* **2012**, *41*, 31–42.

<sup>&</sup>lt;sup>3</sup> Tirotta, I.; Dichiarante, V.; Pigliacelli, C.; Cavallo, G.; Terraneo, G.; Bombelli, F. B.; Metrangolo, P.; Resnati, G. *Chem. Rev.* **2015**, *115*, 1106–1129.

<sup>&</sup>lt;sup>4</sup> a) Müller, K.; Faeh C.; Diederich, F. *Science* 2007, *317*, 1881–1886; b) Hagmann, W. K. *J. Med. Chem.*2008, *51*, 4359–4369; c) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. *Chem. Soc. Rev.* 2008, *37*, 320–330; d) Böhm, H. J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Müller, K.; Obst-Sander, U.; Stahl, M. *ChemBioChem* 2004, *5*, 637–643

<sup>&</sup>lt;sup>5</sup> Wang, J.;Sánchez-Roselló, M.; Aceña, J. L.; del Pozo, C.; Sorochinsky, A. E.; Fustero, S.; Soloshonok, V. A.; Liu, H. *Chem. Rev.* **2013**, *114*, 2432.

characteristics such as lipophilicity, metabolic stability, and bioavailability<sup>6</sup> in potentially active molecules.

Thus, for example, a fluorine atom has been used as a replacement for a hydrogen atom or a hydroxyl group, and a  $-CF_2$  or  $-CF_3$  moiety has been used as a mimic for an oxygen atom; in addition, in many such compounds, a trifluoromethyl group can be considered also as a good mimicry of methyl, isopropyl and phenyl residues.<sup>7</sup> In addition, the presence of the fluorine atoms can confer unusual chemical reactivity and influence the stereochemical transformations of organic compounds compared to their analogous unfluorinated.<sup>8</sup>

Finally, considering the properties of <sup>19</sup>F nucleus,<sup>9</sup> the organofluorine compound structural characterization is supported by the use of <sup>19</sup>F NMR, coupled with the most usual <sup>1</sup>H and <sup>13</sup>C NMR spectra.<sup>10</sup>

For these reasons, the synthesis of fluorinated compounds, especially trifluoromethylated, is a topic of considerable interest into the mainstream organic synthesis community. The synthesis of these compounds can occur either through trifluoromethylation techniques<sup>11</sup> or choosing a suitable CF<sub>3</sub>-containing precursor that can be subsequently converted into a range of different compounds.

The second approach is considered more efficient, easier and versatile method, obviously the basic issue is that the trifluoromethylated precursor has to be inexpensive, available on large scale, non-toxic, environmentally compatible, and potentially multifunctional for use in various reactions.<sup>12</sup>

<sup>&</sup>lt;sup>6</sup> a) Banks, R. E.; Tatlow, J. C.; Smart, B. E. Organofluorine Chemistry Principles and Commercial Applications, Plenum Press: New York, **1994**.; b) Crowley, P. J. Chemistry of Organic Fluorine Compounds II, Hudlicky, M.; Pavlath A. E. Eds., American Chemical Society: Washington, **1995**.

<sup>&</sup>lt;sup>7</sup> Mikami, K.; Itoh, Y.; Yamanaka, M. Chem. Rev. **2004**, 104, 1–16.

<sup>&</sup>lt;sup>8</sup> a) Catalan, S.; Munoz, S. B.; Fustero, S. *Chimia* **2014**, *68*, 382–409; (b) Zimmer, L. E.; Sparr, C.; Gilmour, R. *Angew. Chem., Int. Ed.* **2011**, *50*, 11860–11871; (c) Hunter, L. *Beilstein J. Org. Chem.* **2010**, *6*, No. 38; (d) Resnati, G.; Soloshonok, V. A. *Fluoroorganic chemistry: synthetic challenges and biomedical rewards*, In Proceedings of the Tetrahedron Symposia; *Tetrahedron* **1996**, *58*, 1–330.

<sup>&</sup>lt;sup>9</sup> Saielli, G.; Bini, R.; Bagno, A. RSC Adv. **2014**, *4*, 41605–41611.

<sup>&</sup>lt;sup>10</sup> a) Keita, M.; Kaffy, J.; Troufflard, C.; Morvan, E.; Crousse, B.; Ongeri, S. *Org. Biomol. Chem.* **2014**, *12*, 4576–4581; b) Curtis-Marof, R.; Doko, D., Rowe, M. L.; Richards, K. L.; Williamson, R. A.; Howard, M. J. *Org. Biomol. Chem.* **2014**, *12*, 3808–3812.

<sup>&</sup>lt;sup>11</sup> Langlois, B. R.; Billard, T. Synthesis **2003**, 185–194.

<sup>&</sup>lt;sup>12</sup> Bégué, J. P.; Bonnet-Delpon, D.; Crousse, B.; Legros, J. Chem. Soc. Rev. 2005, 34, 562–572.

The main trifluoromethylated intermediate used in the industrial field is trifluoroacetic acid (TFA), as well as its derivates: trifluoroacetic anhydride, esters, amides;<sup>5</sup> unfortunately the corresponding aldehyde, fluoral (CF<sub>3</sub>CHO), is an unstable gas, therefore difficult to prepare and use.

Compared to fluoral, its hydrate or hemiacetal derivatives (Figure 1) are however widely used in the synthetic field, because of their stability and commercial availability at low cost.



Figure 1. Hydrate or hemiacetal derivatives from fluoral.

Considering that in nature the most biologically active compounds contain nitrogen, the development of efficient synthetic methods for preparing nitrogenated fluorine-containing analogues of natural compounds has received increasing attention in recent years: in particular, 1,2- and 1,3-diffunctionalized compounds, including  $\beta$ -amino alcohols and  $\alpha$ - and  $\beta$ -amino acids, as well as nitrogen heterocycles, important building blocks for more complex structures.

Hydrate or hemiacetal derivatives of fluoral react with primary amines, in the presence of *p*-toluenesulfonic acid (PTSA) as catalyst at toluene reflux and with a Dean–Stark apparatus, giving the corresponding trifluoromethyl aldimines,<sup>13</sup> as important scaffolds characterized by the presence of both a nitrogenous residue and a  $-CF_3$  group (Scheme 1).<sup>14</sup>

<sup>&</sup>lt;sup>13</sup> For a very recent review, see: Fioravanti, S. *Tetrahedron* **2016**, 72, 4449–4489.

<sup>&</sup>lt;sup>14</sup> Pirkle, W. H.; Hauske, J. R. J. Org. Chem. 1977;42, 2436–2439.



Scheme 1. Synthesis of trifluoromethyl aldimines under classical conditions.

However, this methodology does not afford the product in good yields, because of the presence of  $-CF_3$  which can stabilize the hemiaminal intermediate and destabilize the carbocationic intermediate. Consequently, different synthetic strategies have been often required, such as the use of ultrasound or microwave,<sup>15</sup> high reaction temperatures or different activation methods.<sup>16</sup>

In this field, an efficient solvent-free methodology for the synthesis of trifluoromethylated aldimines, ketimines, and hydrazones has been developed in the laboratory where I did my PhD thesis (**Scheme 2**).<sup>17</sup>



Scheme 2. Solvent-free synthesis of trifluoromethyl aldimines.

Starting from an equimolar solution of  $\alpha, \alpha, \alpha$ -trifluoroacetophenone or trifluoroacetaldehyde ethyl hemiacetal with different aliphatic amines or hydrazines, and heating, the desired products were obtained with excellent yields. In addition, the reaction occurred with complete stereoselectivity, giving only the *E* isomer, as determined by NOE experiments.

<sup>&</sup>lt;sup>15</sup> Abid, M.; Savolainen, M.; Landge, S.; Hu, J.; Prakash, G.K. S.; Olah, G. A.; Török B. J. Fluorine Chem. **2007**, *128*, 587–594

<sup>&</sup>lt;sup>16</sup> a) Barney, C. L.; Huber, E. W.; McCarthy, J. R. *Tetrahedron Lett.* **1990**, *31*, 5547–5550; b) Gulevich, A. V.; Shevchenko, N. E.; Balenkova, E. S.; Röschenthaler, G-V.; Nenajdenko, V. G. *Tetrahedron* **2008**, *64*, 11706–11712 and refs therein.

<sup>&</sup>lt;sup>17</sup> Carroccia, L.; Fioravanti, S.; Pellacani, L.; Tardella, P. A. Synthesis 2010, 4096–4100.

The presence in these compounds of the C=N function allows to use them as interesting electrophiles in several reactions (**Scheme 3**); in addition the presence of electron-withdrawing trifluoromethyl group increases the electrophilicity of the carbon–nitrogen double bond compared with that of nonfluorinated imines.<sup>9</sup>



Scheme 3. Families of compounds after nucleophilic addition on trifluoromethyl aldimines.

Alkylation and arylation reactions, using organometallic and related reagents, have been widely developed, also in the asymmetric versions. Funabiki and Enders using the SAMP/RAMP-methodology reported a highly diastereoselective alkylation (> 96% de) of hydrazones with alkyllithium reagents, especially with those derived from primary halides (**Scheme 4**).<sup>18</sup>

<sup>&</sup>lt;sup>18</sup> Enders, D.; Funabiki, K. Org. Lett. 2001, 3, 1575–1577.



Scheme 4. Organometallic addition to trifluoromethyl hydrazones.

As well as trifluoromethyl aldimines undergo arylation reaction when treated with a broad array of aryllithium reagents (**Scheme 5**), as reported by Gosselin *et al.*<sup>19</sup>



Scheme 5. Organometallic addition to trifluoromethyl aldimines.

Through a Strecker-type reaction, Brigaud and co-workers obtained diastereomerically pure trifluoromethyl amino nitriles (**Scheme 6**) starting from chiral –CF<sub>3</sub> aldimines.<sup>20</sup>



Scheme 6. Strecker-type reactions of chiral fluorinated aldimines.

In all cases, these reactions required the presence of catalytic amount of ytterbium(III) trifluoromethanesulfonate [Yb(OTf)<sub>3</sub>] or MgBr<sub>2</sub>.

The reaction of aromatic compounds with trifluoromethyl aldimines by a Friedel-Crafts type reaction can provide an interesting entry to benzylamine

<sup>&</sup>lt;sup>19</sup> Gosselin, F.; Roy, A.; O'Shea, P. D.; Chen, C.-y.; Volante, R. D. Org. Lett. 2004, 6, 641–644.

<sup>&</sup>lt;sup>20</sup> Huguenot, F.; Brigaud, T. J. Org. Chem. **2006**, 71, 7075–7078.

analogues; in this field Kato reported the synthesis of  $\alpha$ -CF<sub>3</sub>  $\alpha$ -aryl methylamines in the presence of BF<sub>3</sub>•Et<sub>2</sub>O (Scheme 7).<sup>21</sup>



Scheme 7. Friedel–Crafts type reactions on trifluoromethyl aldimines.

More recently, Soloshonok and co-workers reported Lewis acid catalyzed Friedel–Crafts-type additions on chiral trifluoromethyl *N-tert*-butylsulfinylimine with various indoles (Scheme 8).<sup>22</sup>



**Scheme 8.** Friedel–Crafts type reactions on substituted N-methyl indoles.

Aza-Diels–Alder reactions have also been investigated with Danishefsky's diene in order to afford the corresponding dihydropyridinone (Scheme 9).<sup>23</sup>



Scheme 9. Aza-Diels–Alder reactions on trifluoromethyl aldimines.

Given that the large majority of modern drugs and agrochemicals contain one or more heterocyclic rings, it is not surprising that the synthesis of trifluoromethyl heterocycles is a topic of current interest to the chemical community. Small CF<sub>3</sub>-

<sup>&</sup>lt;sup>21</sup> Gong, Y.; Kato, K.; Kimoto, H. Bull. Chem. Soc. Jpn. 2002, 75, 2637–2645.

<sup>&</sup>lt;sup>22</sup> Wua, L.; Xie, C.; Mei, H.; Soloshonok, V. A.; Han, J.; Pan, Y. J. Org. Chem. 2014, 79, 7677–7681.

<sup>&</sup>lt;sup>23</sup> Crousse, B.; Narizuka, S.; Bégué, J.-P.; Bonnet-Delpon, D. J. Org. Chem. **2000**, 65, 5009–5013.

containing nitrogen heterocycles, including aziridines, can be integrated in the elaboration of amino acids to create modified peptides with special features.<sup>24</sup> Bégué and co-workers highlighted a straightforward synthesis of aziridine-2-carboxylates, as potential precursors of non-proteogenic  $\alpha$ - and  $\beta$ -amino acids, using ethyl diazacetate as nuchelophile and BF<sub>3</sub>•Et<sub>2</sub>O as catalyst at low temperature (Scheme 10).<sup>25</sup>



Scheme 10. Synthesis of trifluoromethyl aziridines.

In the laboratory in which I am attending my PhD, trifluoromethyl aldimines were used to obtain interesting optically active fluorinated diaziridines and oxaziridines.<sup>26</sup> The amination reaction has been developed without any added base and using, as aminating agents, aza-anions formed *in situ* from different alkyl nosyloxycarbamates (NsONHCO<sub>2</sub>R, Ns=4-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>).



Scheme 11. Synthesis of trifluoromethyl diaziridines.

As reported in **Scheme 11**, the reaction proceeds through an aza-anion nucleophilic attack followed by a ring closure reaction, affording the corresponding trifluoromethyl diaziridines in good yields. It was demonstrated that the stereoselective induction was controlled by steric or electronic effects present on  $\beta$ -

<sup>&</sup>lt;sup>24</sup> Salwiczek, M.; Nyakatura, E. K.; Gerling, U. I. M.; Ye, S.; Koksch, B. Chem. Soc. Rev. **2012**, 41, 2135–2171.

<sup>&</sup>lt;sup>25</sup> Crousse, B.; Narizuka, S.; Bonnet-Delpon D.; Bégué, J.-P. Synlett **2001**, 679–681.

<sup>&</sup>lt;sup>26</sup> Carroccia, L.; Fioravanti, S.; Pellacani, L.; Sadun, C.; Tardella, P. A. Tetrahedron 2011, 67, 5375–5381

or  $\alpha$ -carbon of the aminic residue. In fact, when the phenyl group is present in the  $\alpha$  position a very good diastereometric induction (99:1) was observed, but if this last group is present in the  $\beta$  position a reversal of induction was observed leading to a 1:1.7 mixture of diastereometric

Starting from trifluoromethyl aldimines also trifluoromethyl oxaziridines<sup>26</sup> can be obtained through epoxidation reactions using *m*-CPBA (*m*-chloroperoxybenzoic acid) as oxidant (Scheme 12).

 $\begin{array}{c} & & \\ & &$ 

Scheme 12. Synthesis of trifluoromethyl oxaziridines.

The reactivity of trifluoromethyl aldimines has been also studied in the aza-Henry reactions to successfully synthesize trifluoromethyl  $\beta$ -nitro amines in the presence of catalytic amounts of zirconium tetrachloride (ZrCl<sub>4</sub>) (Scheme 13).<sup>27</sup>

$$F_{3}C \xrightarrow{R} + R' NO_{2} \xrightarrow{ZrCl_{4}} R \xrightarrow{H} X' NO_{2}$$

Scheme 13. ZrCl<sub>4</sub>-catalyzed aza-Henry addition to trifluoromethyl aldimines.

The pathway proposed (**Scheme 14**) for the aza-Henry reaction involves a previous coordination between the imine and Zr(IV), which can coordinate even the nitro compound<sup>28</sup> and this coordination increases the acidity of its hydrogens which can be deprotonated by another imine molecule, thus forming the key intermediate of the reaction (**II**). A final intramolecular attack followed by protonation gave the desired product and restored both the catalyst and the imine.

<sup>&</sup>lt;sup>27</sup> Fioravanti, S.; Pellacani, L.; Vergari M. C. Org. Biomol. Chem. 2012, 10, 8207–8210.

<sup>&</sup>lt;sup>28</sup> a) Johannsen, M.; Jørgensen, K. A. J. Chem. Soc., Perkin Trans. 2 **1997**, 1183–1185; b) Nishiwaki, N.; Knudsen, K. R.; Gothelf K. V.; Jørgensen, K. A. Angew. Chem., Int. Ed. **2001**, 40, 2992–2995.



Scheme 14. Possible pathway of ZrCl<sub>4</sub>-catalyzed aza-Henry addition.

The  $\beta$ -nitro amines were subsequently considered in a selective reduction of nitro group (Scheme 15),



**Scheme 15.** Synthesis of  $\psi$ [CH(CF<sub>3</sub>)NH]-peptido mimetics.

followed by a coupling reaction with suitable N-Boc-protected L- $\alpha$ -amino acids,<sup>29</sup>  $\psi$ [CH(CF<sub>3</sub>)NH]-peptidomimetics.<sup>30,31</sup> obtain interesting to

<sup>&</sup>lt;sup>29</sup> Fioravanti, S.; Pelagalli, A.; Pellacani, L.; Sciubba, F.; Vergari M. C. Amino Acids 2014, 46, 1961–1970.

<sup>&</sup>lt;sup>30</sup> Molteni, M.; Bellucci, M. C.; Bigotti, S.; Mazzini, S; Volonterio, A.; Zanda, M. Org. Biomol. Chem. 2009, 7, 2286–2296. <sup>31</sup> Sani, M.; Volonterio, A.; Zanda, M. *Med. Chem.* **2007**, *2*, 1693–1700.

# Chapter 2

# Mannich-type reaction

In 1912, Carl Mannich reported his systematic studies of the threecomponent reaction (M-3CR) between an enolizable substrate, a primary or secondary amine and a nonenolizable aldehyde, classically formaldehyde, to form  $\beta$ -amino carbonyl compounds, known as Mannich bases.<sup>1</sup>

The classical M-3CR is, however, characterized by a number of serious disadvantages,<sup>2</sup> therefore numerous methods have been developed for the indirect reaction, namely the Mannich-type reaction, through the use of preformed electrophiles (e.g., iminium salts or imines) or nucleophiles (enolates, enol ethers, and enamines) (Scheme 1).



Scheme 1. Direct and indirect Mannich reactions.

The nucleophilic species is usually an aromatic or aliphatic aldehyde or ketone, but even derivatives of carboxylic acids,  $\beta$ -dicarbonyl compounds, nitro alkanes, nitriles, or isocyano acetates, showing to be a versatile reaction. Moreover, the obtained products are useful synthetic intermediates, that can be converted into

<sup>&</sup>lt;sup>1</sup> Mannich, C.; Krosche, W. Arch. Pharm. **1912**, 250, 647.

<sup>&</sup>lt;sup>2</sup>a) Tramontini, M.; Angiolini, L. *Mannich Bases–Chemistry and Uses*; New Directions in Organic and Biological Chemistry Series; CRC Press, Boca Raton, FL, **1994**. b) Tramontini, M.; Angiolini, L. *Tetrahedron* **1990**, *46*, 1791–1837. c) Traxler, P.; Trinks, U.; Buchdunger, E.; Mett, H.; Meyer, T.; Müller, M.; Regenass, U.; Rösel, J.; Lydon, N. *J. Med. Chem.* **1995**, *38*, 2441–2448. d) Dimmock, J. R.; Sidhu, K. K.; Chen, M.; Reid, R. S.; Allen, T. M.; Kao, G. Y.; Truitt, G. A. *Eur. J. Med. Chem.* **1993**, *28*, 313–322.

a great number of derivatives which possess valuable applications in several fields, especially in medicinal chemistry.<sup>28</sup>

The development of the asymmetric Mannich-type reaction has attracted considerable attention and various methods for conducting highly diastereoselective and/or enantioselective Mannich reactions have been developed in the past.<sup>3</sup>

## 2.1 Chiral organometallic catalysts

Traditionally, asymmetric Mannich-type reactions are catalyzed by chiral transition-metal complexes.<sup>4</sup>

The first enantioselective Mannich-type reaction on benzaldehyde imine derivatives has been reported by Kobayashi's group; the reaction was catalyzed by a chiral Lewis acid [Zr(IV)-BINOL], able to coordinate the imine towards the addition of silicon enolates and the silyl transfer, facilitating the catalyst recovery. The *syn-* and *anti*-selectivity was controlled by simply choosing the protective groups of the R-alkoxy and the ester moieties of silyl enolates (**Scheme 2**).<sup>5</sup>

<sup>&</sup>lt;sup>3</sup> a) Friestad, G. K.; Mathies, A. K. *Tetrahedron* **2007**, *63*, 2541–2569; b) Córdova, A. *Acc. Chem. Res.* **2004**, *37*, 102–112; c) Kobayashi, S.; Ishitani, H. *Chem. Rev.* **1999**, *99*, 1069–1094; d) List, B. *Tetrahedron* **2002**, *58*, 5573-5590; e) Mukherjee, S.; Yang, J. W.; Hoffmann, S.; List, B. *Chem. Rev.* **2007**, *107*, 5471–5569.

 <sup>&</sup>lt;sup>4</sup> a) Asymmetric Catalysis in Organic Synthesis; Noyori, R. Wiley, New York, **1994**; b) Catalytic Asymmetric Synthesis Ojima I., Wiley, New York, **2000**; c) Transition Metals for Organic Synthesis, 2nd ed. Beller, M.; Bolm, C. Wiley-VCH, Weinheim, **2004**; d) GrMger, H.; Wilken, J. Angew. Chem., Int. Ed. **2001**, 40, 529–532;
<sup>5</sup> a) Ishitani, H.; Ueno, M.; Kobayashi, S. J. Am. Chem. Soc. **1997**, 119, 7153–7154. b) Kobayashi, S.; Ishitani, H.; Ueno, M. J. Am. Chem. Soc. **1998**, 120, 431–432. c) Ishitani, H.; Ueno, M.; Kobayashi, S. J. Am. Chem. Soc. **2000**, 122, 8180–8186.



Scheme 2. Mannich-type reaction catalyzed by a chiral Lewis acid [Zr(IV)-BINOL].

Subsequently, other BINOL- and BINAP-derived catalysts have been used for the asymmetric Mannich-type reactions.<sup>6</sup> In 1998, Sodeoka's group developed a new binuclear palladium complex prepared from chiral Tol-BINAP for the Mannich reactions of imines derived from glyoxylate (**Scheme 3**).<sup>7</sup>



Scheme 3. Mannich type reaction catalyzed by binuclear palladium complex.

One disadvantage of these stereoselective Mannich reactions is the preparation and stability of the preformed enolate, and a major step for this

<sup>&</sup>lt;sup>6</sup> a) Ihori, Y.; Yamashita, Y.; Ishitani, H.; Kobayashi, S. J. Am. Chem. Soc. **2005**, 127, 15528–15535; b) Yamashita, Y.; Ueno, M.; Kuriyama, Y.; Kobayashi, S. Adv. Synth. Catal. **2002**, 344, 929–931.

<sup>&</sup>lt;sup>7</sup> a) Hagiwara, E.; Fujii, A.; Sodeoka, M. J. Am. Chem. Soc. **1998**, 120, 2474–2475; b) Fujii, A.; Hagiwara, E.; Sodeoka, M. J. Am. Chem. Soc. **1999**, 121, 5450–5458.

important class of reactions has been to develop catalytic enantioselective version that uses carbonyl compounds, especially aldehydes, as nucleophile precursors.

Subsequently, good results in the asymmetric Mannich-type reactions on  $\alpha$ carbonyl esters were obtained using copper(II) complexes. Jørgensen's group disclosed approach to asymmetric Mannich reactions that utilizes an copper(II)/bisoxazoline complexes. These catalysts are very effective for the addition of  $\alpha$ -carbonyl esters to N-tosyl  $\alpha$ -aldimino ethyl ester which make this method a simple synthetic procedure in order to obtain functionalized  $\alpha$ -amino acid derivatives using readily available carbonyl compounds rather than the silvl enol ethers or silvl ketene acetals (Scheme 4).<sup>8</sup>



**Scheme 4.** Mannich type reaction catalyzed by  $Cu(OTf)_2/(R)$ -Ph-BOX.

These same authors disclosed the first asymmetric Mannich-type reaction catalyzed by chiral *tert*-butyl-bisoxazoline/Cu(OTf)<sub>2</sub> using malonic esters as pronucleophiles or  $\beta$ -keto esters as nucleophiles (**Scheme 5**).<sup>9</sup>



**Scheme 5.** Mannich type reaction catalyzed by Cu(OTf)<sub>2</sub>/*t*-Bu-BOX.

<sup>&</sup>lt;sup>8</sup> Juhl, K.; Gathergood, N.; Jørgensen, K. A. Angew. Chem., Int. Ed. 2001, 40, 2995–2997.

<sup>&</sup>lt;sup>9</sup> Marigo, M.; Kjærsgaard, A.; Juhl, K.; Gathergood, N.; Jørgensen, K. A. Chem. Eur. J. 2003, 9, 2359–2367.

It was found that the best results in terms of yield, diastereo- and enantioselectivity were obtained when  $\beta$ -keto esters bearing the *tert*-butyl group on the ester function were used as the substrate.

Chiral Ni(II) complexes, derived from glycine Schiff bases, were used as Mannich donors in the addition reactions to *N-tert*-butylsulfinyl-3,3,3-trifluoroacetaldimine (**Scheme 6**).<sup>10</sup> In that case the chiral transition-metal complex is used as a chiral auxiliary, and a perfectly matched between the two reactants provided satisfactory diastereoselectivity.



(89%, dr = 71:29)

Scheme 6. Chiral Ni(II) complexes as Mannich donors.

Chiral complex are also used in the asymmetric vinylogous Mannich (AVM)-type reactions that can be regarded as a self-class of Mannich-type additions. In this context, Shi and co-workers<sup>11</sup> reported the silver(I)-catalyzed asymmetric Mannich reaction of fluorinated aldimines with trimethylsiloxyfuran, using chiral phosphine–oxazoline ligands (**Scheme 7**).



Scheme 7. AVM-type reaction of trifluoromethyl aldimine and 2 trimethylsiloxyfuran.

<sup>&</sup>lt;sup>10</sup> Kawamura, A.; Moriwaki, H.; Röschenthaler, G.-V.; Kawada, K.; Aceña, J. L.; Soloshonok, V. A. J. Fluorine Chem. **2015**, 171, 67–72

<sup>&</sup>lt;sup>11</sup> Zhao, Q.-Y.; Yuan, Z.-L.; Shi, M. Tetrahedron: Asymmetry 2010, 21, 943–951.

The corresponding adducts were obtained in good to excellent yields and good diastereoselectivities along with moderate to good enantioselectivities.

### 2.2 Chiral organocatalysts

Organocatalytic methods, which generally involves small organic molecules in sub-stoichiometric quantities to promote organic reactions, have emerged as a potent instrument to build chiral intermediates and products. The term "organocatalysis" was coined up by David MacMillan<sup>12</sup> in 2000 to summarize and to describe several classes of organic catalysts that had been used during the last fifty years.

Organocatalysts such as amino acid derivatives, especially those derived from proline,<sup>13</sup> cinchona-type alkaloids,<sup>14</sup> chiral amine thioureas and chiral Brønsted acids<sup>15</sup> have been widely used in the Mannich type reaction.

## 2.2.1 syn-anti Selective chiral organocatalysts

Enamine catalysis using amino acid derivatives has been widely developed<sup>39</sup> since List and co-workers reported the first example of a proline-catalyzed Mannich reaction,<sup>16</sup> to obtain enantiopure *syn-\gamma*-amino alcohols starting from different aldehydes (**Scheme 8**).

<sup>&</sup>lt;sup>12</sup> Ahrendt, K. A.; Borths, C. J.; MacMillan, D. W. C. J. Am. Chem. Soc. 2000, 122, 4243–4224.

<sup>&</sup>lt;sup>13</sup> a) Cordova, A.; Notz, W.; Zhong, G.; Betancort, J. M.; Barbas, C. F., III. J. Am. Chem. Soc. 2002, 124, 1842–1843; b) Cordova, A.; Watanabe, S. I.; Tanaka, F.; Notz, W.; Barbas, C. F., III. J. Am. Chem. Soc. 2002, 124, 1866–1867; c) Carlone, A.; Cabrera, S.; Marigo, M.; Jørgensen, K. A. Angew. Chem., Int. Ed. 2007, 46, 1101–1104.

<sup>&</sup>lt;sup>14</sup> a) McCooey, S. H.; Connon, S. J. *Angew. Chem., Int. Ed.* **2005**, *44*, 6367–6370; b) Han, X.; Kwiatkowski, J.; Xue, F.; Huang, K.-W.; Lu, Y. *Angew. Chem., Int. Ed.* **2011**, *50*, 2653–2664.

<sup>&</sup>lt;sup>15</sup> a) Seayad, J.; Seayad, A. M.; List, B. J. Am. Chem. Soc. **2006**, *128*, 1086–1087; b) Yamanaka, M.; Itoh, J.; Fuchibe, K.; Akiyama, T. J. Am. Chem. Soc. **2007**, *129*, 6756–6764; c) Sickert, M.; Schneider, C. Angew. Chem., Int. Ed. **2008**, *47*, 3631–3634; d) Tillman, A. L.; Dixon, D. J. Org. Biomol. Chem. **2007**, *5*, 606–609; e) Akiyama, T.; Itoh, J.; Yokota, K.; Fuchibe, K. Angew. Chem., Int. Ed. **2004**, *43*, 1566–1568.

<sup>&</sup>lt;sup>16</sup> a) List, B. J. Am. Chem. Soc. **2000**, 122, 9336–9337; b) List, B.; Pojarliev, P.; Biller, W. T.; Martin, H. J. J. Am. Chem. Soc. **2002**, 124, 827–833.



Scheme 8. Mannich reaction catalyzed by L-proline.

Subsequently Barbas III and co-workers reported results similar to those obtained by List's group concerning the proline-catalyzed Mannich reaction, starting from several ketones and involving preformed imines (**Scheme 9**).<sup>17</sup>



Scheme 9. Mannich type reaction catalyzed by L-proline.

The proline approach has been applied in the Mannich reactions with several nucleophiles and electrophiles.<sup>18</sup> In these transformation the *syn* configuration of the final product is generally controlled by a hydrogen-bond interaction between the imine nitrogen and the hydroxyl hydrogen of proline (**Figure 2**).

<sup>&</sup>lt;sup>17</sup> a) Notz, W.; Watanabe, S.; Chowdari, N. S.; Zhong, G.; Betancort, J. M.; Tanaka, F.; Barbas, C. F., III. *Adv. Synth. Catal.* **2004**, *346*, 1131–1140; b) Notz, W.; Tanaka, F.; Watanabe, S. I.; Chowdari, N. S.; Turner, J. M.; Thayumanavan, R.; Barbas, C. F. *J. Org. Chem.* **2003**, *68*, 9624–9634.

<sup>&</sup>lt;sup>18</sup> a) Marques, M. M. B. Angew. Chem. **2006**, 118, 356–360; Angew. Chem., Int. Ed. **2006**, 45, 348–352; b) Còrdova, A. Acc. Chem. Res. **2004**, 37, 102–112.



Figure 1. Proposed transition states.

In order to synthetize all possible stereoisomers, recently, other proline derivatives, namely diarylprolinol ethers (Figure 2), have been developed.<sup>19</sup>



With these catalysts the relative configuration of the product is controlled by the steric hindrance of the  $\alpha$  substituent to the nitrogen (**Figure 3**), in the transition state the only *anti*-type attack being thus favored.



Fustero *et al.*<sup>20</sup> have described the asymmetric Mannich reaction between fluoroalkyl aldimines and propanal catalyzed by proline that, after reduction, gave

<sup>&</sup>lt;sup>19</sup> a) Córdova, A.; Barbas, C. F., III. *Tetrahedron Lett.* **2002**, *43*, 7749–7752; b) Zhang, H.; Mifsud, M.; Tanaka, F.; Barbas, C. F., III. *J. Am. Chem. Soc.* **2006**, *128*, 9630–9631; c) Mitsumori, S.; Zhang, H.; Cheong, P. H.-Y.; Houk, K. N.; Tanaka, F.; Barbas, C. F., III. *J. Am. Chem. Soc.* **2006**, *128*, 1040–1041; d) Franzén, J.; Marigo, M.; Fielenbach, D.; Wabnitz, T. C.; Kjaersgaerd, A.; Jørgensen, K. A. *J. Am. Chem. Soc.* **2005**, *127*, 18296–18304; e) Galzerano, P.; Agostino, D.; Bencivenni, G.; Sambri, L.; Bartoli, G.; Melchiorre, P. *Chem.-Eur. J.* **2010**, *16*, 6069–6076.

syn-3-fluoroalkyl-1,3-amino alcohols. Later the same authors described a highly diastereo- and enantioselective synthesis of *anti-\gamma*-amino alcohols using (*S*)- $\alpha,\alpha$ -diarylprolinol trimethylsilyl ether as catalyst (**Scheme 10**).<sup>21</sup>



Scheme 10. Organocatalyzed Mannich type reaction on fluoroalkyl aldimines.

Recently, in the laboratory in which I am attending my PhD diastereomerically pure fluorinated *syn*- or *anti*- $\gamma$ -amino alcohols (**Scheme 26**) were obtained by an eco-friendly one-pot solvent free L-proline catalyzed Mannich-type reaction only by changing the reaction temperature (complete selectivity *syn* or *anti* at 40 °C or 0 °C, respectively).<sup>22</sup>



Scheme 11. One-pot solvent-free L-proline-catalyzed Mannich-type reaction on chiral aldimines.

<sup>&</sup>lt;sup>20</sup> Fustero, S.; Jiménez, D.; Sanz-Cervera, J. F.; Sánchez-Roselló, M.; Esteban, E.; Simón-Fuentes, A. *Org. Lett.* **2005**, *7*, 3433–3436.

<sup>&</sup>lt;sup>21</sup> Fustero, S.; Mojarrad, F.; Carrion, M. D. P.; Sanz-Cervera, J. F.; Aceña, J. L. *Eur. J. Org. Chem.* **2009**, 5208-5214.

<sup>&</sup>lt;sup>22</sup> Fioravanti S, Parise L, Pelagalli A, Pellacani L, Trulli L. RSC Adv. 2015, 5, 29312–29318.

We decided to extend this work to chiral aldimines functionalized with L- $\alpha$ -amino ester moieties.



Scheme 12. Synthesis of functionalized N- $\alpha$ -amino ester trifluoromethyl aldimines.

A new methodology, starting from the commercial fluoral ethyl hemiacetal and different L- $\alpha$ -amino esters, has been developed for the synthesis of the aldimines (**Scheme 12**) that subsequently were considered in a proline-catalyzed Mannich-type reaction: again a complete *syn* or *anti* selectivity simply by changing the reaction temperature was observed. (**Scheme 13**).<sup>23</sup>



**Scheme 13.** Synthesis of L- $\alpha$ -amino ester functionalized trifluoromethyl (*S*,*S*,*R*)-anti- $\gamma$ -amino alcohols.

<sup>&</sup>lt;sup>23</sup> Fioravanti S, Parise L, Pelagalli A, Pellacani L, Trulli L.; Vergari M. C. Chirality 2015, 27, 571-575.

## 2.2.2 Chiral Brønsted Bases

Readily available and inexpensive chincona alkaloids are among the most useful organocatalysts to date. The family of cinchona alkaloids consists of two pseudoenantiomeric pairs, including cinchonine, cinchonidine, quinine and quinidine (**Figure 4**). The presence of 1,2-amino alcohol moiety, containing the basic and bulky quinuclidine, is responsible for the catalytic activity.



Figure 4. Chincona alkaloids organocatalysts.

They are widely used in the asymmetric Mannich-type reaction, especially with active methylene compounds that, after deprotonation, provide a chiral ionic pair whose anion reacts with the imine in a stereoselective way.

In this context, Schaus *et al.* were the first to describe the cinchona alkaloidcatalyzed Mannich reaction of 1,3-dicarbonyl compounds with *N*-carbamoyl aryl imines. They were able to obtain the desired product, characterized by an  $\alpha$ quaternary carbon, in good yield and high diastereo- and enantioselectivities, using several cinchona alkaloid (Scheme 14).<sup>24</sup>

<sup>&</sup>lt;sup>24</sup> Ting, A.; Lou, S.; Schaus, S. E. Org. Lett. 2006, 8, 2003–2006.



Scheme 14. Mannich type reaction catalyzed by chincona alkaloids.

Subsequently, numerous organocatalysts derived from cinchona and structurally simpler thiourea organocatalysts<sup>25</sup> were developed and investigated in several Mannich-type reactions, with a variety of nucleophiles, including isocyano acetates,<sup>26</sup> nitro compounds,<sup>27</sup> phenyl acetates and thioesters.<sup>28</sup>

Recently, the efficiency of bifunctional thiourea catalyst was also studied in the Mannich-type reaction between *N*-PMP trifluoromethyl aldimine and different  $\beta$ -keto esters; the products, characterized by vicinal chiral centers, were obtained in good diastereo- and enantioselectivity (**Scheme 15**).<sup>29</sup>



Scheme 15. Asymmetric organocatalyzed Mannich-type reaction by bifunctional thiourea.

<sup>&</sup>lt;sup>25</sup> a) Yamaoka, Y.; Miyabe, H.; Yasui, Y.; Takemoto, Y. *Synthesis* **2007**, 2571–2577; b) Wenzel, A. G.; Jacobsen, E. N. *J. Am. Chem. Soc.* **2002**, *124*, 12964–12965.

<sup>&</sup>lt;sup>26</sup> Zhang, Z.-W.; Lu, G.; Chen, M.-M.; Lin, N.; Li, Y.-B.; Hayashi, T.; Chan, A. S. C. *Tetrahedron: Asymmetry* **2010**, *21*, 1715–1721.

<sup>&</sup>lt;sup>27</sup> Wei, Y.; He, W.; Liu, Y.; Liu, P.; Zhang S. Org. Lett. 2012, 14, 704–707.

<sup>&</sup>lt;sup>28</sup> Kohler, M. C.; Yost, J. M.; Garnsey, M. R.; Coltart, D. M. Org. Lett. **2010**, 12, 3376–3379.

<sup>&</sup>lt;sup>29</sup> Ji, S.; Alkhalil, A. E.; Su, Y.; Xia, X.; Chong, S.; Wang, K.-H.; Huang, D.; Fu, Y.; Hu, Y. Synlett **2015**, *26*, 1725–1731.

# Chapter 3

# **Reformatsky reaction**

The Reformatsky reaction, introduced for the first time in 1887,<sup>30</sup> is among the most useful methods for the C–C formation; its classical form involves zinc enolates derived from  $\alpha$ -bromo ester and aldehydes or ketones as suitable electrophiles, affording the corresponding  $\beta$ -hydroxy esters.

Nowadays, we can define Reformastky reaction all the transformations resulting from metal (zinc or other metals in low oxidation state) insertion into a carbon-halogen bond, activated by a carbonyl or carbonyl-related groups, followed by addition to the electrophile species (**Scheme 1**).



Scheme 1. Reformatsky-type reaction.

The main advantage of these transformations is that the enolate is formed under mild and neutral reaction conditions; in fact, no activation by strong acids or bases is needed, it follows its excellent functional group tolerance.

In addition, the enolate formation is highly regioselective, in fact, the position of the halogen atom determines unambiguously the site of metal insertion.

There seems to be no definitive experimental studies defining the mechanism precisely, probably it involves cyclic transition states, for which semiempirical

<sup>&</sup>lt;sup>30</sup> Reformatsky, S. Ber. Dtsch. Chem. Ges. 1887, 20, 1210–1211.

calculations MO (PM3) suggest that the boat like transition state is favored, compared to the chair like transition state, using zinc as a metal.<sup>31</sup>

### 3.1 Aza-Reformatsky reaction

A major extension of the Reformatsky reaction has been achieved by the use of imines as suitable electrophiles. Aza-Reformatsky reaction affords  $\beta$ -amino esters and/or  $\beta$ -lactams, useful and valuable synthetic intermediates in organic synthesis and pharmacologically important compounds (**Scheme 2**).



Scheme 2. Aza-Reformatsky-type reaction.

The first zinc enolate-imine condensation reaction was originally reported by Gilman and Speeter<sup>32</sup> in 1943 who employed a Reformatsky-type reaction between  $\alpha$ -bromo esters with an imine for the production of an *N*-aryl- $\beta$ -lactam (**Scheme 3**).



Scheme 3. Gilman-Speeter reaction.

Subsequently, a great attention has been paid to the study of the aza-Reformatsky reaction,<sup>33</sup> starting from several bromo esters and a variety of imines, with  $\beta$ -amino esters being preferred product especially when an *ortho*-substituent is present in an arylamine-derived imine.

<sup>&</sup>lt;sup>31</sup> Maiz, J.; Arrieta, A.; Lopez, X.; Ugalde, J. M., Cossio, F. P.; Lecea, B. *Tetrahedron Lett.* **1993**, *34*, 6111–6114.

<sup>&</sup>lt;sup>32</sup> Gilman, H.; Speeter, M. J. Am. Chem. Soc., **1943**, 65, 2255–2256.

<sup>&</sup>lt;sup>33</sup> a) Honda, T.; Wakabayashi, H.; Kanai, K. *Chem. Pharm. Bull.* 2002, *50*, 307–308; b) Adrian, J. C.; Barkin, J. L.; Hassib, L. *Tetrahedron Lett.* 1999, *34*, 2457–2460; c) Mecozzi, T.; Petrini, M. *Tetrahedron Lett.* 2000, *41*, 2709–2712; d) Shankar, B. B.; Kirkup, M. P.; McCombie, S. W.; Clader, J. W.; Ganguly, A. K. *Tetrahedron Lett.* 1996, *37*, 4095–4098; e) Robinson, A. J.; Wyatt, P. B. *Tetrahedron* 1993, *49*, 11329–11340.

In 2001 Gong et al.<sup>34</sup> reported a typical aza-Reformatsky reaction starting from trifluoromethyl aldimines: the corresponding  $\beta$ -lactam was the favored product starting from *N-p*-methoxyphenyl (PMP) protected aldimine. On the other hand, using *N*-phenyl protected trifluoromethyl aldimine, the Reformatsky reaction gave the corresponding  $\beta$ -amino esters as major products (**Scheme 4**).



Scheme 4. Aza-Reformatsky-type reaction on trifluoromethyl aldimines.

Later, Bonnet-Delpon reported a modified Reformatsky reaction, between ethyl bromoacetate and trifluoromethyl aldimines, performed under Barbier conditions. The authors were able to obtain the corresponding  $\beta$ -amino  $\beta$ trifluoromethyl esters in satisfactory yields, using a polar solvent (DMF) (**Scheme 5**).



Scheme 5. Aza-Reformatsky-type reaction on trifluoromethyl aldimine.

However, it is necessary to underline that, even if the aza-Reformatsky reaction has a great potential, the corresponding products are often isolated as a mixture of  $\beta$ -amino esters and  $\beta$ -lactams.

<sup>&</sup>lt;sup>34</sup> Gong, Y.; Kato, K. J. Fluorine Chem. 2001, 111, 77–80.

### 3.2 Stereoselectivity in Reformatsky reactions

The main limitation of the Reformatsky transformations is due to observed low yields and diastereoselectivities, probably because it is classically performed under heterogeneous conditions that made the development of stereoselective variants quite difficult.

To date, a few examples of highly diastereo and enantioselective Reformatsky reactions have been reported.<sup>35</sup>

#### <u>3.2.1 Heterogeneous conditions</u>

In recent years several ligands, such as carbohydrates,<sup>36</sup> amino alcohols (ephedrines and *N*-alkyl ephedrines),<sup>37</sup>  $\alpha$ -amino acid esters,<sup>38</sup> were considered as additives in the Reformatsky reactions performed between benzaldehyde and  $\alpha$ -bromo esters in the presence of metallic zinc (**Scheme 6**).



Scheme 6. Enantioselective Reformatsky reactions.

<sup>&</sup>lt;sup>35</sup> Choppin, S.; Ferreiro-Medeiros, L.; Barbarotto, M.; Colobert F. Chem. Soc. Rev. 2013, 42, 937–949.

<sup>&</sup>lt;sup>36</sup> Ribeiro, C. M. R.; Santos, E. S.; Jardim, A. H. O.; Maia, M. P.; da Silva, F. C.; Moreira, A. P. D.; Ferreira, V. F. *Tetrahedron: Asymmetry* **2002**, *13*, 1703–1706.

 <sup>&</sup>lt;sup>37</sup> a) Mi, A.; Wang, Z.; Zhang, J.; Jiang, Y. Synth. Commun. **1997**, 27, 1469–1473; b) Mi, A.; Wang, Z.; Chen,
Z.; Jiang, Y. Tetrahedron: Asymmetry **1995**, 6, 2641–2642; c) Andrés, J. M.; Martin, Y.; Pedrosa, R.; Perez-Encabo, A.Tetrahedron **1997**, 53, 3787–3794; d) Soai, K.; Kawase, Y. Tetrahedron: Asymmetry **1991**, 2, 781– 784; e) Pini, D.; Uccello-Barretta, G.; Mastantuono, A.; Salvadori, P. Tetrahedron **1997**, 53, 6065–6072; f)
Fujiwara, Y.; Katagiri, T.; Uneyama, K. Tetrahedron Lett. **2003**, 44, 6161–6163; g) Andrés, J. M.; Martinez,
M. A.; Pedrosa, R.; Pèrez-Encabo, A. Synthesis **1996**, 1070–1072.

<sup>&</sup>lt;sup>38</sup> Wang, Z. Y.; Shen, J.; Jiang, C. S.; You, T. P. Chin. Chem. Lett. 2000, 11, 659–662.

In some specific cases, good enantiomeric excesses have been obtained. Yamano and co-workers reported a highly enantioselective Reformatsky reaction with ketones using cinchona alkaloids as chiral ligands (**Scheme 7**).<sup>39</sup>



Scheme 7. Enantioselective Reformatsky reaction performed with cinchonine.

In this transformation the high enantioselectivity is due to the chelation of the  $sp^2$ -nitrogen with the cinchonine catalyst.

However, in all the above shown examples most of the ligands were used in more than stoichiometric amounts.

In recent years improvements to perform highly diastereoselective Reformastky reactions have been obtained using chiral auxiliaries, either on the electrophile or on the nucleophile.<sup>66</sup>

Awasthi *et al.* reported the synthesis of  $\beta$ -amino esters by a Zn-mediated Reformatsky-type reaction, starting from chiral imines derived from (*S*)-phenylglycinol. The desired products were obtained with good yields and stereoselectivities up to 98% (**Scheme 8**).<sup>40</sup>



Scheme 8. Diastereoselective Reformatsky reactions.

<sup>&</sup>lt;sup>39</sup> Ojida, A.; Yamano, T.; Taya, N.; Tasaka, A. Org. Lett. **2002**, *4*, 3051–3054.

<sup>&</sup>lt;sup>40</sup> Awasthi, A. K.; Boys, M. L.; Cain-Janicki, K. J.; Colson, P.-J.; Doubleday, W. W.; Duran, J. E.; Farid, P. N. J. Org. Chem. **2005**, 70, 5387–5397.

Chiral trifluoromethyl aldimine, derived from the methyl ether of (*R*)phenylglycinol, was also studied in the Reformatsky reaction by Bonnet-Delpon's group;<sup>41</sup> using THF at reflux, afford the corresponding  $\beta$ -amino ester in good yield (80%) and selectivity (81% dr) (**Scheme 9**).



Scheme 9. Diastereoselective Reformatsky reaction on trifluoromethyl aldimine.

In this context, the reactivity of chiral *N-tert*-butyl-sulfinylimines with several nucleophiles in the aza Reformatsky reaction also has been widely studied.<sup>42</sup> Poon, Brinner *et al.*<sup>43</sup> explain the observed diastereoselectivity with a chiral *N-tert*-butylsulfinylimine by a Zimmerman–Traxler six-membered transition state (**Scheme 10**).



Proposed transition state

Scheme 10. Diastereoselective Reformatsky reaction on chiral *N*-tert-butylsulfinylimine.

The *tert*-butylsulfinyl group on the nucleophile has also been successfully used as chiral auxiliary in SmI<sub>2</sub>-mediated Reformatsky-type reactions. The addition

<sup>&</sup>lt;sup>41</sup> Dos Santos, M.; Crousse, B.; Bonnet-Delpon, D. Synlett 2008, 399–401.

<sup>&</sup>lt;sup>42</sup> a) Jing, Z. T.; Huang, Y. G.; Qing, F. L. Chin. Chem. Lett. **2011**, 22, 919–922; b) Concellon, J. M.; Rodriguez-Solla, H.; Simala, C. Adv. Synth. Catal. **2009**, 351, 1238–1242; c) Wang, L.; Shen, C.; Xu, M.-H. Sci. China Chem. **2011**, 54, 61–65.

<sup>&</sup>lt;sup>43</sup> Brinner, K.; Doughan, B.; Poon, D. J. Synlett **2009**, 991–993.

of an  $\alpha$ -bromo  $\alpha$ -sulfinyl ketone to linear aldehydes<sup>44</sup> or aryl aldimines<sup>45</sup> proceeded with complete *syn* selectivity (Scheme 11).



Scheme 11. Diastereoselective Reformatsky reaction on  $\alpha$ -bromo  $\alpha$ -sulfinyl ketone.

#### 3.2.2 Homogenous conditions

In order to simplify the design of a catalytic asymmetric version of the Reformatsky reaction, homogenous reaction conditions have been considered, using Me<sub>2</sub>Zn or Et<sub>2</sub>Zn, as zinc sources.<sup>46</sup>

In 2006 Cozzi<sup>47</sup> reported the first example of catalytic asymmetric Reformatsky reaction, between ketones and ethyl  $\alpha$ -iodoacetate, in the presence of Me<sub>2</sub>Zn, using a chloromanganese–Salen complex (20 mol %) as catalyst and 4-phenylpyridine *N*-oxide (25 mol %) as additive (**Scheme 12**).



**Scheme 12.** Dimethylzinc-mediated Reformatsky reactions promoted by manganese salen complex.

The reaction shows broad scope and the corresponding products were obtained with moderate to good stereoselection.

<sup>&</sup>lt;sup>44</sup> a) Obringer, M.; Colobert, F.; Neugnot B.; Solladié, G. Org. Lett. **2003**, *5*, 629–632. b) Obringer, M.; Colobert, F.; Solladié, G. Eur. J. Org. Chem. **2006**, 1455–1467.

<sup>&</sup>lt;sup>45</sup> Barbarotto, M.; Choppin S.; Colobert, F. *Tetrahedron: Asymmetry* **2009**, *20*, 2780–2787.

<sup>&</sup>lt;sup>46</sup> Cozzi, P. G. Angew. Chem., Int. Ed. 2007, 46, 2568–2571.

<sup>&</sup>lt;sup>47</sup> a) Cozzi, P. G. Angew. Chem., Int. Ed. **2006**, 45, 2951–2954; b) Cozzi, P. G.; Mignogna, A.; Zoli, L. Synthesis **2007**, 17, 2746–2750.

In the same year Cozzi reported the first catalytic asymmetric aza-Reformatsky reaction using inexpensive and commercially available Nmethylephedrine as chiral ligand. In addition, in order to obtain reproducible results and initiate the radical process, admission of air into the reaction mixture was necessary (**Scheme 13**).<sup>48</sup>



Scheme 13. One-pot three-component Reformatsky reactions.

Two years later Feringa's group<sup>49</sup> reported a catalytic enantioselective Reformatsky reaction for aldehydes, using BINOL derivative as chiral catalyst (**Scheme 14**); the protocol of these transformations also required air to have a good conversion and good enantiomeric excess.



Scheme 14. Reformatsky reactions with aldehydes in the presence of BINOL derivative ligand.

<sup>&</sup>lt;sup>48</sup> Cozzi, P. G. Adv. Synth. Catal. 2006, 348, 2075–2079.

<sup>&</sup>lt;sup>49</sup> Fernández-Ibáñez, M. A.; Maciá, B.; Minnaard, A. J.; Feringa, B. L. Angew. Chem., Int. Ed. **2008**, 47, 1317–1319.
After the pioneering work of Feringa and Cozzi, different catalytic systems based on the formation of radicals from Me<sub>2</sub>Zn have been developed, using Schiff base, bisoxazolidine, or amino alcohol as chiral catalysts.<sup>50</sup>

Recently, given the importance of fluorinated organic compounds, great attention has been paid to the study of fluorinated  $\alpha$ -fluoro halogenated esters as reactants in the Reformatsky reactions, especially in the development of asymmetric versions.<sup>51</sup> Knochel *et al.*<sup>82a</sup> described the enantioselective addition of ethyl bromodifluoroacetate to aromatic and aliphatic aldehydes, using (–)-*N*,*N*-dimethylaminoisoborneol [(–)-DAIB] as chiral ligand (Scheme 15).





Scheme 15. Reformatsky Reaction in the presence of chiral amino alcohol.

The authors were able to obtain the desired products with good yields and satisfactory enantioselectivities.

Good enantiocontrol was also found through the reaction of ethyl iodofluoroacetate with alkyl and aryl ketones in the presence of (1R,2S)-1-phenyl-2-(1-pyrrolidinyl)propan-1-ol that unfortunately must be used in stoichiometric amount (Scheme 16).<sup>82b</sup>

 <sup>&</sup>lt;sup>50</sup> a) Tanaka, T.; Hayashi, M. *Chem. Lett.* 2008, *37*, 1298–1299. b) Wolf, C.; Moskowitz, M. *J. Org. Chem.* 2011, *76*, 6372–6376; c) Cozzi, P. G.; Benfatti, F.; Capdevila, M. G.; Mignogna, A. *Chem. Commun.* 2008, 3317–3318; d) Cozzi, P. G.; Mignogna, A.; Vicennati, P. *Adv. Synth. Catal.* 2008, *350*, 975–978.

<sup>&</sup>lt;sup>51</sup> a)Knochel, P.; Kloetzing, R. J.; Thaler, T. *Org. Lett.* **2006**, *8*, 1125–1128; b) Fornalczyk, M.; Singh, K.; Stuart, A. M. *Chem. Commun.* **2012**, *48*, 3500–3502; c) Fornalczyk, M.; Singh, K.; Stuart, A. M. *Org. Biomol. Chem.* **2012**, *10*, 3332–3342



Scheme 16. Reformatsky Reaction in the presence of chiral amino alcohol.

In 2014, the same chiral amino alcohol was reported by Tarui *et al.*<sup>52</sup> in the first asymmetric aza-Reformastky reaction (Scheme 17).



Scheme 17. Aza-Reformatsky Reaction in the presence of chiral amino alcohol.

Starting from different aldimines, ethyl dibromofluoroacetate led to enantioenriched  $\alpha$ -bromo- $\alpha$ -fluoro- $\beta$ -lactams

<sup>&</sup>lt;sup>52</sup> Tarui, A.; Nishimura, H.; Ikebata, T.; Tahira, A.; Sato, K.; Omote, M.; Minami, H.; Miwa, Y.; Ando, A. *Org. Lett.* **2014**, *16*, 2080–2083.

Thesis Purpose

## Chapter 4

### **Purpose and aims**

1,2- and 1,3-Difunctionalized compounds, including  $\beta$ -amino esters or more generally  $\beta$ -amino carbonyl compounds as well as nitrogen heterocycles, have all been found to possess a variety of biological properties, making them valuable and useful synthetic intermediates in organic synthesis and in medicinal chemistry. Considering the relevance of the presence of fluorine in bioactive molecules, the synthesis of fluorine-containing analogues of before mentioned compounds was the prevalent scope of this PhD thesis.

The studies focused on the reactivity of different active methylene compounds towards different *N*-protected trifluoromethyl aldimines, optimal scaffolds for the construction of fluorinated molecules, in order to obtain interesting potentially bioactive highly functionalized molecules, suitable for further chemoselective transformations.

nucleophilic various methods involving additions Among the on trifluoromethyl imines, Mannich-type and aza-Reformatsky reactions have been considered as powerful approaches obtain interesting trifluoromethyl to compounds.

To the best of our knowledge, few examples of Mannich-type additions of active methylene compounds on trifluoromethyl imines are reported in the literature<sup>1</sup> and so the reactivity of *C*-CF<sub>3</sub> substituted *N*-protected addimines with malonate or  $\beta$ -keto esters has been here studied (**Scheme 1**).

<sup>&</sup>lt;sup>1</sup> a) Ji, S.; Alkhalil, A. E.; Su, Y.; Xia, X.; Chong, S.; Wang, K.-H.; Huang, D.; Fu, Y.; Hu, Y. *Synlett* **2015**, *26*, 1725–1731; b) Shibata, N.; Nishimine, T.; Shibata, N.; Tokunaga, E.; Kawada, K.; Kagawa, T.; Aceña, J. L.; Sorochinsky, A. E.; Soloshonok, V. A. *Org. Biomol. Chem.* **2014**, 12, 1454–1462; c) Shibata, N.; Nishimine, T.; Shibata, N.; Tokunaga, E.; Kawada, K.; Kagawa, T.; Sorochinsky, A. E.; Soloshonok, V. A. *Org. Chem.* **2014**, 12, 1454–1462; c) Shibata, N.; Nishimine, T.; Shibata, N.; Tokunaga, E.; Kawada, K.; Kagawa, T.; Sorochinsky, A. E.; Soloshonok, V. A. *Chem. Commun.* **2012**, 4124–4126.



**Scheme 1.** Mannich-type reactions on malonate or  $\beta$ -keto esters.

The aim was to find an efficient methodology to obtain interesting compounds, characterized by different sites that can allow a further molecular growth. In addition, the usefulness of these Mannich-type reactions may be enhanced by a decarboxylation reaction of the newly obtained  $\beta$ -keto esters. Indeed, it is well-known that the direct addition reaction of enolizable ketones to imines suffers from low yields and/or low selectivity.<sup>2</sup>

Just as interesting is the synthesis of heterocycles that constitute a major family of pharmaceuticals and agrochemicals.<sup>3</sup> Therefore, trifluoromethyl-functionalized heterocyclic compounds are becoming modern attractive targets in medicinal chemistry.<sup>4</sup> Thus, the attention has been directed towards the synthesis of 2-imidazoline derivatives which have attracted considerable interest because of their wide applications in the synthesis of biologically active compounds such as  $\alpha,\beta$ -diamino acids and also their presence in some biologically active natural products.<sup>5</sup>

<sup>&</sup>lt;sup>2</sup> Funabiki, K.; Nagamori, M.; Goushi, S.; Matsui, M. Chem. Commun. 2004, 1928–1929.

<sup>&</sup>lt;sup>3</sup> a) Eguchi, S. *Bioactive Heterocycles I*, Springer, Heidelberg, **2006**; b) Joule J. A.; Mills, K. *Heterocyclic Chemistry at a Glance*, Blackwell, Oxford, **2007**.

<sup>&</sup>lt;sup>4</sup> a) Petrov, V. A. Fluorinated Heterocyclic Compounds: Synthesis, Chemistry, and Applications, Wiley, Hoboken, New Jersey, 2009; b) Kirsch, P. Modern Fluoroorganic Chemistry, Wiley-VCH, Weinheim, 2004; c) Muzalevskiy, V. M.; Shastin, A. V.; Balenkova, E. S.; Haufe, G.; Nenajdenko, V. G. Synthesis 2009, 3905–3929; d) Erian, A. W. J. Heterocycl. Chem. 2001, 38, 793–808; e) Lin, P.; Jiang, J. Tetrahedron 2000, 56, 3635–3638; f) Silvester, M. J. Adv. Heterocycl. Chem. 1994, 59, 1–38; g) Welch, J. T. Tetrahedron, 1987, 43, 3123–3198.

<sup>&</sup>lt;sup>5</sup> a) Viso, A.; Pradilla, R. F.; García, A.; Flores, A. *Chem. Rev.* **2005**, *105*, 3167–3196. b) Liu, H.; Du, D. M. *Adv. Synth. Catal.* **2009**, *351*, 489–519.

One of the most efficient methods for the synthesis of imidazolines is the Mannich-type addition/cyclization cascade reaction between imines and suitable  $\alpha$ -isocyano acetates. With the aim to obtain trifluoromethyl functionalized imidazolines, this reaction was then studied during my thesis for the first time starting from trifluoromethyl aldimines and several substituted  $\alpha$ -isocyano acetates (Scheme 2).



Scheme 2. Mannich-type reactions on isocyano acetates.

Trifluoromethyl aldimines were also considered in the aza-Reformatsky reaction with different  $\alpha$ -bromo esters, hoping to find also an efficient methodology to obtain univocally  $\beta$ -lactam or  $\beta$ -amino ester (**Scheme 3**).



Scheme 3. Aza-Reformatsky reactions on trifluoromethyl aldimines.

The  $\beta$ -amino esters,  $\beta$ -amino keto esters, and  $\beta$ -amino malonates obtained through aza-Reformatsky and Mannich type-reactions respectively, are characterized by the [CH(CF<sub>3</sub>)] group.

The [CH(CF<sub>3</sub>)] group can be introduced into a peptidic structure to obtain a fluorinated  $\psi$ [CH(CF<sub>3</sub>)NH]-peptidomimetic.<sup>6</sup> Indeed, this group is a known isoster of the carbonyl group and can mimic his behavior. The term of "isoster" was

<sup>&</sup>lt;sup>6</sup> See ref.30 and 31 in the **Chapter 1**.

coined by Langmuir, indicating a group of similar steric and electronic profile to the original functional group. This definition has been also extended to the compounds with similar biological properties or compounds eliciting a similar biological effect, the terms used in this case is "bioisoster".

And it is precisely the synthesis of molecules characterized by an acetyl lysine bioisoster portion, the aim of the project carried out at the University of Oxford (UK) under the supervision of Professor Darren J. Dixon and in collaboration with the SGC (Structural Genomics Consortium).

The project was focused on the development of epigenetic probes against PCAF (p300/CBP-associated factor). Starting from the lead compound reported in Figure 1,



Figure 1. Lead compound.

compound that showed a weak affinity for the bromodomain module of PCAF, a library of compounds was developed in order to clarify the key binding elements and therefore increase the affinity for the abovementioned site.

## **Results and Discussion**

## Chapter 5

# Mannich type reactions of 1,3-dicarbonyl compounds with trifluoromethyl aldimines

The reactivity of 1,3-dicarbonyl compounds in the Mannich type reaction is well established, especially in the asymmetric version. Nowadays, there are few data reported in literature about the reactivity of trifluoromethyl aldimines towards 1,3-dicarbonyl compounds.<sup>1</sup>

However, these nitrogen containing organofluorine are extremely attractive synthetic targets.

#### 5.1 Preliminary studies

The entire trifluoromethyl (*E*)-aldimines tested in the subsequent Mannichtype reactions were synthesized followed the reported solvent-free protocol between the trifluoroacetaldehyde ethyl hemiacetal and amines<sup>2</sup> and used without further purification.

The investigation of Mannich-type reaction with 1,3-dicarbonyl compounds started with the reaction of trifluoromethyl aldimines 1a,b and diethyl malonate 2 in equimolar ratio. As reported in Table 1, different reaction conditions were considered.

<sup>&</sup>lt;sup>1</sup> See ref.13 in the **Chapter 1**.

<sup>&</sup>lt;sup>2</sup> See ref.17 in the **Chapter 1**.

 Table 1. Optimization of the reaction conditions on diethyl malonate 2.

Pg	<sup>I</sup> `N ∥ ℃F	+ U H		vent-free atalyst F	<sup>3</sup> g NH C <sub>3</sub> C	OEt
	1a,b	2	2		3a,b	J
P	g: <b>a</b> = B	n; <b>b</b> = MeO	ρ- <b>√</b> ξ(ΡΙ	MP)		
Entry	Pg	Catalyst	Molar	Time	T (°C)	Yield
5	0	5	(%)	(min)	. ,	(%) <sup>a</sup>
1			25	5	25	50
2		CuCl <sub>2</sub>	25	30	0	35
3			25	60	-20	40
4	Bn		50	30	25	_
5			25	30	25	-
6			10	30	25	-
7		ZrCl <sub>4</sub>	10	10	25	75
8			50	30	25	-
9		$CuCl_2$	25	30	25	_
10			10	30	25	-
11	PMP		50	30	25	_
12		AlCl <sub>3</sub>	25	30	25	_
13			10	30	25	—
14		ZrCl <sub>4</sub>	10	30	25	79
<sup><i>a</i></sup> After	flash c	hromatogra	phy on silica	gel (eluent h	nexane/eth	nyl acetate
= 8:2).						

To promote the Mannich-type reaction, the Lewis acid catalysis was considered hoping to increase, through the coordination with the carbonyl groups, the acidity of methylene protons. These latter could be deprotonated by trifluoromethyl aldimines 1, giving the nucleophilic species and activating themselves through self-protonation at the same time. Three Lewis acids were considered as catalysts,  $CuCl_{2}$ ,<sup>3</sup> widely used to promote different addition

<sup>&</sup>lt;sup>3</sup> a) Li, J.-L.; Liu, L.; Pei, Y.-N.; Zhu, H.-J. *Tetrahedron* **2014**, *70*, 9077–9083; b) Liu, Y.; Wan, J.-P. *Org. Biomol. Chem.* **2011**, *9*, 6873–6894; c) Le Engers, J.; Pagenkopf, B. L. *Eur. J. Org. Chem.* **2009**, 2009, 6109–6111, d) Shintani, R.; Hayashi, T. *In New Frontiers in Asymmetric Catalysis*; Mikami, K.; Lautens, M., Eds.; Wiley: New York, **2007**; Ch 3, pp 59–100.

e) Gonzalez, A. S.; Arrayas, R. G.; Carretero, J. C. Org. Lett. 2006, 8, 2977-2980.

reactions, AlCl<sub>3</sub>, and ZrCl<sub>4</sub>,<sup>4</sup>as easily disposable, eco-friendly, and efficient Lewis acid.<sup>5</sup>

All the reactions were performed under solvent-free condition; in the presence of AlCl<sub>3</sub> no reaction occurs starting from either **1a** or **1b** (entries 4-6 and 11-13). On the other hand, the use of ZrCl<sub>4</sub> (entries 7 and 14) as catalyst gave the corresponding Mannich adducts **3a**,**b** in higher yields and shorter times than when the reactions were performed with CuCl<sub>2</sub> (entries 1-3 and 8-10).

Thus, in order to study the stereofacial induction of reaction, a diastereoselective  $ZrCl_4$ -catalyzed Mannich-type reaction was performed, under the fixed optimal reaction conditions, starting from optically pure trifluoromethyl aldimine (*R*)-1c (Scheme 1).

The desired products 4,5c were obtained in satisfactory yield, but no induction was observed. The reaction was repeated by varying the temperature (0 and -20 °C), but no significant changes in the diastereomeric ratio (dr) were determined by the <sup>19</sup>F NMR analysis performed on the crude mixtures.



Scheme 1. ZrCl<sub>4</sub>-Catalyzed Mannich-type reaction on optically pure 1c.

Therefore, the interest has been directed towards the reactivity of  $\beta$ -keto esters.

In order to find the optimal reaction conditions for direct catalytic Mannichtype additions of  $\beta$ -keto esters to trifluoromethyl aldimines, the trifluoromethyl

<sup>&</sup>lt;sup>4</sup> a) See ref. 27 and ref 28 in the **Chapter 1**; b) Morandi, B.; Carreira, E. M. Angew. Chem. **2011**, 123, 9251–9254; Angew. Chem., Int. Ed. **2011**, 50, 9085–9088.

<sup>&</sup>lt;sup>5</sup> a) Zhang, Z.-H.; Li, T.-S. *Curr. Org. Chem.* **2009**, *13*, 1–30; b) Smitha, G.; Chandrasekhar, S.; Reddy, C. S. *Synthesis* **2008**, 2008, 829–855.

aldimine 1a and the simplest  $\beta$ -keto ester, methyl acetoacetate (6), were considered as reactants in equimolar ratio under different reaction conditions (Table 2).

Bn N CF <sub>3</sub> +		 $F_3C$
19	6	7.7'a

<b>Table 2.</b> Optimization	of the reaction	conditions of	$\beta$ -keto ester 6.
------------------------------	-----------------	---------------	------------------------

6

1a

Entry	Catalyst	Molar (%)	Solvent	Time	T (°C)	Yield $(\%)^a$
1	_	_	-	2 d	25	_
2	Et <sub>3</sub> N	100	THF	4 h	25	_
3	KF	100	THF	4 h	25	—
4	Cinchonidine	10	$CH_2Cl_2$	1 d	25	_
5		10	-	24 h	25	-
6		30	-	2 h	25	_
7	L-proline	10	DMSO	24 h	25	_
8		10	NPM	3 h	25	$<5^{c}$
9		10	THF	2 d	25	$<5^{\circ}$
10	$\bigvee_{N} \overset{Ph}{\longleftarrow} \overset{Ph}{\longleftarrow} \overset{h}{\longleftarrow} \overset{h}{\longleftarrow} \overset{h}{\longrightarrow} \overset{h}$	10	—	1 d	25	—
11	H OH <sup>D</sup>	10	NPM	3 d	25	$<5^{c}$

<sup>*a*</sup>After flash chromatography on silica gel (eluent hexane/ethyl acetate = 8:2).  ${}^{b}(S)$ - $\alpha,\alpha$ -diphenylprolinol (Hayashi's catalyst). Conversion determined by <sup>19</sup>F NMR.

Considering the higher acidity of the  $\beta$ -keto esters compared to the malonates, at first, the Mannich-type reaction was performed without catalyst (entry 1), to test if the same imine could generate in situ the nucleophile, acting as both base and substrate.<sup>6</sup> Unfortunately, the reaction did not give the expected product, and both reagents were quantitatively recovered (entry 1).

Subsequently, the most common organic or inorganic bases (entries 2 and 3) were considered to promote the formation of nucleophilic species, but once again, both aldimine 1a and methyl acetoacetate 6 were quantitatively recovered in every cases

<sup>&</sup>lt;sup>6</sup>In the aziridination reactions with ethyl nosyloxycarbamate the same fluorinated imines were able to deprotonate in situ the aminating agent, acting as both base and substrate: see ref. 26 in the Chapter 1 and Barani, M.; Fioravanti, S.; Loreto, M. A.; Pellacani, L.; Tardella, P. A. Tetrahedron 1994, 50, 3829-3834.

It is possible to suppose that, once obtained the nucleophile, it is necessary also an activation of the imine in order that the Mannich addition could occur. Then bifunctional catalysts (entry 4-11), able to activate both the imine and the  $\beta$ -keto ester, were considered.

As shown in **Table 2**, while no reaction occurs with cinchonidine, using Lproline (entries 8 and 9) or (*S*)- $\alpha$ , $\alpha$ -diphenylprolinol (entry 11) in the presence of a suitable solvent the formation of expected Mannich adducts was observed, but only in traces (<5%) by NMR. On the contrary, working under solvent-free conditions, the  $\beta$ -enamino ester **8** (Scheme 2), was obtained as major product, resulting from a L-proline-catalyzed nucleophilic addition of benzylamine, *in situ* formed by hydrolysis of **1a**, to the ketone moiety of **6**.<sup>7</sup>



**Scheme 2.** Synthesis of  $\beta$ -enamino ester 8.

Finally, based on previous results, a Lewis acid catalysis was considered (Table 3).

<sup>&</sup>lt;sup>7</sup> Kundu, D.; Majee, A.; Hajra, A. Chin. J. Chem. 2008, 26, 1545–1548.

**Table 3.** Lewis acid catalyzed Mannich-type reactions.

Bn <sub>∖N</sub> ∬ 1a	CF3 -	0 0 ↓ ↓ 0 6	solvent free	Bn ➤ F <sub>3</sub> C <i>syn</i>	NH O * * 0 7,7'a /anti = 1:1
Entry	Catalyst	Molar (%)	Time	T (°C)	Yield $(\%)^a$
1		25	5 min	25	50
2	CuCl <sub>2</sub>	25	30 min	0	35
3		25	1 h	-20	40
4		25	15 min	25	40
5	AlCl <sub>3</sub>	25	25 min	0	36
6		25	45 min	-20	30
7		10	10 min	25	75
8		10	1 h	0	35
9	ZrCl <sub>4</sub>	10	3 h	-20	30
10		10	6 h	-70	_
11		25	6 h	-70	_
<sup><i>a</i></sup> After acetate	flash chron $e = 8:2$ ).	natography or	n silica gel (elu	ent hexar	ne/ethyl

The reactions, performed under solvent-free conditions, gave the expected products 7,7'a. The best reaction conditions, reported in entry 7, involve the ZrCl<sub>4</sub> as catalyst allowing to obtain the desired products in only 10 min and in good yield. No diastereoselectivity was observed; in fact, the two *syn/anti* diastereomers were obtained in equimolar ratio even by changing the reaction temperature, in lower yields and longer reaction time (entries 8-9).

Fixed the best conditions and in order to investigate the scope of addition, ZrC4-catalyzed Mannich-type reactions were performed starting from different  $\beta$ -keto esters **9-11** and *N*-protected trifluoromethyl addimines **1a**,**b** (**Table 4**).

In all cases the reactions took successfully place in a short time, and the expected Mannich adducts were obtained in satisfactory yields after flash chromatography on silica gel. In addition very high stereoselectivity was achieved, especially when six-membered cyclic  $\beta$ -keto ester **11** was used (entries 3 and 6).

**Table 4.** Solvent-free ZrCl<sub>4</sub>-catalyzed Mannich-type reaction of different  $\beta$ -keto esters.



In order to explain the  $ZrCl_4$ -catalyzed Mannich-type reaction pathway performed on trifluoromethyl (*E*)-aldimines a catalytic cycle can be proposed (Scheme 3).



Scheme 3. Proposed pathway for ZrCl<sub>4</sub>-catalyzed Mannich-type addition of 6.

As shown in the **Scheme 3**, Zr (IV) could coordinate both  $\beta$ -dicarbonyl oxygen atoms (I) so determining an increase in acidity of methylene protons, which can then be deprotonated by trifluoromethyl aldimine. Finally, an intermolecular nucleophilic attack to form II brings to the formation of the expected fluorinated  $\beta$ -amino  $\beta$ -dicarbonyl compounds and restores the catalytic cycle.

Subsequently, in order to develop a catalytic asymmetric Mannich-type reaction, the use of chiral ligand was considered. As reported in the introduction of this thesis, Zr(IV)-BINOL is an efficient organometallic catalyst widely used in the Mannich-type reactions of silyl enol ethers with aldimines.<sup>8</sup> Thus, on the basis of the collected data, the same chiral catalyst was considered for the reaction between the aldimine **1a** and the methyl acetoacetate **6** (Scheme 4).

<sup>&</sup>lt;sup>8</sup>a) Ishitani, H.; Ueno, M.; Kobayashi, S. J. Am. Chem. Soc. **1997**, 119, 7153–7154. b) Kobayashi, S.; Ishitani, H.; Ueno, M. J. Am. Chem. Soc. **1998**, 120, 431–432; c) Ishitani, H.; Ueno, M.; Kobayashi, S. J. Am. Chem. Soc. **2000**, 122, 8180–8186.



Scheme 4. Mannich-type reaction catalyzed by Zr(IV)-BINOL.

The catalyst was prepared *in situ* starting from zirconium-(IV) *tert*-butoxide  $[Zr(Ot-Bu)_4]$  and (R)-(+)-1,1'-bi(2-naphthol) as ligand. Unfortunately, the desired product was obtained in low yield and neither diastereo- or enantioselectivities were observed even by changing the reaction temperature.

Therefore, considering the proposed reaction pathway (Scheme 3), the optically pure trifluoromethyl aldimine (*R*)-1c was considered as suitable chiral auxiliary in the Mannich type reaction with  $\beta$ -keto esters, hoping that the chiral centre on the aldimine could give diastereoselective addition.

The Mannich type reactions were performed with different  $\beta$ -keto esters, ZrCl<sub>4</sub> as catalyst and under solvent free conditions. The results are reported in **Table 5**.

 Table 5. ZrCl<sub>4</sub>-catalyzed Mannich-type reaction on optically pure 1c.

Ph					Ph	
	6: R = CH <sub>3</sub> , F 9: R, R' = CH 10: R-R' = -(C 11: R-R' = -(C	O = O = O = O = O = O = O = O = O = O =	solvent-fr ZrCl <sub>4</sub> (10 mo = CH <sub>3</sub> H <sub>5</sub> = C <sub>2</sub> H <sub>5</sub> = C <sub>2</sub> H <sub>5</sub>	<u>ree</u> I%), rt a		O R CO <sub>2</sub> R" yn-17',18'
	15: R = CH <sub>3</sub> , F 16: R, R' = CH	≺' = H, R'' I <sub>3,</sub> R'' = C(	= C(CH <sub>3</sub> ) <sub>3</sub> CH <sub>3</sub> ) <sub>3</sub>	a	24	y 11-22 ,23
Entry	β-Keto ester	Time (min)	Product	$d\mathbf{r}^{a}$	anti/syn ª	Yield $(\%)^b$
1	6	30	anti- 17,18 syn- 17',18'	5:5	5:5	72
2	9	10	19	≥ 9.9	9.9:0.1	68
3	10	10	20	≥ 9.9	9.9:0.1	78
4	11	20	21	≥9.9	9.9:0.1	78
5	15	30	anti- 22,23 syn- 22',23'	5:5	5:5	65
6	<b>16</b> <sup>9</sup>	30	24	≥9.9	9.9:0.1	64
<sup><i>a</i></sup> Determined by <sup>19</sup> F NMR spectra performed on the crude mixtures. <sup><i>b</i></sup> After						

flash chromatography on silica gel.

Starting from (*R*)-1c and methyl acetoacetate (6), the reaction was successful leading to syn-17/18'anti-17/18' addition products in good yield, but the stereoselective control failed; in fact all the four possible diastereomers were obtained (entry 1).

As shown in the entry 5, also the presence of a bulky group in the ester residue did not influence the reaction stereochemistry,<sup>10</sup> in fact with *tert*-butyl ester **15** (entry 5), dr and *anti/syn* ratio did not change compared with methyl ester **6** (entry 1). On the contrary, the presence of the ever-increasing steric hindrance on the nucleophilic site led to highly stereocontrol (entry 16).

<sup>&</sup>lt;sup>9</sup> Hashimoto, T.; Naganawa, Y.; Maruoka, K. J. Am. Chem. Soc. 2011, 133, 8834-8837.

<sup>&</sup>lt;sup>10</sup> See ref.40 in the **Chapter 2**. The authors reported that the absolute configuration of Mannich adducts was reversed when going from a  $\beta$ -keto ester with an ester group derived from a secondary to a tertiary alcohol.

High diastereomeric and *anti/syn* ratios were obtained starting from methyl substituted or cyclic methylene active compounds **9-11** and **16** (entries 2-4, 6): in all cases only one of the four possible diastereomers, characterized by the presence of a quaternary chiral center, was obtained.

In order to unequivocally assign the absolute configuration of the quaternary chiral center, as well as the relative configuration *syn* or *anti* of the obtained diastereomers, the diastereoselective decarboxylation of compound **24** was performed (**Scheme 5**), following the procedure reported in the literature.<sup>10</sup>



Scheme 5. Decarboxylation reaction of 24.

Treatment of the Mannich adduct **24** with trimethylsilyltrifluoromethanesulfonate and saturated aqueous NaHCO<sub>3</sub> gave the corresponding ketone **25** and a high diastereoselectivity was maintened in this transformation.

Following an already reported methodology,<sup>11</sup> 2D NOESY <sup>1</sup>H NMR analysis (Figure 1).were acquired on 24 and 25 that, coupled with computational studies, permits to assign the relative and the absolute configurations to the  $C_{\beta}$  and to the  $C_{\alpha}$ , respectively.

<sup>&</sup>lt;sup>11</sup> a) Fioravanti, S.; Parise, L.; Pellacani, L., Sciubba, F.; Trulli, L. J. Org. Chem. **2015**, 80, 8300–8306 and see ref.29, 54 in the **Chapter 1** and **2**.



Figure 1. NOESY <sup>1</sup>H NMR spectra of 24 and 25.

The 2D NOESY <sup>1</sup>H NMR analysis permitted to determinate the relative interproton distances and thus molecular geometry, by the following equation:

$$\frac{V_X}{V_R} = \left(\frac{d_R}{d_X}\right)^6$$

in which  $V_R$  is the volume of the reference cross peak,  $d_R$  is the corresponding interproton distance and  $V_X$  is the volume relative to the unknown distance  $d_X$ .

Therefore, starting from a reference cross peak whose interproton distance is known, it is possible to calculate the distances between other protons.

Since the chiral center on the amine residue has *R* configuration, the interproton distance between  $H_b$  and the protons  $H_c$  in both 24 and 25 can be considered as a fixed value and used to determine the distance between  $H_a$  and  $H_b$  in 24 and the distance between  $H_d$  and  $H_e$  in 25 through the previous equation.

Subsequently, the comparison between the values measured by NOESY spectra with those determined by minimization structure permitted to assign the *R* absolute configuration to C<sub> $\beta$ </sub> for 24, and the *R* absolute configuration to C<sub> $\alpha$ </sub> for *syn*-25. As a consequence, the (*R*,*R*,*S*) absolute configuration and the *anti* relative configuration can be assigned to the starting  $\beta$ '-amino  $\beta$ -keto ester 24. The same (*R*,*R*,*S*) absolute configuration can be assigned to all obtained  $\beta$ '-amino  $\beta$ -keto ester *anti*-isomer 19, 20, and 21(Figure 2), for which 2D NOESY <sup>1</sup>H NMR spectra were also performed on the purified compounds.

All optimized geometries were located using hybrid functional theory  $(B3LYP)^{12}$  and the 6-31G(d, p)<sup>13</sup> basis set using the continuum solvation model<sup>14</sup> with chloroform ( $\epsilon = 4.71$ ) as the solvent conforming to the experimental conditions. All calculations were carried out using the Gaussian 09 program.<sup>15</sup>

<sup>&</sup>lt;sup>12</sup>Becke, A. D. J. Chem. Phys. **1993**, 98, 1372–1377.

<sup>&</sup>lt;sup>13</sup>a) Ditchfield, R.; Hehre, W. J.; Pople, J. A. J. Chem. Phys. 1971, 54, 724–728; b) Hehre, W. J.; Ditchfield, R.; Pople, J. A. J. Chem. Phys.1972, 56, 2257–2261; c) Hariharan, P. C.; Pople, J. A. Theor. Chim. Acta 1973, 28, 213–223.

<sup>&</sup>lt;sup>14</sup> Barone, V.; Cossi, M.; Tomasi, J. J. Comp. Chem. **1998**,19, 404–17.

<sup>&</sup>lt;sup>15</sup>Gaussian 09, Revision D.01, Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.;Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery Jr., J. A. J.; Peralta, E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Keith, T.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J.C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, O.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian, Inc., Wallingford CT, **2013**.



Figure 2. Assigned absolute configurations.

Considering the previously supposed mechanism (Scheme 3), it is possible to rationalize the stereochemical outcome of these Zr-catalyzed Mannich-type reactions.

The enolate, coordinated in an octahedral-like intermediate around the zirconium center, is constrained in a planar geometric disposition, which allows the nucleophilic attack take place only on the sterically less hindered prochiral Re face of optically pure aldimine (R)-1c (Figure 3).



Figure 3. Proposed transition state.

Considering the stereochemical results reported in Table 5, a steric hindrance on the E double bond of zirconium complex III was required to obtain complete stereoselective control.

In fact, starting from unsubstituted acyclic  $\beta$ -keto esters 6 or 16 low dr values and no *syn/anti* selectivity was observed.

Therefore, in order to study the importance of zirconium on the high diastereoselectivity observed, the Mannich-type addition reaction between (R)-1c and 8 was repeated but using AlCl<sub>3</sub> as catalyst (Scheme 6).



Scheme 6. AlCl<sub>3</sub>-catalyzed Mannich-type reaction.

As shown by the <sup>19</sup>F NMR analysis performed on the crude mixture, AlCl<sub>3</sub>catalyzed Mannich-type reaction led to all the four possible diastereomers in equimolar ratios (**Figure 4**).



**Figure 4.** <sup>19</sup>F NMR spectra of a mixture of *anti*-19, 26 and *syn*-19',26' obtained in the presence of AlCl<sub>3</sub>; only *anti*-19 isomer obtained in the presence of ZrCl<sub>4</sub>.

In order to explain the obtained results, a reaction pathway is proposed, in which Al coordinates only the carbonyl oxygen (IV) giving, consequently, the acyclic anionic intermediate V (Scheme 7).



Scheme 7. Proposed pathway for AlCl<sub>3</sub>-catalyzed Mannich-type addition of 9.

Finally, the solvent effect on the stereoselective reaction outcome was investigated. Thus, the ZrCl<sub>4</sub>-catalyzed Mannich-type reaction of **9** with chiral aldimine (R)-1c (Scheme 8)was performed by using some different organic solvents (DMSO, THF, CHCl<sub>3</sub>, and PhCH<sub>3</sub>).



**Scheme 8.** ZrCl<sub>4</sub>-catalyzed Mannich-type reaction on optically pure 1c in the presence of the solvent.

The reaction did not occur using DMSO as solvent, probably because  $ZrCl_4$  is coordinated to the solvent and no longer available to promote the catalytic cycle. On the other hand, performing the reaction in almost non polar toluene, the Mannich addition takes place in satisfactory yields (68%), but all the four possible diastereomers *anti*-19,26 and *syn*-19',26' are formed in equimolar ratios. Indeed,

the use of less polar THF or  $CHCl_3$  gave only the diastereomerically pure **19**, although in yields lower than those obtained in reactions performed under solvent-free conditions (32 and 43%, respectively).

## Chapter 6

## Synthesis of trifluoromethyl 2-imidazolines through Mannichtype reactions with isocyano acetates

The reaction of  $\alpha$ -isocyano acetates with imines represents a convenient method for the synthesis of 2-imidazolines, an interesting class of five-membered ring,<sup>1</sup> which can be found in natural product chemistry, in medicinal chemistry, in organic synthesis, in coordination chemistry, and even in homogeneous catalysis.<sup>2</sup> Therefore, the broad utility of these heterocyclic compounds have prompted considerable interest to develop an efficient method for the preparation of trifluoromethyl 2-imidazolines, considering even the general relevance of  $-CF_3$  group.

A traditional synthetic approach towards 2-imidazolines usually involves the use of BuLi to generate the nucleophile.<sup>3</sup> Other synthetic methods concerning the use of metal catalyst complexes (Cu, Ag, Au, Pd, Ni),<sup>4</sup> or of weaker bases,<sup>5</sup> or the simultaneous use of both<sup>6</sup> have also been developed.

An alternative strategy involves a direct reaction between primary amines,  $\alpha$ isocyano acetates, and carbonyl compounds performed in the presence of a metal catalyst or even without catalyst,<sup>7</sup> the same imine being able to act as a base.

<sup>&</sup>lt;sup>1</sup> Grimmett, M. R. *Comprehensive Heterocyclic Chemistry*, Eds.: A. R. Katrizky, C. W. Rees, E. F. V. Scriven, Pergamon, Oxford, **1996**, *3*, 77–120.

<sup>&</sup>lt;sup>2</sup> a) Betschart, C.; Hegedus, L. S. *J. Am. Chem. Soc.* **1992**, *114*, 5010–5017; b) Rondu, F.; Bihan, G. L.; Godfroid, J. J. *J. Med. Chem.* **1997**, *40*, 3793–3803, c) Haiao, Y.; Hegedus, L. S. *J. Org. Chem.* **1997**, *62*, 3586–3591; d) Liu, H.; Du, D.-M. *Adv. Synth. Catal.* **2009**, 351, 489–519 and references therein; e) Dalko, P. I.; Langlois, Y. *Chem. Commun.* **1998**, 331–332.

<sup>&</sup>lt;sup>3</sup> Both activated and unactivated isocyanides can successfully be deprotonated because of the high basicity of BuLi. a) Meyer, R.; Schöllkopf, U.; Böhme, P. *Liebigs Ann. Chem.* **1977**, 1183–1193, b) van Leusen, D.; van Leusen, A. M. *Org. React.* **2001**, *57*, 417–666.

<sup>&</sup>lt;sup>4</sup> Hayashi, T.; Kishi, E.; Soloshonok, V. A.; Uozumi, Y. Tetrahedron Lett. 1996, 37, 4969–4972.

<sup>&</sup>lt;sup>5</sup> Zhang, Z.; Lu, G.; Chen, M.; Lin, N.; Li, Y.; Hayashi, T.; Chan, A. S. C. *Tetrahedron:Asymmetry* **2010**, *21*, 1715–1721.

<sup>&</sup>lt;sup>6</sup> Qi, X.; Xiang, H.; Yang, C. Org. Lett. 2015, 17, 5590–5593.

<sup>&</sup>lt;sup>7</sup> a) Bon, R. S.; Hong, C.; Bouma, M. J.; Schmitz, R. F.; de Kanter, F. J. J.; Lutz, M.; Spek, A. L. Org. Lett.
2003, 5, 3759-3762. b) Bon, R. S.; van Vliet, B.; Sprenkels, N. E.; Schmitz, R. F.; de Kanter, F. J. J.; Stevens, C. V.; Swart, M.; Bickelhaupt, F. M.; Groen, M. B.; Orru, R. V. A. J. Org. Chem. 2005, 70, 3542–3553. c)

Recently also catalytic asymmetric Mannich-type/cyclization cascade reactions between  $\alpha$ -isocyano acetates and imines has received much attention.<sup>8</sup>

#### 6.1 Preliminary studies

equimolar ratio of (E)-1-phenyl-N-(2,2,2-At first an trifluoroethylidene)methanamine (1a) and methyl 2-isocyanoacetate (2) was reacted without catalyst but no reaction occurred, not even changing the reaction conditions (solvent, temperature, molar ratio), and both reagents were quantitatively recovered.

Therefore, starting from data reported in the literature,<sup>5</sup> different inorganic or organic bases were considered to promote the nucleophile formation: the expected product was obtained only by using  $Et_3N$  as added base and THF as solvent in very low yield (**Scheme 1**) but high diastereoselectivity, only *trans* isomers being detected.<sup>9</sup>



Scheme 1. Base catalyzed Mannich-type reaction.

Therefore, to increase the reaction yield, a Lewis acid catalysis was attempted, hoping that the coordination of a metal at the terminal isocyano acetate carbon allows for an easier  $\alpha$ -deprotonation.

Elders, N.; Schmitz, R. F.; de Kanter, F.J. J.; Ruijter, E.; Groen, M. B.; Orru, R. V. A. J. Org. Chem. 2007, 72, 6135–6142.

<sup>&</sup>lt;sup>8</sup> a) Zhou, X.-T.; Lin, Y.-R.; Dai, L.-X. *Tetrahedron: Asymmetry* **1999**, *10*, 855–862. b) Shao, P.-L.; Liao, J.-Y.; Ho, Y. A.; Zhao, Y. *Angew. Chem., Int. Ed.* **2014**, *53*, 5435–5439. c) Nakamura, S.; Maeno, Y.; Ohara, M.; Yamamura, A.; Funahashi,

Y.; Shibata, N. Org. Lett. **2012**, 14, 2960–2963. d) Ortín, I.; Dixon, D. J. Angew. Chem., Int. Ed. **2014**, 53, 3462–3465. e) de la Campa, R.; Ortín, I.; Dixon, D. J. Angew. Chem., Int. Ed. **2015**, 54, 4895–4898.

<sup>&</sup>lt;sup>9</sup> The *trans* relative configuration was assigned by comparing H/H coupling constant values ( ${}^{3}J_{trans} = 5.0-6.0$  Hz) reported in the literature for similar compounds. a) Xie, H., Zhu, J.; Chen, Z.; Li, S.; Wu, Y. J. Org. Chem. **2010**, 75, 7468–7471. b) Aydin, J.; Kumar, K. S.; Eriksson, L.; Szabò, K. J. Adv. Synth. Catal. **2007**, 349, 2585–2594

Considering the successful use of  $ZrCl_4$  as catalyst in the Mannich-type reactions of 1,3-dicarbonyl compounds (see **Chap. 5**), this Lewis acid was added in catalytic amounts in the reaction between **1a** and **2**, but only a complex reaction mixture was formed. Thus, to promote the Mannich-type/cyclization cascade reaction of isocyano acetate **2** with *N*-protected trifluoromethyl aldimine **1a** some classic silver derivatives were considered (**Table 1**).

Pg N	+ C CF <sub>3</sub> iuiv)	N <sup>CO</sup> 2N	cata (10 m solve	alyst nol %) ent, rt	Pg <sub>N</sub> F <sub>3</sub> C	<sup>∕∼</sup> N ⟨ CO₂Me	
1a-l	b	2			3a	,b	
Pg: <b>a</b> = Bi	n, <b>b=</b> PN	/IP			trans	> 99%	
Entry	Pg	Product	Catalyst	Solvent	Time (h)	Yield $(\%)^a$	
1			AgOAc	THF	22	46	
2			AgNO <sub>3</sub>	THF	24	52	
3			$Ag_2O$	THF	18	60	
4			Ag <sub>2</sub> O	$CH_2Cl_2$	20	62	
5	Bn	20	$Ag_2O$	DMSO	15	66	
6	DII	Ja	Ag <sub>2</sub> O	NMP	15	63	
7			Ag <sub>2</sub> O	DMF	15	65	
8			Ag <sub>2</sub> O	EtOH	16	45	
9			Ag <sub>2</sub> O	iPrOH	15	40	
10			Ag <sub>2</sub> O	-	5	85	
11	PMP	<b>3</b> b	Ag <sub>2</sub> O	-	5	88	
<sup><i>a</i></sup> After flash chromatography on silica gel.							

**Table 1.** Optimization of the reaction conditions of 2.

As shown in **Table 1**, Ag<sub>2</sub>O turned out to be the best catalyst compared to AgOAc and AgNO<sub>3</sub> (entries 1-3); in fact the desired product *trans*-**3a** was obtained in higher yield and in shorter time. Then, the Ag<sub>2</sub>O-catalyzed Mannich-type reaction was repeated by changing the solvent, ranging from polar aprotic and protic (entries 3–9), but the performance of addition does not seem to be influenced by the solvent nature. On the contrary, working under solvent-free condition (entry 10), *trans*-**3a** was obtained in shorter time and in very high yield and purity. Working under the same solvent-free conditions, imidazoline *trans*-**3b** (entry 11)

was successfully obtained starting from *N*-protected trifluoromethyl aldimine **1b**. On the basis of collected data, a possible reaction mechanism is proposed in **Scheme 2**.



Scheme 2. Possible reaction mechanism.

The silver-isocyano acetate complex **I**, generated according to the literature,<sup>10</sup> is deprotonated by a molecule of trifluoromethyl aldimine and, then, the attack of a second molecule of aldimine, leads to **II**. The ring closure reaction followed by the exchange silver(**I**) cation/proton provides the 2-imidazoline.

<sup>&</sup>lt;sup>10</sup> a) Gulevich, A. V.; Zhdanko, A. G.; Orru, R. V. A.; Nenajdenko, V. G. *Chem. Rev.* 2010, *110*, 5235–5331;
b) Bon, R. S.; van Vliet, B.; Sprenkels, N. E.; Schmitz, R. F.; Kanter, F. J. J.; Stevens, C. V.; Swart, M.; Bickelhaupt, F. M.; Groen, M. B.; Orru, R. V. A. J. Org. Chem. 2005, *70*, 3542–3553

#### 6.2 Reaction scope

In order to explore the reaction scope, additional  $\alpha$ -isocyano esters (4-6), prepared by  $\alpha$ -amino acid methyl ester hydrochlorides were obtained in high purity and yield (Scheme 3), through slight modifications of standard protocols,<sup>11</sup>



**Scheme 3** Synthesis of different  $\alpha$ -isocyano esters.

and then considered in the Mannich-type reactions with aldimines **1a-b**. The results are reported in **Table 2**.

Table	2.	Mannich-type	reactions	of α-isocyand	o esters	<b>4-6</b> .
-------	----	--------------	-----------	---------------	----------	--------------

Ρg	Pg <sub>N</sub> R ℓ + CN CO₂Me			A Me <u>(10 ا</u>	g₂O mol %) <b>→</b>	Pg~N	N +
	CF3		_		rt	F₃C	∖≏CO₂Me R
(1	.2 equiv)	(1€	equiv)			cis:tra	ns = 1/1
	1a,b	4-	-6			7/7'-9	)/9'a,b
	Fntry	R	Ρσ	Product	Solvent	Time	Yield
	Linu y	IX.	15	Tioduct	bolvent	(h)	$(\%)^{a}$
	1	Bn	Мо	7/7'a	-	4	60
	2	PMP	IVIC	7/7'b	-	4	48
	3	Bn	iBu	8/8'a	$CH_2Cl_2$	16	45
	4	PMP	шu	8/8'b	$CH_2Cl_2$	16	55
	5	Bn	Rn	9/9'a	$CH_2Cl_2$	12	38
	6	PMP	DII	9/9'b	$CH_2Cl_2$	10	40
	<sup><i>a</i></sup> After	flash chi	romato	graphy on s	ilica gel.		

While in all cases the stereoselectivity was completely lost,<sup>12</sup> the reactions involving **4** proceeded as expected under solvent-free conditions (entries 1-2). On

<sup>&</sup>lt;sup>11</sup> Elders, N.; Schmitz, R. F.; Kanter, F. J. J.; Ruijter, E.; Groen, M. B.; Orru, R. V. A. J. Org. Chem. 2007, 72, 6135-6142.

<sup>&</sup>lt;sup>12</sup> Even by changing the reaction conditions (molar ratios, silver catalysts, and temperature) no improvements of stereoselectivity were observed.

the contrary, starting from **5** or **6** the use of CH<sub>2</sub>Ch as solvent was required to afford the desired products albeit in moderate yields (entries 3-6), showing that these reactions suffer from the steric hindrance on the  $\alpha$  carbon, that can determine the decrease of yields and the increase of reaction time. Moreover, the substituent on the nucleophile carbon could be responsible also for the similar energy between the *E* and *Z* enolates, resulting in a total loss of geometric selectivity, which instead is controlled by the formation of the only *E* enolate isomer of  $\alpha$ -isocyano acetate **2**.

#### <u>6.3 Control of stereofacial induction</u>

Turning the interest towards the possible stereofacial attack, the Mannichtype additions were performed starting from the optically pure aldimine **1c**. The presence of an  $\alpha$ -alkyl substituent on the imine nitrogen coupled with an R group of isocyano acetates **4-6** seems to approach the limits for these Mannich-type reactions, the expected products being obtained only in traces. On the contrary, the Mannich-type reaction between methyl 2-isocyanoacetate (**2**) and the imine **1c**, performed under solvent-free conditions, afforded the expected *trans* 2imidazolines (**Scheme 4**) but in very low diastereomeric ratio (dr = 6:4), even when the reactions were attempted at lower temperatures (from -20 to 0 °C). Anyway, the diastereomeric could be separated between them by flash chromatography on silica gel, and diastereomerically pure compounds **10** (major isomer) and **10'** (minor isomer) were obtained.<sup>13</sup>



Scheme 4. Mannich-type reactions on optically pure aldimine 1c.

<sup>&</sup>lt;sup>13</sup> For these latter, the absolute configurations were determinate using the same previously described methodology (see **Chap 5**, pp. 59–60) involving computational studies coupled with the data obtained from 2D NOESY NMR spectra.

With the hope to increase the stereofacial induction, very interesting optically active trifluoromethyl aldimines deriving from L- $\alpha$ -amino esters<sup>14</sup> were considered.

The additions of 2 to aldimines 1d-f occurred with very high diastereoselectivity, leading in all cases only to (S,R,R) diastereomers. The results are reported in Table 3.

Table 3. Mannich-type reactions on aldimines 1d-f.



To explain the high diastereoselectivity and the absolute configurations obtained, a possible transition state could be suggested (Figure 1).



Figure 1. Proposed transition state.

The imine ester group could be coordinate by silver of the activated methyl 2-isocyanoacetate (2). This interaction could create a well-defined chiral pocket that can readily differentiate the enantiotopic faces of aldimine, favoring the attack of the enolate preferentially to the *Re* imine face and the formation of enantiopure valuable trifluoromethyl imidazolidines, enriched by an  $\alpha$ -amino acid residue.

<sup>&</sup>lt;sup>14</sup> See ref. 54 in the **Chapter 2**.
# **Chapter 7**

## Aza-Reformatsky reactions on trifluoromethyl aldimines

Fluorinated 1,2- and 1,3-difunctionalized compounds, including  $\beta$ -amino esters as well as nitrogen heterocycles like  $\beta$ -lactams, could have a variety of interesting biological properties, making them useful and versatile synthetic intermediates in organic synthesis.  $\beta$ -Amino esters and  $\beta$ -lactams could be obtained through the aza-Reformatsky reaction. Thus, the aim of this chapter is the study of the reactivity of trifluoromethyl aldimines in the aza-Reformastky reaction.

## 7.1 Heterogeneous conditions

## 7.1.1 Preliminary studies

The preliminary aza-Reformatsky reaction was performed between methyl-2bromoacetate (**2a**) and trifluoromethyl aldimine **1a**. A two-step procedure was used: in the first step the Reformatsky reagent (**I**) was synthesized by refluxing **2a** with freshly-activated zinc dust; after 5 min at 60 °C, 0.5 equiv of aldimine **1a**<sup>1</sup> were added.

Different reaction conditions were screened in order to find an efficient methodology: in all cases the reaction lead to the formation of only  $\beta$ -lactams (**Table 1**).

<sup>&</sup>lt;sup>1</sup> See ref.17 in the **Chapter 1**.

Table 1. Optimization of the reaction conditions on methyl-2-bromoacetate (2a).



Initially, using THF as solvent, the addition of **1a** was carried out at room temperature (entry 1), but after 36 h only the same aldimine was recovered. Increasing the addition step temperature (40 °C, entry 2), the expected product was obtained in very good yields. Decreasing the amount of metal Zn (entry 3),  $\beta$ -lactam **3** was obtained in lower yield as well as changing the reaction solvent (entries 4 and 5). Interestingly, following the reactions by <sup>1</sup>H NMR spectroscopy, in all cases only the simultaneous disappearance/appearance of the aldimine **1a** signals and those of  $\beta$ -lactam **3**, respectively, was observed. It is important to underline that the signals relating to a possible  $\beta$ -amino ester intermediate were not detected.

With the optimal two-step reaction conditions in hand, the heterogeneous aza-Reformatsky reaction was investigated starting also from  $\alpha$ -bromo esters **2b**,c (Scheme 1).



Unexpectedly, while the reaction with  $\alpha$ -bromo ester **2b** proceeded smoothly leading to *trans*-**4**,<sup>2</sup> although in very low yield, the reaction did not occur by using **2c**, even by chancing some reaction conditions (solvent, temperature and/or molar ratios). Hoping to get better results, a one-pot procedure was tested, following a procedure reported in the literature (**Table 2**).<sup>3</sup>





As shown in **Table 2**, aldimine **1a** was converted into the products *trans*-**4**,**5** in good yield by a convenient one-pot protocol. Once again, only  $\beta$ -lactams in *trans* configuration were achieved, showing that reactions proceeded also with high diastereoselectivity.

<sup>&</sup>lt;sup>2</sup> The *trans* relative configuration was assigned by comparing the H/H coupling constant values ( ${}^{3}J_{trans} = 1.5-2.5 \text{ Hz}$ ;  ${}^{3}J_{cis} = 4.5-6.0 \text{ Hz}$ ) of ring protons and the  $\delta$  values of  $-\text{CF}_{3}$  group on the  ${}^{19}\text{F}$  NMR spectra recorded by us with those reported in the literature for similar compounds: Bevilacqua P. F.; Keith D. D.; Roberts J. L. J. Org. Chem. **1984**, 49, 1430–1434.

<sup>&</sup>lt;sup>3</sup> Tarui, A.; Kawashima, N.; Sato, K.; Omote, M.; Miwa, Y.; Minami, H.; Ando, A. *Tetrahedron Lett.* **2010**, *51*, 2000–2003.

To explain this, two possible reaction pathways can be suggested: a *via* ketene-imine mechanism<sup>4</sup> or an addition-cyclization mechanism<sup>5</sup> (**Scheme 2**).<sup>6</sup> The former hypothesized that the reaction was occurring *via* a ketene Staudinger-type mechanism (**A**). The ketene, formed by  $\alpha$ -bromo ester due to the presence of Zn,<sup>7</sup> could add to imine through a formal [2+2] cycloaddition, leading to *trans*  $\beta$ -lactam *via* the favored transition state **II**.



Scheme 2. Proposed reaction pathways.

Alternatively, the zinc enolate addition to the (*E*)-aldimine could lead to the *anti*- $\beta$ -amino ester (**V**), never detected during these reactions, which quickly cyclize giving the corresponding *trans*  $\beta$ -lactam (**Scheme 2, B**).

<sup>&</sup>lt;sup>4</sup> Jian, S.-Z.; Ma, C.; Wan, Y.-G. Synthesis **2005**, *5*, 725–730.

<sup>&</sup>lt;sup>5</sup> Hart, D. J.; Ha, D. C. Chem. Rev. **1989**, 89, 1447-1465.

<sup>&</sup>lt;sup>6</sup> For brevity only the synthesis of one enantiomer has been reported.

<sup>&</sup>lt;sup>7</sup> Hafner, A.; Ley, S. V. Synlett **2015**, 26, 1470–1474

In the last hypothesis, the stereochemical data could be rationalized through a rigid cyclic chair- and/or a boat-type transition states, depending by the *E* or *Z* enolate configuration. Whereas the *E* isomer should be the most stable, only the boat-like transition state **III** could be invoked to explain the observed *trans* diastereoselectivity of the addition,<sup>8</sup> because the chair Zimmerman-Traxler transition state would give *cis*  $\beta$ -lactam. However, such as reported in the literature,<sup>9</sup> it cannot be excluded that both isomers are in fast equilibrium between them and that the minor *Z* isomer reacts, through a chair-type transition state (**IV**), much faster than the *E* enolate, leading to the *anti*- $\beta$ -amino ester (**V**).

#### 7.1.2 Enantio- and diastereoselective studies

In order to achieve optically pure *trans*  $\beta$ -lactams, a suitable chiral ligand was considered, namely the inexpensive and commercially available amino alcohol (1*R*,2*S*)-1-phenyl-2-(1-pyrrolidinyl)propan-1-ol (**6**, **Figure 1**), already used in the asymmetric Reformatsky reaction.<sup>10</sup>



## (1*R*,2S)-**6**

Figure 1. (1*R*,2*S*)-1-phenyl-2-(1-pyrrolidinyl)propan-1-ol.

To test the enantioselective addition, methyl 2-bromoacetate (2a) and imine 1a were reacted both under two-step (A) and one-pot (B) conditions (Scheme 3).

<sup>&</sup>lt;sup>8</sup> a) Georg, G. I.; Harriman, G. C. B.; Hepperle, M.; Clowers, J. S.; Vander Velde, D. G.; Himes, R. H. J. Org. Chem **1996**, 61, 2664–2676. b) Annunziata, R.; Benaglia, M.; Cinquini, M.; Cozzi, F.; Martini, O.; Molteni, V. Tetrahedron. **1996**, 52, 2583–2590. c) Ishihara, T.; Ichihara, K.; Yamanaka, H. Tetrahedron, **1996**, 52, 255–262. d) Cainelli, G.; Panunzio, M.; Bandini, E.; Martelli, G.; Spunta, G. Tetrahedron. **1996**, 52, 1685–1698. e) Evans, D. A.; Nelson, J. V.; Taber, T. R. Topics in Stereochemistry, Stereoselective Aldol Condensations, ed. by N.L. Allinger, E. L, Eliel and S. H. Wilen, Wiley, New York (**1982**).

<sup>&</sup>lt;sup>9</sup> a) Maanen, H.; Kleijn, H.; Jastrzebski, J. T. B. H.; Van Koten, G. *Bull Soc Chim Pr* **1995**, *132*, 86–94. b) Van der Steen, F.H.; Kleijn, H.; Jastrzebski, J. T. B. H.; Van Koten, G. *J. Org. Chem.* **1991**, *56*, 5147–5158. c) Van der Steen, F.H.; Kleijn, H.; Britovsek, G. J.P.; Jastrzebski, J. T. B. H.; Van Koten, G. *J. Org. Chem.* **1992**, *57*, 3906–3916.

<sup>&</sup>lt;sup>10</sup> a) Andrés, J. M.; Martinez, M. A.; Pedrosa, R.; Pèrez-Encabo, A. Synthesis **1996**, 1070–1072. b) Kloetzing, R. J.; Thaler, T.; Knochel, P. Org. Lett. **2006**, 8, 1125–1128



Scheme 3. Enantioselective Reformatsky reactions.

The classical two-step reaction was attempted at high temperature (the second step was performed at a range between 40–60 °C) also by using a large excess (12 equiv) of Zn metal, but **3** was still obtained in very low yield (10 and 18 % respectively) and as a racemic mixture, as determined by chiral HPLC analyses. On the contrary, working at lower temperature (0 and 25 °C) no reaction occurred and both aldimine **1a** and  $\alpha$ -bromo ester **2a** were recovered in all cases.

Consequently, a one-pot procedure was considered, but again the  $\beta$ -lactam was obtained only in trace and as a racemic mixture.

Failed the enantioselective control, we attempted to obtain chiral  $\beta$ -lactams starting from optically pure trifluoromethyl aldimine (*R*)-1c,<sup>1</sup> still bearing a benzyl residue on the nitrogen atom easily removable under mild hydrogenolytic conditions (Scheme 4).



Scheme 4. Aza-Reformatsky reactions on optically pure 1c.

The reaction successfully gave the expected  $\beta$ -lactams 7/7' in satisfactory yield, but once again no selectivity was observed. However, hoping that an

increasead steric hindrance on the pre-nucleophile species could give better results, the one-pot aza-Reformatky reactions were performed even by using  $\alpha$ -bromo esters **2b-c** (Table 3).

$Br + Ph N = CF_3 \xrightarrow{Zn} (6 \text{ equiv}) \xrightarrow{Ph N} O \xrightarrow{R} F_3C R$							
<b>2b-c</b> (3 equiv)       (R)-1c       trans-8/8'         R: <b>b</b> = Me, <b>c</b> = Ph       (0.5 equiv)       trans-9/9'							
Entry	R	Time (h)	Product	dr <sup>a</sup>	trans:cis <sup>a</sup>	Yield (%) <sup>b</sup>	
1	Me	12	8/8′	1:1	>99:1	65	
2	Ph	15	9/9′	1:1	>99:1	61	
<sup><i>a</i></sup> Determined by <sup>19</sup> F NMR spectra of the crude reaction mixture. <sup><i>b</i></sup> After flash chromatography on silica gel.							

 Table 3. Aza-Reformatsky reactions on optically pure 1c.

Once again, high yields and high geometric selectivity were obtained, the only diastereomers *trans*-7/7' and 8/8' being obtained, but no stereoinduction was observed (dr = 1/1), probably due to the high required reaction temperature.

All diastereomers were purified by flash chromatography on silica gel to obtain optically pure compounds; absolute configurations of the newly formed stereocenters (**Figure 2**) was assigned by 2D NOESY <sup>1</sup>H NMR spectra coupled with geometric optimization processes through the reported methodology (see **Chap 5**, pp 58-59).<sup>11</sup>

<sup>&</sup>lt;sup>11</sup> See ref.11 in the **Chapter 5**.



Figure 2. Assigned absolute configurations.

### 7.2 Homogeneous conditions

Then, the interest has been directed towards the aza-Reformatsky reactions on trifluoromethyl aldimines under homogeneous conditions, by using commercially available Et<sub>2</sub>Zn as source of metal.

## 7.2.1 Preliminary studies

The investigation begin by reacting methyl 2-bromoacetate (2a) and trifluoromethyl aldimine 1a in the presence of diethylzinc, changing some reaction parameters (Table 4).

/ \_

١

Table 4. Optimization of the homogeneous aza-Reformatsky reaction conditions on 1a.

O Br	Bn. 0+	$\sum_{i=1}^{N} \frac{Et_2Z}{N_2}$	In (1 equiv)	Bn NH C	$P_{O} = \left( \begin{array}{c} Bn \\ NH \\ F_{3}C \end{array} \right)$	
2a		1a		10	\ 11	
(1 equ	iv) (0	.5 equiv)				,
	Entry	Salvant	T(°C)	Timo	Yield of	
	Епиу	Solvent	$I(\mathbf{C})$	1 mile	<b>10</b> $(\%)^a$	
	1	THF	40	12 h	-	
	2	THF	25	36 h	5	
	3	THF	0	3 d	-	
	4	THF	-10	3 d	-	
	$5^b$	THF	25	36 h	-	
	6	$CH_2Cl_2$	25	24 h	68	
	<sup><i>a</i></sup> After 1	flash chrom	atography o	n silica gel.	<sup>b</sup> Performed	
	by using	g 1 equiv of	<sup>^</sup> 2a			

Working in THF at 40 °C (entry 1), a very complex crude mixture was recovered after 12 h. At room temperature, only  $\beta$ -amino ester 10 was formed but in trace (entry 2). Furthermore, decreasing the reaction temperature (entries 3, 4), the major observed product was the adduct 11, resulting from the addition of diethylzinc to aldimine 1a, even working in equimolar ratios (entry 5). Finally by changing the reaction solvent (from THF to CH<sub>2</sub>Cl<sub>2</sub>, entry 6), only 10 was achieved in satisfactory yield.

It must be emphasized that, working under homogeneous conditions,  $\beta$ lactam **3** was not observed in any case even in trace, on the contrary to what reported in the literature for analogous aza-Reformatsky reactions performed on unfluorinated aldimines.<sup>12</sup>

Thanks to the more reactivity of diorganozinc reagents  $(R_2Zn)^{13}$  obtained using Et<sub>2</sub>Zn, we are able to promote the reaction at room temperature and, since only  $\beta$ -amino esters were obtained, the enolate-imine mechanism is the only reasonable Then, the best homogeneous aza-Reformatsky reaction conditions has been extended to the  $\alpha$ -bromo esters **2b-c**. The results are reported in **Table 5**. **Table 5.** Homogeneous aza-Reformatsky reactions.



<sup>&</sup>lt;sup>12</sup> Tarui, A.; Kawashima, N.; Sato, K.; Omote, M.; Miwa, Y.; Minami, H.; Ando, A. *Tetrahedron Letters* **2010**, *51*, 2000–2003.

<sup>&</sup>lt;sup>13</sup>a) Knochel, P; Perea, J. J. A.; Jones, P. *Tetrahedron*, **1998**, *54*, 8275–8319; b) Knochel, P.; Jones, P. *Organozinc Reagents: A Practical Approach*, Oxford Press, **1999**.

As shown in **Table 5**, the reactions proceeded smoothly to afford only  $\beta$ amino esters in satisfactory yields, which increase when temperatures decrease (entries 3 and 6). Concerning the diastereoselective reaction outcome, the *syn* or *anti* selectivity was observed depending from the different starting  $\alpha$ -bromo esters **2b-c**, namely starting from **2b**, only  $\beta$ -amino ester *syn*-**12** was obtained and from **2c** only the isomer *anti*-**13** was formed.<sup>14</sup>

Assuming the enolate in the only *E* configuration, two possible transition states, chair-like transition state VI for *syn*-12 and boat-like transition state VII for *anti*-13, can be invoked in order to rationalize the different stereochemical results (Figure 3).<sup>8</sup> This difference is probably due to the increased planarity of the (*E*)-enolate resulting from 2c, by favouring the boat-like transition state VII.<sup>15</sup>



Figure 3. Proposed transitions states.

In order to confirm the relative configuration of both, the homogeneous aza-Reformatsky reactions were repeated and the obtained  $\beta$ -amino ester crude mixtures were allowed to rise to 25 °C to promote the intramolecular cyclization (14 d, **Scheme 5**).

<sup>&</sup>lt;sup>14</sup> The *syn* and *anti* relative configurations were assigned by comparing H/H coupling constant values ( ${}^{3}J_{syn}$ = 6.5–7 Hz;  ${}^{3}J_{anti}$ = 8.5–9 Hz) with the data reported in the literature. Stiles, M.; Winkler, R. R.; Chang, Y.-L.; Traynor, L. J. Am. Chem. Soc., **1964**, 86, 3337–3342.

<sup>&</sup>lt;sup>15</sup> The *anti*- stereochemistry could be also explained through a chelated six-membered chair transition involving the Z enolate (see p. 78, ref. 9).



Scheme 5. Homogeneous aza-Reformatsky reactions followed by intramolecular cyclization.

As expected,  $\beta$ -lactams *cis*-14 and *trans*-5 were obtained starting from *syn*-12 and *anti*-13, respectively.

#### 7.2.2 Enantio- and diastereoselective studies

As reported in the introduction (see Chap. 3) homogeneous conditions could make the development of asymmetric aza-Reformatsky reaction easier. Therefore, in order to achieve enantioselective reaction control, the aza-Reformatsky additions of  $\alpha$ -bromo ester **2a-c** on **1a** were performed in the presence of chiral amino alcohol (*R*,*S*)-**6** by using a moderate excess of Et<sub>2</sub>Zn. The results are reported in **Table 6**.

lable	<b>6.</b> Enantiose	elective homog	geneous aza-l	Reformatsky	reactions.

Bi	r, L	Bn	'`N	Et <sub>2</sub> Zn (1.2 ( <i>R,S</i> )- <b>6</b> (0.3	2 equiv) 38 equiv)	Bn NH (	) 	
$R$ $CF_3$ $N_2 a$ $CF_3$ $CF_2$					$N_2$ atmosphere $F_3C$ $*$ $O$ $CH_2CI_2$ , -20 °C R			
<b>2a-c</b> (1 equiv) <b>1a</b> (0.5 equiv)       Ph       Me <b>10'</b> HO       N       syn-12'         (1R,2S)-6       anti-13'							2' 3'	
_	Entry	R	Time (d)	Product	syn:anti <sup>a</sup>	$Yield(\%)^b$	$ee (\%)^c$	
-	1	Н	5	10'	-	50	98	
-	2	Me	6	syn-12′	>99:1	52	98	
	3	Ph	9	anti-13'	>1:99	58	91	
-	<sup>a</sup> Determined by <sup>19</sup> F NMR spectra of the crude reaction mixture.							
	<sup>b</sup> After flash chromatography on silica gel. <sup>c</sup> Determined by chiral							
	HPLC							

The expected  $\beta$ -amino esters 10', syn-12' and anti-13' were obtained in satisfactory yields and excellent enantioselectivity.

## **7.3** Synthetic elaboration of obtained compounds: synthesis of <u> $\psi$ [CH(CF\_3)NH]-peptidomimetic precursors</u>

In order to demonstrate the utility of optically pure  $\beta$ -amino  $\beta$ -trifluoromethyl ester *syn*-12', the synthesis of small  $\psi$ [CH(CF<sub>3</sub>)NH]-peptidomimetic precursors was considered through appropriate chemical transformations.

In fact, the obtained compounds can be considered as starting point for the synthesis of peptidomimetics precursors characterized by a chiral  $\psi$ [CH(CF<sub>3</sub>)NH]-<sup>16</sup> cores in which a carbonyl group is replaced by its isoster, the -CHCF<sub>3</sub> group. Two are the possible molecular growth sites: the carboxylic group, that after methyl ester group removal permits a *C*-terminal molecular growing or to fix the trifluoromethylated core to solid matrix, and a free NH<sub>2</sub> moiety obtainable by a benzyl group hydrogenolysis reaction (**Scheme 6**).



Scheme 6. Molecular growth sites.

The second chemical elaboration was considered, to obtain the primary amine group as molecular growing site.

After removal of the benzylic residue, DCC coupling reaction with the *N*-Boc-L-Val was performed on *syn*-14' following the classical conditions (Scheme 7).<sup>17</sup>



Scheme 7. Synthesis of 15'.

<sup>&</sup>lt;sup>16</sup> a) Aresu, E.; Fioravanti, S.; Gasbarri, S.; Pellacani, L.; Sciubba, F. *RSC Adv.* **2013**, *3*, 13470-13476; b) Aresu, E.; Fioravanti, S.; Gasbarri, S.; Pellacani, L.; Ramadori, F. *Amino Acids* **2013**, *44*, 977-982 and see ref.30 in the **Chapter 1**.

<sup>&</sup>lt;sup>17</sup> Fioravanti, S.; Massari, D.; Morreale, A.; Pellacani, L.; Tardella, P. A. *Tetrahedron* **2008**, *64*, 3204–3211.

The coupling reaction gave in satisfactory yields the corresponding 15' as a pure diastereomer compound.

#### 7.4 Determination of the absolute configuration

In order to assign unequivocally the absolute configuration of the new chiral centers formed in the organocatalyzed aza-Reformatsky reactions and hence to the diastereomer 15', the addition reactions was repeated starting from the chiral aldimine (*R*)-1c and further chemical modifications were required.

To begin the study, trifluoromethyl aldimine (R)-1c and 12b were reacted, either in the presence or in the absence of the chiral ligand 6 (Table 7).





chromatography on silica gel.

As shown in **Table 7**, performing the addition without chiral ligand only the geometric stereocontrol was achieved, being controlled by the nucleophilic species (entry 1). The result showed also that a resident chiral center of the imine cannot influenced the facial selectivity. On the contrary, adding to the reaction (R,S)-**6**, a complete stereofacial selectivity was obtained (entry 2), only one *syn* diastereomer having been formed. Then, the organocatalyzed homogenous aza-Reformatsky reactions was brought at room temperature (14 d) to form the corresponding *cis*- $\beta$ -lactam **17** (**Scheme 8**).



Scheme 8. Homogeneous aza-Reformatsky reactions followed by intramolecular cyclization.

The same previously described methodology, based on the 2D NOESY <sup>1</sup>H NMR spectra and geometric optimization processes, permitted to assign the (*S*,*S*) absolute configuration to the newly chiral centers of **17**, and as a consequence even to those of starting  $\beta$ -amino ester **16**'.

After removal of chiral benzyl group of (R,S,S)-16', chiral HPLC analysis showed that the obtained primary amine (S,S)-14' is the same isomer formed by hydrogenolysis reaction carried out from *syn*-12' to which, therefore, the same configuration can be attributed (Scheme 9).



Scheme 9. Hydrogenolysis reactions on 16' and 12'.

In order to confirm this, DCC coupling reaction with the *N*-Boc-L-Val was also performed on the  $\beta$ -amino ester obtained by hydrogenolysis of (*R*,*S*,*S*)-16' (Scheme 10).



Scheme 10. Synthesis of 15'.

The coupling reaction gave, as expected, the same diastereomer 15', already obtained starting from (S,S)-12', thus confirming the matching between the absolute configurations.

Extending these studies even to the other enantioriched  $\beta$ -amino esters (**Table 6**, entry 1 and 3), the absolute configurations of the new synthesized chiral trifluoromethyl compounds are reported below (**Figure 4**).



Considering the found absolute configuration, the chiral ligand **6** promotes the nucleophilic attack preferentially on the *Si* face of the starting imine and Noyori's representative transition model can be used to explain the stereoselectivity of this Reformatsky reaction (**Figure 5**).<sup>18</sup>



Figure 5. Proposed transitions states.

Transition model **VIII** and **IX** provide the products with the observed stereochemistry. The proposed stereochemical models are based on the formation

<sup>&</sup>lt;sup>18</sup> Kitamura, M.; Suga, S.; Niwa, M.; Noyori, R. J. Am. Chem. Soc. **1995**, 117, 4832–4842.

of a coordination network involving the imine nitrogen, zinc ion, ligand, and Reformatsky reagent, which would allow for the successful formation of multiple chiral inductions.

In order to investigate how the presence of a further ester group could influence the chemical outcome, the trifluoromethyl aldimine  $1g^{19}$  derived from  $\beta$ -alanine was reacted under one-pot heterogeneous aza-Reformatsky conditions with  $\alpha$ -bromo esters **2a-c** to give, as expected, only  $\beta$ -lactams. The results are showed in **Table 8**.





While lower yields compared to those obtained starting from imine 1g (Table 1 and 2) were observed, the same high *trans* diastereoselectivity (entry 2-3) and chemoselectivity were found. One again the compounds can be derived by the two different pathways before reported: *via* ketene-imine mechanism and a condensation-cyclization mechanism (see Chap. 7, pp 76-77). It is noteworthy to stress that, if the second suggested mechanism was the one involved, no trace of a possible  $\beta$ -lactam resulting by cyclization of aza-Reformastky adduct on the imine

<sup>&</sup>lt;sup>19</sup> See ref.54 in the **Chapter 2**.

ester group was observed, consistent with a high reaction chemoselectivity.<sup>20</sup> Next, the homogeneous  $Et_2Zn$ -promoted aza-Reformatsky reactions, were performed, even in the asymmetric version (**Table 9**).





Entry	R	Time (h)	Et <sub>2</sub> Zn (equiv)	6 (equiv)	Product	syn/antt <sup>a</sup>	Yield (%) <sup>b</sup>
$1^d$	Н	18			21	-	40
$2^d$	Me	18	1.0	-	syn-22	>99:1	45
3 <sup>d</sup>	Ph	12			anti-23	>1:99	56
4	Н	72	1.2	0.38	<b>21'</b> (74% ee)	-	50
5	Me	72	1.2	0.50	syn-22'	>99:1	48
6	Ph	72			anti- <b>23'</b>	>1:99	51

<sup>*a*</sup>Determined by <sup>19</sup>F NMR spectra of the crude reaction mixture <sup>*b*</sup>After flash chromatography on silica gel. <sup>*c*</sup>Determined by chiral HPLC. <sup>*d*</sup> Reaction performed at room temperature

As shown in **Table 9**, the expected  $\beta$ -amino esters **21-23** were obtained in satisfactory yields; however, a change of the solvent was required (PhCH<sub>3</sub> instead of CH<sub>2</sub>Cl<sub>2</sub>). In addition, while a high *syn/anti* stereochemical outcome was observed, a lower enantiocontrol was found (see **Table 6**).

A reasonable explanation, taking into account the ester group on the *N*-chain of the aldimine, may be given. On the basis of the stereochemical model proposed before, another transition state could be suggested (**Figure 6**). In this latter the network of coordination involves the ester moiety of the  $\beta$ -alanine chain, instead of the imine nitrogen, thereby giving lower stereoselectivity of attack.

<sup>&</sup>lt;sup>20</sup> The presence of the strong electron-withdrawing  $-CF_3$  group increases the electrophilicity of the ester moiety in the β-position of β-amino ester intermediate, so directing the nucleophilic attack



Figure 6. Proposed transitions state

# **Chapter 8**

# Work towards the discovery of selective and potent PCAF inhibitors

During my PhD, I spent a period of six months at the University of Oxford (UK) under the supervision of Professor Darren J. Dixon and in collaboration with the SGC (Structural Genomics Consortium).

During this period the attention was focused on the development of different phthalazine-based derivatives in order to obtain epigenetic probes able to clarify key binding elements for the good affinity with the bromodomain module of PCAF (p300/CBP-associated factor).

The chemical probes are selective small-molecules that specifically bind and potently control the activity of a cellular target in order to deciphering biochemical pathways.<sup>1,2,3</sup> They can rapidly and reversibly inhibit a protein or a protein domain in cells or animals, modulate individual functions of multifuctional proteins and they can be used in almost any cell type and disclose temporal features of target inhibition;<sup>4</sup> in addition a probe that shows a positive effect can serve as a chemical starting point for drug discovery and in this way they can be quite useful at invalidating drug targets.<sup>5</sup> Target discovery currently uses a number of tools to associate a protein target with a disease, including the use of chemical probes in cellular or animal disease models.

<sup>&</sup>lt;sup>1</sup> Knapp, S.; Arruda, P.; Blagg, J.; Burley, S.; Drewry, D. H.; Edwards, A.; Fabbro, D.; Gillespie, P.; Gray, N. S.; Kuster, B.; Lackey, K. E.; Mazzafera, P.; Tomkinson, N. C.; Willson, T. M.; Workman, P.; Zuercher, W. J. Net, Chem. Piol. **2013**, 0, 2, 6

Nat. Chem. Biol 2013, 9, 3-6.

<sup>&</sup>lt;sup>2</sup> Kroeze, W. K.: Sassano, M. F.; Huang, X. P.; Lansu, K.; McCorvy, J. D.; Giguère, P. M.; Sciaky, N.; Roth, B. L. *Nat. Struct. Mol. Biol.* **2015**, *22*,362–369.

<sup>&</sup>lt;sup>3</sup> King, R.; Finley, D. Nat. Chem. Biol. 2014, 10, 870-874.

<sup>&</sup>lt;sup>4</sup> Arrowsmith, C.; Audia, J.; Austin, C.; Baell, J.; Bennett, J.; Blagg, J.; Bountra, C.; Brennan, P. et al. *Nat. Chem. Biol* **2015**, *11*, 536-541.

<sup>&</sup>lt;sup>5</sup> Sweis, R. F. ACS Med. Chem. Lett. 2015, 6, 618–621.

In fact, in order to find new medicines for diseases, like Alzheimer's disease, cancer and chronic inflammation, we first need to discover a new diseaseassociated protein target.

Epigenetic is an exciting new area for target discovery: especially epigenetic chemical probes, allowing the investigation of the epigenome, are having a strong impact in biological discovery and target validation for several classes of chromatin-interacting proteins.<sup>6</sup>

We can consider three classes of epigenetic proteins, discovered through the study of post-translational modification (PTM) of lysine and/or arginine residues in histones and other proteins through methylation and acetylation: a) those which add a methyl or acetyl group (writers) using *S*-adenosylmethionine (methylation) and acetyl-CoA (acetylation) as co-factors, b) those which remove a methyl or acetyl group (erasers) and c) those which bind histones/proteins containing a particular PTM (readers).

Therefore, as long as it is recognized that these proteins contribute to the control of various genes and they represent a rich source of potential therapeutic targets, it is important to unravel the biology of these proteins by developing small-molecule inhibitors and antagonists with the following properties:<sup>4</sup>

- IC<sub>50</sub> or  $K_d < 100 \text{ nM}$
- Selectivity > 30-fold over proteins in the same family
- Significant cellular activity below  $1 \mu M$ .

#### 8.1 Bromodomain

The interest has been directed towards the development of chemical probes against the bromodomain proteins family in recent years. The bromodomain, named for the *Drosophilia* gene *brahma* from which it was first identified,<sup>7</sup> is a conserved module that has been found in a number of proteins involved in

<sup>&</sup>lt;sup>6</sup> Huston, A.; Arrowsmith, C. H.; Knapp, S.; Schapira, M. Nat. Chem. Biol 2015, 11, 542-545.

<sup>&</sup>lt;sup>7</sup> Haynes, S. R.; Dollard, C.; Winston, F.; Beck, S.; Trowsdale, J.; Dawid, I. B. Nucleic Acids Res. **1992**, 20, 2603

transcription regulation that selectively recognize  $\varepsilon$ -*N*-acetylated lysine residues,<sup>8,9</sup> acting as "readers" of the histone code. The bromodomain family shall consist of 61 diverse domains in humans that have been described in 41 nuclear proteins,<sup>10,11</sup> (**Figure 1**)



Figure 1. Human bromodomain family.

all of these characterized by 110 amino acids arranged in a characteristic structure made up of four  $\alpha$ -helices ( $\alpha Z$ ,  $\alpha A$ ,  $\alpha B$ ,  $\alpha C$ ) connected by interhelical loops, termed the BRD fold (**Figure 2**).

<sup>&</sup>lt;sup>8</sup> Müller, <u>S.</u>; Knapp, <u>S. Med. Chem. Commun. **2014**</u>, *5*, 288–296.

<sup>&</sup>lt;sup>9</sup> Mujtaba, S.; Zeng, L.; Zhou, M. Oncogene **2007**, 26, 5521–5527.

 <sup>&</sup>lt;sup>10</sup> Filippakopoulos, P.; Picaud, S.; Mangos, M.; Keates, T; Lambert, J. P.; Barsyte-Lovejoy, D.; Felletar, I.;
 Volkmer, R.;. Muller, S.; Pawson, T.; Gingras, A. C.; Arrowsmith, C. H.; Knapp, S. *Cell* **2012**, *149*, 214–231.
 <sup>11</sup> Filippakopoulos, P.; Knapp, S. *FEBS Lett.* **2012**, *586*, 2692–2704.



Figure 2. General structure of a bromodomain module.

The interaction with the acetylated lysine residue occurs *via* a hydrogen bond with a conserved asparagine. In addition the water molecules in the binding pocket can mediate further interaction between the anchored acetylated lysine and the hydroxyl of a conserved tyrosine residue.<sup>12</sup> Bromodomains have recently been implicated in the development of cancer and have been shown to contain a "druggable" binding pocket, however their precise biological role is still poorly understood.

Hence development of selective chemical probes targeting the bromodomainhistone interaction is highly desirable for our understanding of the biological roles of these proteins within the human genome and to provide starting points for new molecular therapeutics against cancer.

### 8.1.1 p300/CBP-associated factor, PCAF

PCAF, also known as K(lysine) acetyltransferase 2B, KAT2B, is a transcriptional coactivator that works both as a histone lysine acetyltransferase, through its HAT domain which is highly homologous to the yeast GCN5

<sup>&</sup>lt;sup>12</sup> Liu, Y.; Wang, X.; Zhang, J.; Huang, H.; Ding, B.; Wu, J.; Shi, Y. Biochemistry, 2008, 47, 6403–6417.

(yGCN5),<sup>13</sup> and as an acetyl-lysine reader through its conserved bromodomain located directly C-terminal to the HAT domain.<sup>14,15</sup>

The simultaneous presence of these two domains is a sign of the importance of PCAF and a direct link between transcriptional regulation and chromatin modification. Given the significant role in regulation of gene expression, PCAF has been implicated in numerous types of cancer.

The Hedgehog signaling pathway, that plays an important role in embryonic patterning and development of many tissues and organs as well as in maintaining and repairing mature tissues in adults, has been implicated in developmental abnormalities as well as in several types of cancer, including brain tumors like medulloblastoma and glioblastoma, and PCAF is involved as a cofactor of the genes involved in this pathway.<sup>16</sup>

In addition it has been found that PCAF can acetylate and stabilize overexpressed ATP-citrate lyase that promotes tumor growth of human lung cancers.<sup>17</sup> PCAF has also been found to regulate the stability of  $\beta$ -catenin, which is involved in colorectal tumors.<sup>18</sup> No probes against the bromodomain of PCAF have yet been described; on the contrary the HAT domain of PCAF has been targeted with a number of broad-activity HAT inhibitors. Therefore, given the number of diseases in which PCAF is involved, it is necessary to develop selective inhibitors to treat these pathologies.

In the group where I spent a period of my PhD they are making progress toward the development of PCAF inhibitors, starting from different acetyl lysine bioisosters (Figure 3),

<sup>&</sup>lt;sup>13</sup> Marcus, G.A.; Silverman, N.; Berger, S.L.; Horiuchi, J.; Guarente, L. *EMBO J.* **1994**, *13*, 4807–4815.

<sup>&</sup>lt;sup>14</sup> Marmorstein, R. Cell Mol Life Sci, **2001**, 58, 693–703.

<sup>&</sup>lt;sup>15</sup> Carrozza, M.J.; Utley, R.T.; Workman, J.L. Trends Genet, 2003, 19, 321–327.

<sup>&</sup>lt;sup>16</sup> Malatesta, M.; Steinhauer, C.; Mohamma, F.; Pandey, D. P.; Squatrito, M.; Helin, K. *Cancer Res.* **2013**, *73*, 6323-6333.

<sup>&</sup>lt;sup>17</sup> Lin, R.; Tao, R.; Gao, X.; Li, T.; Zhou, X.; Guan, K. L.; Xiong, Y.; Lei, Q. Y. Mol. Cell. **2013**, *51*, 506–518.

<sup>&</sup>lt;sup>18</sup> Xinjian, G.; Qihuang, J.; Fang, Z.; Tingting, Y.; Qiwei, Z. Mol. Biol. Cell. **2009**, 20, 419–427.



**Figure 3.** Families of compounds to be synthesized against PCAF, the acetyl lysine mimic motif of each structure is highlighted (red).

and the best compound **1** in the different families is reported to have a  $K_D$  of 1.0  $\mu$ M a significantly weak affinity.

However all the molecular portions, the position of the phenyl ring, the length of the chain and the tertiary amine, that could be responsible binding elements, they were simultaneously changed.

The aim of my project was to understand the key binding elements from 1, especially the phenyl residue position, the importance of terminal tertiary amine and the effect of chain; in addition my goal was to try to investigate a range of N-substituents derivatives in order to explore new binding elements and to optimize the terminal H-bond

The measuring of biological activity of potential probes, through biophysical assay [Differential Scanning Fluorimetry (DSF)], was used to guide the optimization process toward a future design of high-affinity PCAF probes.

The synthetic approach of potential PCAF ligands was based on the condensation between different amines and an acetyl lysine mimic, namely the 6-chloro-3-methyl-[1,2,4]triazolo[3,4-a]phthalazine (2), that can be obtained following the procedure reported in the literature<sup>19</sup> (Scheme 1).

<sup>&</sup>lt;sup>19</sup> Xue, D.; Zhang, Y.; Wang, C.; Zhu, N.; Shao, K.; Zhang, X.; Zhang, Z. *Eur. J. Med. Chem.* **2014**, 85, 235-244.



Scheme 1. Synthesis of 2.

Starting from the lead compound 1, several amines were chosen in order to understand the important moieties (Figure 4).



Figure 4 Amines chosen, the modified moieties of each structure are highlighted.

The amines **4-7** were obtained by classical reactions of organic chemistry, because they are either expensive or not commercially available.

The synthesis of amine **4** involved a Michael addition reaction of an opportune Grignard reagent to  $\beta$ -nitrostyrene,<sup>20</sup> followed by nitro group reduction.<sup>21</sup>



(v) THF, -20 °C, 1.1h, 40%; (vi) NiCl<sub>2</sub>·6H<sub>2</sub>O/ NaBH<sub>4</sub>, MeOH, 25 °C, 1h, 90%

Scheme 2 Synthesis of 4.

The *gem*-diamine 5, characterized by the presence of both a primary and secondary amine moiety, was obtained through a Strecker reaction, involving

<sup>&</sup>lt;sup>20</sup> Yao, C.; Kao, K.; Liu, J.; Wang, Y.; Chen, W.; Lin, Y.; Yan, M.; *Tetrahedron* **1998**, *54*, 791–822.

<sup>&</sup>lt;sup>21</sup> Martinelli, E.; Vicini, A. C.; Mancinelli, M.; Mazzanti, A.; Zania, P.; Bernardi, L.; Fochi, M. Chem. Commun. **2015**, *51*, 658-660.

benzaldeyde, methylamine solution and trimethylsilyl cyanide (TMSCN),<sup>22</sup> followed by a nitrile reduction with LiAlH<sub>4</sub> (Scheme 3).



A similar Strecker reaction,<sup>23</sup> followed by alkylation with iodomethane and nitrile group reduction, leads to the amine 6 (Scheme 4).



Finally, to synthesize amine **7** a procedure reported in the literature<sup>24</sup> was followed (**Scheme 5**), but strangely the last step of reported synthetic pathway did not give the desired product.



(*xii*) Me<sub>2</sub>NH, K<sub>2</sub>CO<sub>3</sub>, MeCN, 25 °C, 18h, 88%; (*xiii*) CH<sub>3</sub>ONH<sub>2</sub> · HCl, Pyridine, 25 °C, 12h, 79%; (*xiv*)H<sub>2</sub>, Pd/C, MeOH

Scheme 5. Attempted synthesis of 7.

<sup>&</sup>lt;sup>22</sup> Vongvilai, P.; Linder, M.; Sakulsombat, M.; Svedendahl Humble, M.; Berglund, P.; Brinck, T.; Ramstrm, O. *Angew. Chem., Int. Ed.* **2011**, *50*, 6592–6595.

<sup>&</sup>lt;sup>23</sup> Taylor, H. M.; Hauser, C. R. Organic Syntheses, Coll. Vol. 5, p.437 (1973).

<sup>&</sup>lt;sup>24</sup> Gomtsyan, A.; Bayburt, E.; Keddy, R.; Turner, S.; Jinkerson, T.; Didomenico, S.; Perner, R.; Koenig, J.; Drizin, I.; McDonald, H.; Surowy, C.; Honore, P.; Mikusa, J.; Marsh, Wetter, J.; Faltynek C.; Lee C. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 3894–3899.

Then, in order to obtain 7, a new synthetic approach, involving a reductive amination reaction with ammonium acetate, was developed starting from the ketone 8 (Scheme 6).



The commercial piperazine **3** was the first tested amine and its reaction with **2** was performed in the presence of NaOH, following a procedure reported in the literature<sup>19</sup> (**Table 1**).

Table 1	Optimization	of the coupling	reaction.
---------	--------------	-----------------	-----------



Once again, the reaction, performed by following the literature conditions (entry 1), gave the undesired bifunctionalized **10** as major product in all cases, even by changing some parameters (entries 2–3). Then, to obtain only **9**, a methodology developed by the Dixon's group was followed, using catalytic KI and HCl (entry 4) to form *in situ* a more reactive aryl iodide. Under these conditions, the substitution

reaction lead to 9 as the only product from which 11 was obtained through the Eschweiler-Clarke reaction.<sup>25</sup>



Scheme 7. Synthesis of 11.

The same tandem procedure was repeated starting from synthesized amines 4–7 and the expected products 12-15 were obtained as the only products (Table 2).





<sup>&</sup>lt;sup>25</sup> Sahakitpichana, P.; Ruchirawat, S.; *Tetrahedron Lett.* **2003**, *44*, 5239–5241.

Unfortunately, the DSF<sup>26</sup> analysis performed on all obtained compounds (**Figure 4**) suggested a general very low affinity of these compounds for PCAF, only the compound **13** resulting to be better than the lead compound **1**, whose value to cause  $\Delta T_m$  is 1.7 °C.

Average of CompScreen: Tm Shift (C)	Column Labels						
Row Labels	BRD4A	BRD9A	CECR2A	CREBBPA	PCAFA	TAF1A	Grand Total
LT053	0.07	0.4	0.41	-0.48	-0.46	0.53	0.078333333
LT056	1.04	0.97	0.42	0.18	0.05	0.34	0.5
LT074	0.08	1.54	0.53	-0.07	2.13	0.47	0.78
LT077	-0.82	2.56		-0.08	1.01	2.28	0.99
LT101	0.27	0.48	0.37	0.28	0.44	0.31	0.358333333
LT103	0.29	0.43	0.31	0.06	0.71	0.22	0.336666667
	•				••••••	••••••	

Figure 4. Thermal shifts of 11-15.

Encouraged by the results, we decided to create a series of different homologous of **13** generating a library of compounds from which structure-activity relationships (SARs) can be readily explored.

So, we thought that a nucleophilic substitution of a suitable leaving group, such as the methanesulfonate group, with different primary amines could be a simple and quick methodology to obtain different compounds (Schema 8).



Schema 8. Synthesis of 17 followed by mesylation reaction.

However during the mesylation of the hydroxylic group of 17, formed through  $S_{NAr}$  coupling reaction between 2 and phenylethanolamine (16), the expected product undergoes a very fast nucleophilic intramolecular attack, giving 18 as major compound.

<sup>&</sup>lt;sup>26</sup> DSF is an inexpensive and rapid screening method to detect low-molecular-weight ligand interactions promoting protein stability: Niesen, F. H.; Berglund, H.; Vedadi, M. *Nat. Protoc.* **2007**, *2*, 2213.

Therefore, we attempted to convert the amino alcohol **16** in the corresponding cyclic sulfamidate, which, used in its asymmetric version,<sup>27</sup> could moreover provide enantioenriched products after ring-opening reaction.

But once again, following the classical mesylation procedure (**Scheme 9**),<sup>26</sup> the reaction did not occur and only a complete crude mixture was obtained.



Scheme 9. Attempted synthesis of cyclic sulfamidate.

Then, we decided to completely change the synthetic strategy and, after oxidation of **16**, a reductive amination finally gave the synthetic targets in good yield (**Scheme 10**).



Scheme 10. Synthesis of 20-27.

Given the relevance of H-bond donors and acceptors in the pocket, the reductive amination was used to obtain the primary amine 28 allowing also the

<sup>&</sup>lt;sup>27</sup>Moss, T. A.; Alonso, B.; Fenwick, D. R.; Dixon, D. J. Angew. Chem. **2010**, 122, 578–581; Angew. Chem., Int. Ed. **2010**, 49, 568–571.

derivatization of the terminal position with alternative H-bond donors and acceptors (Scheme 11).



Scheme 11. Synthesis of 28-32.

In conclusion a series of potential epigenetic probe was generated and to date biophysical assay are currently underway to test the affinity with the bromodomanin module of PCAF.

# **Chapter 9**

## **Conclusions**

In this thesis the reactivity of N-protected trifluoromethyl (E)-aldimines towards different active methylene compounds in the Mannich-type and aza-Reformatsky reactions was studied.

At first, suitable trifluoromethyl aldimines were reacted with  $\beta$ -dicarbonyl compounds, including diethyl malonate and several  $\beta$ -keto esters. The presence of a trifluoromethyl group, lowering both nitrogen basicity and carbon electrophilicity of the imine C=N group, greatly affects the Mannich-type addition of  $\beta$ -dicarbonyl compounds. In fact, the most common organic or inorganic bases, such as some organocatalysts (cinchonidine, L-proline or their derivatives), frequently used to promote Mannich-type reactions between aromatic aldimines and  $\beta$ -dicarbonyl compounds,<sup>1</sup> did not give the expected results.

Excellent results were obtained only through a Lewis acid catalysis, indeed an efficient solvent-free Zr-catalyzed Mannich-type reaction has been developed for the synthesis of fluorinated  $\beta$ -amino  $\beta$ -dicarbonyl compounds starting from *N*protected trifluoromethyl aldimines and cyclic or acyclic  $\beta$ -keto esters bearing different ester residues.

The presence of an alkyl substituent on the nucleophilic carbon and the use of Zr as coordinating metal lead to a high stereoselective control of reactions (Scheme 1).

<sup>&</sup>lt;sup>1</sup> a) Ting, A.; Lou, S.; Schaus, S. E. *Org. Lett.* **2006**, *8*, 2003–2006; b) Song, J.; Shih, H.-W.; Deng, L. *Org. Lett.* **2007**, *9*, 603–606, c) Fini, F.; Bernardi, L.; Herrera, R. P.; Pettersen, D.; Ricci, A.; Sgarzani, V. Adv. Synth. Catal. **2006**, *348*, 2043–2046.



**Scheme 1.** Solvent-free ZrCl<sub>4</sub>-catalyzed Mannich-type reaction of different  $\beta$ -keto esters.

Instead, contrary to what reported in the literature for similar reaction,<sup>2</sup> the ester residue did not affect the reaction outcome: in fact, no difference in reactivity was found by changing the ester moiety.

Then, in order to develop a catalytic asymmetric Mannich-type reaction, failing all attempts using an added chiral catalyst, we successfully developed a new asymmetric Zr-catalyzed Mannich-type reaction at low cost starting from the optically pure aldimine derived by the inexpensive chiral (R)- $\alpha$ -methylbenzylamine. A complete facial and geometric stereoselective induction with formation of a chiral quaternary center was so obtained, the same chiral substrate acting as chiral ligand (**Figure 1**).



Figure 1. Proposed transition state.

<sup>&</sup>lt;sup>2</sup>See ref. 40 in the **Chapter 2**.

The nucleophilic attack takes place only on the sterically less hindered prochiral Re face of optically pure aldimine, giving R,R,S pure diastereometric compounds bearing a quaternary chiral center.

In addition, the diastereoselective catalytic Mannich-type reaction represents, thanks to a diastereoselective decarboxylation reaction of the new obtained  $\beta$ -keto esters, a valid approach to obtain optically active trifluoromethyl  $\beta$ -amino ketones.



Scheme 2. Decarboxylation reaction.

Extending my studies, the interest has been directed towards the possibility to trifluoromethylated 2-imidazolines by synthesize attractive Mannich-type addition/cyclization cascade reaction of  $\alpha$ -isocyano acetates on trifluoromethyl aldimines. Silver(I) oxide is turned out to be a very efficient catalyst for the reaction performed under solvent-free conditions between methyl 2isocyanoacetate (2) and trifluoromethyl aldimines 1a,b (Scheme 3).



Scheme 3. Ag<sub>2</sub>O-catalyzed Mannich-type ractions.

High *cis/trans* stereoselective control was obtained, the reaction affording only *trans* imidazolines **3a,b**.

Subsequently, the study has been extended to the reactivity of  $\alpha$ -isocyano esters bearing a tertiary carbon center. Though the silver(I) catalysis appeared once again to be a good reaction catalyst, the use of dichloromethane as solvent was required and the total loss of geometric selectivity was recorded because of the steric hindrance on the nucleophilic site (**Scheme 4**).



Scheme 4. Ag<sub>2</sub>O-catalyzed Mannich-type reactions.

Excellent stereoselectivity was obtained starting from the trifluoromethyl (*E*)aldimines **1d**,**f** deriving from L- $\alpha$ -amino esters (**Scheme 5**).



Scheme 5. Ag<sub>2</sub>O-catalyzed Mannich-type reactions on 1d-f.

A complete stereoselective control was obtained and the reactions lead to the formation of the only optically pure *trans* isomers. To explain the high diastereoselectivity observed and the stereochemical outcome, a transition state can be proposed (**Figure 2**).



Figure 2. Proposed transition state.
The coordination of the imine ester group to the silver promotes the enolate attack preferentially to the Re imine face, obtaining enantiopure valuable trifluoromethyl imidazolines enriched by an  $\alpha$ -amino ester residue.

As a further and last class of active methylene compounds,  $\alpha$ -bromo esters have been considered in the aza-Reformatsky reactions, always with different trifluoromethyl aldimines.

The reactions were studied under two different conditions: heterogeneous conditions, using activated metal zinc as catalyst, and homogenous conditions, using Et<sub>2</sub>Zn as source of the metal.

Working under heterogeneous conditions, only  $\beta$ -lactams in good yields and high *trans* geometric selectivity were achieved when the reactions were performed starting from  $\alpha$ -bromo esters (**Scheme 6**).



Scheme 6. Aza-Reformatsky reaction under heterogeneous conditions.

However, adding (1R,2S)-1-phenyl-2-(1-pyrrolidinyl)propan-1-ol as chiral ligand no enantioselective control was obtained. Even the presence of a chiral center on the aldimine does not seem able to control the facial attack selectivity.

Then, we moved on to study the homogeneous reaction outcome.

Under optimal conditions, the additions lead to the only  $\beta$ -amino esters, in good isolated yields and high geometric selectivity, the *syn* or *anti* isomer formation depending from the R substituent. In fact, while a complete *syn* selectivity was achieved starting from methyl substituted  $\alpha$ -bromo ester **2b**, the *anti*  $\beta$ -amino ester was obtained starting from phenyl substituted  $\alpha$ -bromo ester **2c** (Scheme 7).



Subsequently, the first example of a convenient enantioselective aza-Reformatsky reaction on trifluoromethyl aldimines has been successfully developed.

Using diethyl zinc and substoichiometric amount of (1R,2S)-1-phenyl-2-(1pyrrolidinyl)propan-1-ol as chiral ligand, trifluoromethyl enantioenriched  $\beta$ -amino esters in good yields and enantioselectivities (up to 91% ee) were synthesized (Scheme 8).



Scheme 8. Enantioselective aza-Reformatsky reaction.

The *S* absolute configuration assigned to C-CF<sub>3</sub> substituted chiral center suggested that the *Si*-face of the coordinate imine was preferentially exposed, as shown in the proposed transition model reported below (**Figure 3**).



**Figure 3.** Proposed transition states in the presence of (1*R*,2*S*)-6.

Finally, in order to investigate how the presence of a further ester group could influence the chemical outcome, the trifluoromethyl aldimine  $1g^3$  derived from  $\beta$ -alanine was considered in the two different approaches (Scheme 9).



Scheme 9. Aza-Reformatsky reactions performed on 1g under homogeneous and heterogeneous condition.

Under heterogeneous conditions, the reactions lead to the expected  $\beta$ -lactams with high chemoselectivity and also high *trans* diastereoselectivity. In addition, corresponding expected  $\beta$ -amino esters were obtained under homogeneous conditions. Confirming our proposed transition states, the presence of an ester group on the  $\beta$  position of imine nitrogen, is responsible for the low or absent enantiocontrol found in the asymmetric aza-Reformatsky reactions.

<sup>&</sup>lt;sup>3</sup> See ref. 54 in the **Chapter 2**.

 $\beta$ -Amino esters, keto esters, and malonates obtained through aza-Reformatsky and Mannich type-reactions respectively, allow to approach, through appropriate chemical transformations, new  $\psi$ [CH(CF<sub>3</sub>)NH]-peptidomimetics. In fact, the [CH(CF<sub>3</sub>)] group is a known isoster of the carbonyl group.

Similarly, the synthesis of bioisoster has been the aim of the project carried out at the University of Oxford (UK) under the supervision of Professor Darren J. Dixon and in collaboration with the SGC (Structural Genomics Consortium).

I have turned the attention on the development of potential epigenetic probes, characterized by a portion of acetyl lysine bioisoster, in order to draw conclusions about the binding elements, which are important for affinity with the bromodomain module of PCAF. A library of 20 compounds was developed and improvements in terms of affinity, compared to the lead compound, were obtained.

Experimental section

#### **General Experimental Methods**

IR Perkin-Elmer 1600 recorded on Series FT/IR spectra were а spectrophotometer in CHCl<sub>3</sub> as the solvent, and reported in . <sup>1</sup>H NMR, <sup>13</sup>C NMR, and <sup>19</sup>F NMR spectra were recorded on a Varian-Mercury 300 instrument and on a Bruker Avance III 400 instrument, and reported in  $\delta$  units. CDCl<sub>3</sub> was used as the solvent and CHCl<sub>3</sub> as the internal standard. ESI MS analyses were performed using a quadrupole-time of flight (Q-TOF) mass spectrometer equipped with an ESI source and a syringe pump. The experiments were conducted in the positive ion mode.

HPLC analyses were performed with a Varian 9001 instrument using an analytical column  $(3.9 \times 300 \text{ mm}, \text{ flow rate } 1.3 \text{ mL/min}; \text{ detector: } 254 \text{ nm})$  equipped with a Varian RI-4 differential refractometer, or a Varian 9050 UV/VIS detector. Eluents were HPLC grade. Enantiomeric excess were determined using analytical high performance liquid chromatography (HPLC) performed on Varian 9001 instrument (column and solvent conditions are given with the compound).

Analytical thin-layer chromatography (TLC) was carried out on precoated (0.25 mm) silica gel plates.

Silica gel 230-400 mesh was used for column chromatography.

#### **Computational details**

All optimized geometries were located using hybrid functional theory (B3LYP) and the 6-31G(d, p) basis set using the continuum solvation model with chloroform ( $\varepsilon = 4.71$ ) as the solvent conforming to the experimental conditions. All calculations were carried out using the Gaussian 09 program.<sup>1</sup>

<sup>&</sup>lt;sup>1</sup> Gaussian 09, Revision D.01, Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery Jr., J. A. J.; Peralta, E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Keith, T.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.;

Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, O.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian, Inc., Wallingford CT, **2013**.

## **Chapter 10**

## <u>Mannich type reactions of 1,3-dicarbonyl compounds with</u> <u>trifluoromethyl aldimines</u>

<u>Synthesis of trifluoromethyl imines (1a-c)</u>. The trifluoromethyl imines were synthesized following a procedure reported in the literature.<sup>1</sup> **1a-c** are known compounds.

#### *General procedure for the ZrCl<sub>4</sub>-Catalyzed Mannich-type reactions.*

To a mixture of trifluoromethyl aldimines **1a-c** (1 mmol) and diethyl malonate (**2**) or  $\beta$ -keto esters **6**, **9-11**, and **15-16** (1 mmol), ZrCl<sub>4</sub> (10 mol %) was added. The reactions were performed under solvent-free conditions and stirred at room temperature for 10-30 min. After H<sub>2</sub>O addition, the crude mixtures were extracted with Et<sub>2</sub>O. The collected organic layers were dried on anhydrous Na<sub>2</sub>SO<sub>4</sub>, the solvent evaporated *in vacuo* and the residues purified by flash chromatography on silica gel (eluent hexane/ethyl acetate = 8:2).

Diethyl2-[1-(benzylamino)-2,2,2-trifluoroethyl]malonate $F_3C$  $CO_2Et$ (3a). Yellow oil (299 mg, 80%). IR: 1748, 1760. <sup>1</sup>H NMR $CO_2Et$  $(CDCl_3)$ : 1.22–1.33 (m, 6H), 2.40 (br, 1H), 3.71 (d, J = 6.0Hz, 1H), 3.86–4.07 (m, 3H), 4.15–4.29 (m, 4H), 7.21–7.31 (m, 5H). <sup>19</sup>F NMR $(CDCl_3)$ :-72.2 (d, J = 7.2 Hz). <sup>13</sup>C NMR (CDCl\_3): 13.8, 13.9, 52.0, 52.3, 58.7 (q, J = 28.4 Hz), 61.8, 62.1, 125.8 (q, J = 286.3 Hz), 127.2, 128.1 (2C), 128.2 (2C),139.2, 166.5, 166.6. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>21</sub>F<sub>3</sub>NO4348.1423, found 348.1424.

<sup>&</sup>lt;sup>1</sup> See ref.17 in the **Chapter 1**.



(s, 3H), 3.82 (d, J = 3.5 Hz, 1H), 4.12 (q, J = 7.1 Hz, 2H), 4.25 (q, J = 7.1 Hz, 2H), 4.61–4.76 (m, 2H), 6.69–6.79 (m, 4H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -74.1 (d, J = 7.2 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 13.8, 13.9, 50.7, 55.6, 57.3 (q, J = 30.2 Hz), 62.1, 62.5, 114.7 (2C), 115.7 (2C), 125.1 (q, J = 284.7 Hz), 139.8, 153.3, 166.0, 167.0. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>21</sub>F<sub>3</sub>NO<sub>5</sub> 364.1372, found 364.1375.

2-[2,2,2-trifluoro-1-{[(R)-1-Diethyl phenylethyl]amino}ethyl]malonate (4/5c). Colorless oil  $CO_2$ Et (263 mg, 73%). IR: 1743, 1751. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.28–1.35 (m, 18H), 2.73 (br, 2H), 3.64 (d, J = 5.1 Hz, 1H), 3.71 (d, J =CO<sub>2</sub>Et 5.1 Hz, 1H), 3.93–4.31 (m, 12H), 7.24–7.34 (m, 10H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -73.4 (d, J = 7.4 Hz), -70.66 (d, J = 7.0 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 13.8, 13.9 (2C), 14.0, 23.6, 25.1, 51.3, 51.7, 55.4, 55.7, 56.4 (q, J = 28.0 Hz), 56.5 (q, J = 28.8 Hz), 61.7, 61.8, 62.0, 62.2, 125.5 (q, J = 284.3 Hz), 126.0 (q, J = 288.4 Hz), 126.8 (2C), 127.1 (2C), 127.2, 127.3, 128.3 (2C), 128.4 (2C), 143.7, 144.7, 166.4, 166.8 (2C), 166.9. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>23</sub>F<sub>3</sub>NO<sub>4</sub> 362.1579, found 362.1582.

Methyl 2-acetyl-3-(benzylamino)-4,4,4-trifluorobutanoate  $F_{3C}$ , T/7'a). Yellow oil (227 mg, 75%). IR: 1740, 1715. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.84 (br, 1H), 2.01 (br, 1H), 2.20 (s, 3H), 2.24 (s, 3H), 3.73 (s, 3H), 3.75 (s, 3H), 3.78 (d, J = 2.1 Hz, 1H), 3.79 (d, J = 3.7 Hz, 1H), 3.82–3.86 (m, 2H), 3.92–4.05 (m, 4H), 7.23–7.34 (m, 10H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): – 72.0 (d, J = 7.2 Hz) –71.9 (d, J = 7.1 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 29.1, 29.8, 52.3 (2C), 52.7, 52.9, 58.0 (q, J = 28.6 Hz), 58.6, 58.9 (q, J = 28.1 Hz), 59.4, 127.3, 127.4, 127.5 (q, J = 282.5 Hz, 2C), 128.3 (4C), 128.4 (4C), 138.8, 139.1, 167.2, 167.5, 198.8, 199.8. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>17</sub>F<sub>3</sub>NO<sub>3</sub> 304.1161, found 304.1165.

 Ph
 NH
 O
 Methyl
 (Z)-3-(benzylamino)but-2-enoate
 (8).
 Colorless
 oil

 (68%).
 IR:
 1740,
 1650.
 <sup>1</sup>H
 NMR
 (CDCl<sub>3</sub>):
 1.93
 (s,
 3H),
 3.65

 (s,
 3H),
 4.44
 (d,
 J = 6.4 Hz,
 2H),
 4.55
 (s,
 1H),
 7.22–7.42
 (m,
 5H),
 8.95
 (br,
 1H).

 <sup>13</sup>C
 NMR
 (CDCl<sub>3</sub>):
 19.4,
 46.8,
 50.0,
 82.8,
 126.7
 (2C),
 127.3,
 128.8
 (2C),
 138.7,

 161.9,
 179.8.
 HR-MS
 (ESI Q-TOF)
 (m/z) [M + H]<sup>+</sup> calcd for C<sub>12</sub>H<sub>16</sub>NO<sub>2</sub> 206.1181,
 found
 206.1203.



Ethyl2-acetyl-3-(benzylamino)-4,4,4-trifluoro-2-methylbutanoate(12/12'a). Red oil (215 mg, 65%). IR:1743, 1720. <sup>1</sup>H NMR (CDCb): 1.21–1.28 (m, 6H), 1.40 (s,3H, minor syn isomer), 1.48 (s, 3H, major anti isomer), 1.83

(br, 2H), 2.18 (s, 6H), 3.79–3.85 (m, 2H), 4.07–4.30 (m, 7H), 4.38 (q, J = 7.3 Hz, 1H), 7.26–7.34 (m, 10H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): –65.60 (d, J = 7.6 Hz, minor syn isomer), –65.4 (d, J = 7.0 Hz, major anti isomer). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 13.4, 13.8, 13.9, 15.5, 25.8, 26.3, 52.7, 53.1, 61.9, 62.1, 62.2 (q, J = 26.6 Hz), 62.3, 62.6 (q, J = 26.7 Hz), 63.2, 126.0 (q, J = 288.6 Hz), 126.2 (q, J = 288.2 Hz), 127.3, 127.5, 128.0 (2C), 128.2 (2C), 128.3 (2C), 128.4 (2C), 138.8, 139.3, 169.4, 169.5, 200.7, 202.2. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>21</sub>F<sub>3</sub>NO<sub>3</sub> 332.1474, found 332.1570.



## 2-acetyl-4,4,4-trifluoro-3-(4-

methoxyphenylamino)-2-methylbutanoate (12/12'b). Red oil (236 mg, 68%). IR: 1750, 1729. <sup>1</sup>H NMR (CDCb): 1.16 (t, J = 7.1 Hz, 3H, major *anti* isomer),

1.25 (t, J = 7.0 Hz, 3H, minor syn isomer), 1.54 (s, 3H, syn isomer), 1.56 (s, 3H, major *anti* isomer), 2.19 (s, 6H), 3.73 (s, 6H), 4.02–4.27 (m, 6H), 4.76–4.87 (m,

Ethyl

1H, major *anti* isomer), 4.92–5.03 (m, 1H, minor *syn* isomer), 6.67–6.78 (m, 8H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -67. 3 (d, J = 7.4 Hz, minor *syn* isomer), -67.6 (d, J = 8.0 Hz, major *anti* isomer). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 13.7, 13.8, 15.1, 16.4, 26.2, 26.5, 55.5 (2C), 58.7 (q, J = 28.4 Hz), 59.8 (q, J = 28.2 Hz), 61.3 (2C), 62.0, 62.3, 114.7 (2C), 114.8 (2C), 115.2 (2C), 115.5 (2C), 125.3 (q, J = 286.9 Hz), 125.4 (q, J = 286.5Hz), 139.3, 139.6, 153.2, 153.4, 169.5, 169.6, 201.8, 202.0. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>21</sub>F<sub>3</sub>NO<sub>4</sub> 348.1423, found 348.1425.

1-[1-(benzylamino)-2,2,2-trifluoroethyl]-2-Ethyl Ph' 'NH О oxocvclopentanecarboxvlate (13/13'a). Red oil (257 mg, 75%). F<sub>3</sub>C IR: 1758. 1725. <sup>1</sup>H NMR (CDCb): 1.21–1.31 (m, 6H), 1.59 (br, EtO<sub>2</sub>C 2H), 1.98-2.05 (m, 6H), 2.17-2.76 (m, 6H), 3.78-4.09 (m, 4H), 4.12-4.41 (m, 6H), 7.24–7.34 (m, 10H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -65.25 (d, J = 8.4 Hz, minor syn isomer), -65.5 (d, J = 8.4 Hz, major *anti* isomer). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 13.8, 13.9, 19.5, 20.2, 27.0, 27.1, 37.2, 38.5, 52.7, 54.2, 62.0, 62.2 (q, J = 26.5 Hz, 2C), 62.2, 63.1, 64.5, 125.9 (q, J = 287.6 Hz, 2C), 127.3, 127.4, 128.0 (4C), 128.3 (4C), 139.0, 139.3, 166.7, 166.8, 210.1, 210.4. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>F<sub>3</sub>NO<sub>3</sub> 344.1474, found 344.1471.



Ethyl

#### 2-oxo-1-[2,2,2-trifluoro-1-(4-

methoxyphenylamino)ethyl]cyclopentanecarboxylate

(13/13'b). Brown oil (262 mg, 73%). IR: 1762, 1759. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.04 (t, J = 7.1 Hz, 3H, major *anti* isomer), 1.23 (t, J = 7.1 Hz, 3H, minor *syn* isomer), 1.93–2.47 (m,

10H), 2.54–2.83 (m, 2H), 3.54 (br, 1H), 3.74 (s, 6H), 3.85 (br, 1H), 3.90–4.04 (m, 2H), 4.10–4.25 (m, 2H), 4.82–4.96 (m, 2H), 6.69–6.78 (m, 8H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): –69.9 (d, J = 7.2 Hz, minor syn isomer), –68.37 (d, J = 7.0 Hz, major anti isomer). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 13.7, 13.9, 19.5, 20.0, 27.2, 28.2, 37.1, 38.3, 55.6 (2C), 59.7 (q, J = 28.1 Hz), 61.0 (q, J = 27.7 Hz), 62.0, 62.3, 62.5, 63.9, 114.7 (4C), 115.7 (2C), 116.4 (2C), 125.1 (q, J = 285.9 Hz), 125.6 (q, J = 286.6 Hz), 139.5, 139.9, 153.5,

153.8, 166.4, 167.2, 209.4, 210.7. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>F<sub>3</sub>NO<sub>4</sub> 360.1423, found 360.1427.

Ethyl 1-[1-(benzylamino)-2,2,2-trifluoroethyl]-2oxocyclohexanecarboxylate (14a). White oil (278 mg, 78%). IR: 1743, 1729.<sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.21 (t, J = 7.1 Hz, 3H), 1.64–1.94 (m, 6H), 2.36–2.52 (m, 3H), 3.73–4.10 (m, 2H), 4.13–4.28 (m, 3H), 7.22–7.33 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -63.8 (d, J = 7.8 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 13.8, 21.9, 25.9, 30.9, 40.7, 52.8, 61.6 (q, J = 27.4 Hz), 61.9, 64.3, 126.0 (q, J =288.7 Hz), 127.3, 128.1 (2C), 128.3 (2C), 139.1, 168.5, 203.8. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>23</sub>F<sub>3</sub>NO<sub>3</sub> 358.1630, found 358.1635.



Ethyl

#### 2-oxo-1-[2,2,2-trifluoro-1-(4-

#### methoxyphenylamino)ethyl]cyclohexanecarboxylate

(14b). White oil (317 mg, 85%). IR: 1745, 1728. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.11 (t, J = 7.1 Hz, 3H), 1.63–2.03 (m, 6H), 2.42–2.54 (m, 3H), 3.73 (s, 3H), 3.97 (q, J = 7.2 Hz, 1H),

4.08 (q, J = 7.1 Hz, 1H), 4.83–4.91 (m, 1H), 6.66–6.76 (m, 4H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -67.0 (d, J = 7.5 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 13.7, 22.0, 26.2, 31.4, 40.8, 55.7, 58.9 (q, J = 29.1 Hz), 62.2, 63.8, 114.8 (2C), 115.3 (2C), 125.1 (q, J = 286.2 Hz), 139.8, 153.3, 168.3, 203.9. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>23</sub>F<sub>3</sub>NO<sub>4</sub> 374.1579, found 374.1571.



22.7, 23.1, 24.7, 24.8, 28.7, 29.3, 29.9, 30.9, 52.5, 52.7 (2C), 52.9, 55.3, 55.4, 55.6 (q, J = 26.3 Hz), 55.7 (2C), 55.7 (q, J = 27.8 Hz), 56.6 (q, J = 28.3 Hz), 56.7 (q, J = 27.7 Hz), 57.6, 58.2, 59.0, 59.1, 125.6 (q, J = 277.4 Hz), 126.0 (q, J = 288.1 Hz), 126.6 (2C), 126.7 (2C), 127.1 (q, J = 284.4 Hz), 127.2 (q, J = 280.4 Hz), 127.3 (2C), 127.4 (4C), 127.6 (2C), 128.3 (2C), 128.4 (4C), 128.5 (2C), 143.1, 143.2, 144.7, 144.8, 167.3, 167.5, 167.7, 167.8, 199.0, 199.1, 200.4 (2C). HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>19</sub>F<sub>3</sub>NO<sub>3</sub> 318.1317, found 318.1312.

Ph NH O  $\overline{F_3C}$  CO<sub>2</sub>Et Ethyl (2*S*,3*R*)-2-acetyl-4,4,4-trifluoro-2-methyl-3-{[(*R*)-1phenylethyl]amino}butanoate (19). Light yellow oil (234 mg, 68%). [ $\alpha$ ]<sub>D</sub> = +86.0 (*c* = 1 g/100 mL, CHCl<sub>3</sub>). IR: 1742, 1726. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.28–1.31 (m, 6H), 1.46 (s, 3H), 1.97

(br, 1H), 2.22 (s, 3H), 4.04 (q, J = 6.2 Hz, 1H), 4.18 (q, J = 7.1 Hz, 1H), 4.29 (q, J = 7.1 Hz, 1H), 4.36 (q, J = 8.1 Hz, 1H), 7.22–7.32 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): – 65.0 (d, J = 8.5 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 13.9, 15.3, 21.6, 26.6, 55.5, 59.1 (q, J = 26.7 Hz), 62.1, 63.2, 126.0 (q, J = 288.4 Hz), 126.5 (2C), 127.4, 128.5 (2C), 145.5, 169.4, 202.2. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>23</sub>F<sub>3</sub>NO<sub>3</sub> 346.1630, found 346.1633.



Ethyl (1*S*)-2-oxo-1-[(1*R*)-2,2,2-trifluoro-1-{[(*R*)-1phenylethyl]amino}ethyl]cyclopentanecarboxylate (20). Light yellow oil (278 mg, 78%). [ $\alpha$ ]<sub>D</sub> = +54.0 (*c* = 1 g/100 mL, CHCl<sub>3</sub>). IR: 1731, 1718. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.23–1.28 (m, 6H), 1.60 (br, 1H), 1.85–1.96 (m, 3H), 2.12–2.23 (m, 1H), 2.19–2.28

(m, 1H), 2.59–2.63 (m, 1H), 3.96 (q, J = 6.5 Hz, 1H), 4.15 (q, J = 7.1 Hz, 1H), 4.21 (q, J = 7.1 Hz, 1H), 4.29 (q, J = 7.3 Hz, 1H), 7.16–7.29 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -65.0 (d, J = 8.5 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 14.0, 19.6, 21.6, 27.2, 37.2, 55.3, 59.2 (q, J = 26.3 Hz), 62.3, 64.5, 126.5 (2C), 126.9 (q, J = 288.4 Hz), 127.5, 128.6 (2C), 146.4, 166.8, 210.0. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>23</sub>F<sub>3</sub>NO<sub>3</sub> 358.1630, found 358.1636.



Ethyl (1S)-2-oxo-1-[(1R)-2,2,2-trifluoro-1-{[(R)-1-

phenylethyl]amino}ethyl]cyclohexanecarboxylate (21).

Colorless oil (289 mg, 78%).  $[\alpha]_D = +79.0$  (c = 1 g/100 mL, CHCl<sub>3</sub>). IR: 1740, 1715. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.26–1.30 (m, 6H),

1.57–1.67 (m, 3H), 1.84–1.99 (m, 4H), 2.37–2.41 (m, 1H), 2.52–2.65 (m, 1H), 4.02 (q, J = 7.1 Hz, 1H), 4.20 (q, J = 7.1 Hz, 1H), 4.22 (q, J = 7.2 Hz, 1H), 4.31 (q, J = 7.2 Hz, 1H), 7.23–7.33 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -65.0 (d, J = 8.5 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 13.9, 21.5, 22.1, 25.7, 30.3, 40.9, 55.2, 58.2 (q, J = 26.6 Hz), 61.9, 64.3, 126.4 (q, J = 287.8 Hz), 126.5 (2C), 127.4, 128.5 (2C), 146.6, 168.4, 203.6. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>25</sub>F<sub>3</sub>NO<sub>3</sub> 372.1787, found 372.1785.

# $\begin{array}{c|ccccc} tert-Butyl & 2-acetyl-4,4,4-trifluoro-3-\{[(R)-1-phenylethyl]amino\}butanoate & (anti-22,23/syn-22',23'). \\ \hline Ph & Ph & Ph & Phenylethyl]amino}butanoate & (anti-22,23/syn-22',23'). \\ \hline Ph & Colorless & oil (233 mg, 65\%). IR: 1737, 1712. ^1H & NMR & (CDCl_3): 1.48-1.58 (m, 52H), 2.04 (s, 3H), 2.07 (s, 3H), \\ \end{array}$

2.29–2.30 (m,6H), 3.50– 3.73 (m, 6H), 3.99–4.08 (m, 6H), 7.26–7.36 (m, 20H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): –70.1 (d, J = 8.6 Hz), –70.50 (d, J = 7.7 Hz), –72.21 (d, J = 8.5 Hz), –72.83 (d, J = 7.5 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 22.6, 23.3, 24.9, 25.5, 27.6 (2C), 27.8 (12C), 28.3 (2C), 54.6, 55.3, 55.4, 55.6, 56.1 (q, J = 28.0 Hz), 56.3 (q, J = 27.5 Hz), 56.4 (q, J = 30.0 Hz), 56.5 (q, J = 28.0 Hz), 59.2, 59.7, 59.9, 60.5, 82.8, 82.9, 83.0, 83.1, 125.7 (q, J = 278.8 Hz), 125.8 (q, J = 279.8 Hz), 125.9 (q, J = 285.5 Hz), 126.1 (q, J = 288.5 Hz), 126.7 (2C), 126.9 (2C), 127.0 (2C), 127.3 (2C), 127.4, 127.5, 127.6 (2C), 128.4 (4C), 128.5 (2C), 128.7 (2C), 143.0, 143.4, 143.8, 144.8, 165.9, 166.1, 166.7, 166.8, 199.7, 199.8, 200.5, 200.8. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> cakd for C<sub>18</sub>H<sub>25</sub>F<sub>3</sub>NO<sub>3</sub> 360.1787, found 360.1789.

*tert*-Butyl (2S,3R)-2-acetyl-4,4,4-trifluoro-2-methyl-3-{[(R)-1-Ph NH O F<sub>3</sub>C  $F_3$ C  $F_3$ C phenylethyl]amino}butanoate (24). Yellow oil (238 mg, 1719. <sup>1</sup>H NMR (CDCb): 1.25 (d, J = 6.4 Hz, 3H) 1.34 (s, 3H), 1.40 (s, 9H), 1.95 (br, 1H), 2.15 (s, 3H), 3.98 (q, J = 6.4 Hz, 1H), 4.15-4.24 (m, 1H), 7.14–7.26 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -64.3 (d, J = 6.3 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 15.8, 21.4, 26.5, 27.7 (3C), 55.3, 59.5 (q, *J* = 26.5 Hz), 63.6, 82.7, 126.1 (q, J = 288.9 Hz), 126.4 (2C), 127.2, 128.4 (2C), 146.5, 168.4, 202.6. HR-MS (ESI O-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>27</sub>F<sub>3</sub>NO<sub>3</sub> 374.1943 found 374.1941.



 $(3R,4R)-5,5,5-trifluoro-3-methyl-4-{[(R)-1 phenylethyl]amino}pentan-2-one (25). Yellow oil (75 mg,$  $F_3C <math>43\%$ ). [ $\alpha$ ]<sub>D</sub> = +72.0 (c = 1 g/100 mL, CHCl<sub>3</sub>). IR: 1715. <sup>1</sup>H MR (CDCb): 1.19 (d, J = 7.1 Hz, 3H), 1.26 (d J = 6.4 Hz,

3H), 1.51 (br, 1H), 2.15 (s, 3H), 2.76–2.83 (m, 1H), 3.60–3.67 (m, 1H), 3.91 (q, J =6.4 Hz, 1H), 7.20–7.29 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -72.3 (d, J = 8.9 Hz). <sup>13</sup>C NMR (CDCb): 11.1, 23.3, 28.6, 46.4, 55.6, 56.4 (q, J = 27.0 Hz), 126.8 (2C), 127.4, 127.7 (q, J = 245.8 Hz), 128.5 (2C), 144.7, 208.8. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>19</sub>F<sub>3</sub>NO 274.1419, found 274.1421.

## General procedure for the AlCl<sub>3</sub>-Catalyzed Mannich-type reactions of $\beta$ -keto ester 9 with aldimine 1c.

To a mixture of trifluoromethyl aldimines 1c (1 mmol) and  $\beta$ -keto esters 9 (1 mmol), AlCl3 (10 mol %) was added. The reaction was performed under solventfree conditions and stirred at room temperature for 30 min. After  $H_2O$  addition, the crude mixtures were extracted with Et2O. The collected organic layers were dried on anhydrous Na<sub>2</sub>SO<sub>4</sub>, the solvent evaporated *in vacuo* and the residues purified by flash chromatography on silica gel (eluent hexane/ethyl acetate = 8:2).



3H), 2.22 (s, 3H), 2.32 (s, 3H), 3.89–4.39 (m, 16H), 7.22–7.35 (m, 20H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -63.3 (d, J = 7.0 Hz), -63.54 (d, J = 6.7 Hz), -64.99 (d, J = 8.3 Hz), -65.22 (d, J = 6.8 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 13.6, 13.7, 13.8, 13.9, 14.2, 15.2, 16.5 (2C), 21.3 (2C), 21.6 (2C), 24.3, 24.8, 26.1, 26.4, 53.1, 55.3, 55.5, 55.8, 59.0 (q, J = 27.3 Hz), 59.1 (q, J = 26.6 Hz), 60.0 (q, J = 26.6 Hz), 60.8 (q, J = 26.3 Hz), 61.9, 62.0, 62.2 (2C), 62.6 (3C), 63.2, 125.8 (q, J = 280.8 Hz ), 125.9 (q, J = 267.5 Hz ), 125.9 (q, J = 288.1 Hz ), 126.4 (2C), 127.0 (2C), 127.4 (4C), 127.7 (2C), 128.0 (2C), 128.3 (2C), 128.4 (2C), 128.6 (4C), 127.7 (q, J = 245.8 Hz), 142.8, 143.4, 145.2, 145.5, 169.4 (2C), 169.8, 169.9, 201.2, 201.3, 202.4, 202.6. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>23</sub>F<sub>3</sub>NO<sub>3</sub> 346.1630 found 346.1623.

## 2D NMR spectra and optimized geometries to determine the absolute configuration of the new chiral centers.

1. To determine the absolute configuration of the new trifluoromethyl substituted chiral-center ( $C_{\beta}$ ), 2D NMR spectra and optimized geometries of  $\beta$ '-amino  $\beta$ -dicarbonyl compound **24** was considered.



2D NMR spectra and optimized geometries of 24

Figure 1. 2D NOESY spectrum of 24.

The cross peak between the protons  $H_b$  and  $H_c$  was used as a distance ruler and its volume was set to 10.00 a.u.; the cross peak between  $H_b$  and  $H_a$  was measured 1.55 a.u. (corresponding to an interproton distance of 3.62 Å), in order to determine the absolute configuration.



**Figure 2.** Optimized geometries of all possible diastereomers. By NOESY analysis coupled with computational studies the *R* absolute configuration can be assigned to  $C_{\beta}$ 

Calculated Coordinates:

(R,R,S)					
Center	Atomic	Atomic	Coord	inates (Angs	stroms)
Number	Number	туре	х	Y	Z
1 2 3 4 5 6 7 8 9 10 11 12	7 6 6 6 1 6 6 1 6 8 6 1 1 1 1	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1.353000 2.634923 0.231243 -1.117646 0.511232 0.073892 -1.441875 -2.865231 -0.600533 -1.071981 -1.00374 -0.194811	1.281210 1.445779 0.578607 0.914567 -0.935341 0.849472 2.440723 2.872160 3.274706 0.539603 -0.541088 0.994347	0.374545 0.369280 0.257404 0.484439 -0.281814 -1.310867 0.389550 0.684341 0.102997 1.983105 2.104431 2.446201
13 14	6 8	0	-2.278150	0.247562 0.492086	-0.298806
15 16 17 18 19 20 21	8 6 6 6 1		-3.038662 -4.207689 -3.733754 -5.257150 -4.715811 -3.364603	-0.528972 -1.283163 -2.270561 -0.302849 -2.01815 -1.75216	0.469784 -0.065690 -1.133846 -0.592669 1.174932 -2.019084
20 21	1 1	0 0	-3.364603 -4.572380	-1.75216 -2.909560	-2.01908 -1.42674

22 223 225 227 229 331 333 335 37 339 412 445 447 450 447 490 512 52	199916616161611611111111111111		$\begin{array}{c} -2.938509\\ 0.914712\\ 1.469300\\ -0.583459\\ 1.009073\\ 3.650213\\ 4.530156\\ 4.468211\\ 5.496458\\ 6.164617\\ 5.601617\\ 6.352222\\ 4.729534\\ 4.799334\\ 3.766839\\ 3.080078\\ 3.052143\\ 2.472565\\ 2.154168\\ 3.414766\\ 1.730530\\ -1.967867\\ -3.399926\\ -2.852409\\ -3.406698\\ -4.895210\\ -5.529449\\ -5.529449\\ -3.943714\\ -5.589010\\ -5.006395\end{array}$	$\begin{array}{c} -2.908240 & -0.739137 \\ -1.426436 & 0.905353 \\ -1.231893 & -1.18866 \\ -1.653149 & -0.647891 \\ 2.221562 & 0.535895 \\ 0.345746 & -0.037899 \\ -0.181004 & -0.991362 \\ 0.136904 & -2.026467 \\ -1.125954 & -0.634165 \\ -1.522293 & -1.393812 \\ -1.560287 & 0.686400 \\ -2.294445 & 0.964846 \\ -1.041666 & 1.647458 \\ -1.372365 & 2.680247 \\ -0.100539 & 1.287030 \\ 0.290652 & 2.030027 \\ 2.358590 & 0.077756 \\ 1.743256 & -1.868307 \\ 0.863492 & -2.433473 \\ 2.095842 & -2.296937 \\ 2.534912 & -2.008778 \\ 0.877623 & 2.506345 \\ 2.181477 & 1.338202 \\ 3.873062 & 1.118320 \\ 2.919852 & -0.266848 \\ 0.232370 & -1.470620 \\ 0.420705 & 0.181669 \\ -0.857538 & -0.868492 \\ -2.680225 & 1.576588 \\ -2.622905 & 0.914945 \\ -1.308683 & 1.954920 \\ \end{array}$
---	--------------------------------	--	--	---

### (R,S,R)

Center	Atomic	Atomic		Coordinates	(Angstrom)
Number	Number	Type		X	Y Z
$1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 9 \\ 20 \\ 22 \\ 23 \\ 25 \\ 26 \\ 27 \\ 29 \\ 30 \\ 13 \\ 23 \\ 34 \\ 35 \\ 35 \\ 35 \\ 35 \\ 35 \\ 35 \\ 3$	76661668688666166161616161111111		$\begin{array}{c} -1.357758\\ -2.737391\\ -0.161322\\ 1.027518\\ -0.326339\\ 0.196281\\ 0.506876\\ 0.036108\\ 0.544968\\ 2.235864\\ 3.377847\\ 1.855242\\ 3.759187\\ 1.855242\\ 3.759187\\ 1.855242\\ 3.77947\\ 1.855242\\ 3.77947\\ 1.855242\\ 3.759187\\ -3.594969\\ 1.926260\\ -1.273111\\ -2.971902\\ -2.735238\\ -2.360108\\ -2.972016\\ -2.782174\\ -3.454846\\ -3.644447\\ -3.697350\\ -4.078726\\ -3.456342\\ -3.649128\\ -3.56209\\ -3.219497\\ -2.687255\\ -4.287393\\ -3.080605\\ -0.696248\\ -0.401138\\ 0.886536\end{array}$	$\begin{array}{c} -1.547574\\ -1.227190\\ -1.002971\\ -1.130858\\ 0.055219\\ -1.621553\\ -0.611060\\ 0.821188\\ -1.345084\\ -0.246981\\ -0.531952\\ 0.861662\\ 1.164273\\ 2.496152\\ 2.866530\\ -2.549523\\ 0.277920\\ 1.021414\\ 0.530388\\ 2.398061\\ 2.954415\\ 3.055559\\ 4.124525\\ 2.327540\\ 2.827021\\ 0.953578\\ 0.392318\\ -1.580920\\ -2.000065\\ -1.723840\\ -1.818905\\ -3.075034\\ 1.083477\\ 0.959412\\ 1.501451\end{array}$	0.569733 0.117875 0.044267 0.971198 0.246899 2.46899 2.482677 3.327657 0.577982 0.878236 -0.071816 -1.607990 0.557829 -1.297122 0.706910 0.036463 -1.129193 -2.019906 -1.160270 -2.073611 -0.028180 -0.055476 1.138604 2.077304 0.951382 -1.282992 -0.96802 1.717574 3.472275 2.370226

36 37 38 39 40 41 42 43 44 45 46 47 48 50 51 52	9 9 6 1 1 1 1 1 1 1 1 1 1 1 1 1	$\begin{array}{c} -0.522373\\ -0.054337\\ 1.499142\\ 2.832733\\ 1.359755\\ 2.531503\\ 1.219468\\ 3.172176\\ 4.420529\\ 4.370368\\ 2.899188\\ 4.237466\\ 4.2182766\\ 4.2182766\\ 1.516452\\ 1.915510\\ 0.706474\\ 2.305542\end{array}$	$\begin{array}{c} -1.057478\\ -2.949735\\ -1.458361\\ 1.850528\\ 2.391514\\ 3.669945\\ 3.306671\\ 0.640254\\ 0.449888\\ 1.921739\\ 2.946779\\ 3.291862\\ 1.768164\\ -2.578072\\ -2.976366\\ -3.221009\\ -2.607223\end{array}$	-2.421792 -1.454945 -1.756726 -0.601249 -2.103088 -1.726287 -0.588057 -2.367216 -1.117299 -2.108129 1.272439 0.168112 1.077371 1.148035 0.214741 1.497136 1.897568

(R,R,R)

Center Number	Atomic Number	Atomic Type	x	Coordinates Y	(Angstroms) Z
$\begin{array}{c} 1\\ 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 9\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ 48\end{array}$	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6		4.364189 5.374628 4.129563 2.981107 3.117385 1.632525 0.444864 -0.317848 -1.675542 -1.406783 -2.382213 -2.52407 1.644334 0.380646 1.628871 -2.3822407 1.644334 0.380646 1.628871 -2.871403 0.489555 -2.682616 -2.344597 -2.871403 -2.871403 -2.583139 -0.442473 -0.5626155 -4.418346 -2.409387 -2.4521555 -1.332144 -3.1241688 -2.241368 0.507556 -2.4521555 -1.332144 -3.1241688 -2.241368 0.507556 -2.4521555 -1.332144 -3.1241688 -2.465822 6.246339 4.049542 1.537299 1.7652433 2.75709 -3.665299 -2.775701 -2.3642533 -2.815344 -1.362484 -3.68480	1. $189489$ 0. $394555$ -0. $994514$ -1. $570876$ -0. $781221$ 0. $607359$ -1. $487461$ -0. $624902$ -0. $088201$ 0. $474218$ 1. $687834$ 2. $599583$ 3. $726103$ -2. $357673$ 0. $933748$ 0. $539159$ 1. $051073$ 2. $181468$ 0. $858813$ -0. $572208$ -1. $859894$ -2. $571300$ -2. $950216$ 4. $273644$ 4. $349611$ 3. $384539$ 0. $048692$ 1. $629859$ -2. $654360$ -2. $188920$ -1. $629859$ -2. $654360$ -2. $188920$ -1. $762000$ -3. $064080$ -2. $945542$ 1. $055787$ 0. $064589$ 1. $76363$ -3. $944105$ -2. $600812$ -3. $035914$ -2. $850689$ -1. $122193$	$\begin{array}{c} -0.795717\\ -0.949026\\ -0.862977\\ -0.618485\\ -0.442337\\ -0.548181\\ -0.214327\\ -0.310054\\ 0.797005\\ 0.239694\\ -0.691771\\ -0.623172\\ -1.515894\\ 1.0524300\\ 1.735659\\ 2.963999\\ 2.904362\\ 1.221785\\ 1.352993\\ -0.724749\\ -0.320302\\ -1.860348\\ -1.424018\\ 1.484564\\ -0.306626\\ 1.022005\\ -1.449777\\ -1.303850\\ -1.324475\\ -2.552627\\ -1.065530\\ -0.443103\\ -0.870227\\ -1.141397\\ -0.992760\\ -0.573951\\ -1.056859\\ 1.958268\\ 1.002618\\ -0.573951\\ -1.056859\\ 1.958268\\ 1.006137\\ 1.30591\\ 0.922328\\ 2.093415\\ 1.870647\\ -1.254624\\ -2.417552\\ -1.501983\\ -0.155515\\ 0.503312\\ -0.53312\\ -0.53515\\ -0.53312\\ -0.53515\\ -0.53312\\ -0.53515\\ -0.53312\\ -0.53515\\ -0.53312\\ -0.53312\\ -0.53515\\ -0.53312\\ -0.53312\\ -0.53515\\ -0.53312\\ -0.53312\\ -0.53312\\ -0.53515\\ -0.53312\\ -0.53312\\ -0.55515\\ -0.53312\\ -0.55515\\ -0.53312\\ -0.55515\\ -0.53312\\ -0.55515\\ -0.53312\\ -0.55515\\ -0.53312\\ -0.55515\\ -0.53312\\ -0.55515\\ -0.53312\\ -0.55515\\ -0.53312\\ -0.55515\\ -0.53312\\ -0.55515\\ -0.53312\\ -0.55515\\ -0.53312\\ -0.55515\\ -0.55312\\ -0.55515\\ -0.53312\\ -0.55515\\ -0.55312\\ -0.55515\\ -0.55312\\ -0.55515\\ -0.55312\\ -0.55515\\ -0.55312\\ -0.55515\\ -0.55312\\ -0.55515\\ -0.55312\\ -0.55515\\ -0.55312\\ -0.55515\\ -0.55312\\ -0.55515\\ -0.55312\\ -0.55515\\ -0.55312\\ -0.55312\\ -0.55515\\ -0.55312\\ -0.55312\\ -0.55515\\ -0.55312\\ -0.55312\\ -0.55515\\ -0.55312\\ -0.55515\\ -0.55312\\ -0.55515\\ -0.55312\\ -0.55515\\ -0.55312\\ -0.55515\\ -0.55515\\ -0.55312\\ -0.55515\\ -0.55515\\ -0.55312\\ -0.55515\\ -0.55515\\ -0.55515\\ -0.55515\\ -0.55515\\ -0.55515\\ -0.55515\\ -0.555$
5Ŏ	ī	ŏ	-2.914923	-3.531289	1.169846

51	1	0	-1.337074	-2.773881	1.031340
52	1	0	-2.660475	-1.947113	1.882333

(R,S,S)

Center Number	Atomic Number	Atomic Type	x	Coordinates Y	(Angstroms) Z
Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 4 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 41 42 43 34 45 36 37 38 39 40 41 42 43 34 45 36 37 38 39 40 41 42 43 34 45 36 37 38 39 40 41 42 43 34 45 36 37 38 39 40 41 42 43 34 45 36 37 38 39 40 41 42 43 34 45 36 37 38 39 40 41 42 43 34 45 36 37 38 39 40 41 42 43 44 45 46 47 48 48 47 48 48 47 48 48 47 48 48 47 48 48 47 48 47 48 48 48 48 48 47 48 48 48 48 48 47 48 48 48 48 48 48 48 48 48 48	Atomic Number 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	Atomic Type 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	3.022367 3.117871 3.637700 4.050025 3.946591 3.430802 2.670064 2.829155 1.335535 0.191399 -0.499815 -0.123349 -0.803303 -0.058746 -2.000101 -3.131012 -1.590159 -2.518217 -3.103721 -1.585669 -3.131012 -1.5893401 -1.33613 -2.014019 -1.33613 -2.014019 -1.854869 -0.177619 -2.151416 0.543747 1.109340 2.630302 3.347876 4.269642 4.456715 3.722089 3.336713 2.178075 3.864114 2.583013 -1.122467 -3.131411 -4.269136 -4.175444 -2.303131 -3.685287	Y           1. 192352           0.035683           0.156904           1.391146           2.537378           2.433605           1.338303           1.536212           1.675461           0.835655           1.147072           2.326988           0.811568           0.236222           0.132148           0.073377           1.221643           2.299757           2.993475           3.232094           1.716080           -2.239340           -3.135791           -2.510743           -1.164485           -0.194702           4.079812           0.190421           -2.6498203           3.316849           3.500162           1.45866           -0.731149           -2.065903           -0.8812866           -1.343625           -2.515597           -3.492030           -1.737111           2.698643           3.616447           1.151321           1.057250           2.534435	(Angstroms) Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
50 51 52	1 1 1 1	0 0 0	-3.737427 0.323451 -0.727796 0.787182	2.322304 0.760906 -0.156093 -0.876519	-1.400974 -2.023620 -3.113125 -2.506377

2. In order to determine the absolute configuration of the new quaternary chiral center  $(C_{\alpha})$  of  $\beta$ '-amino  $\beta$ -dicarbonyl compound **24**, and thus also the *syn* or *anti* configuration, a diastereoselective decarboxylation, in which the same high selectivity was retained, was performed (**Scheme 1**), following the procedure reported in the literature.<sup>2</sup> Then, the absolute configuration of  $\alpha$ -methyl substituted carbon in **25** was determined.



Scheme 1. Decarboxylation reaction of 24.

#### 2D NMR spectra and optimized geometries of (R,R,R)- $\beta$ -amino ketone 25



Figure 3. 2D NOESY spectrum of 25.

The cross peak between the protons  $H_b$  and  $H_c$  was used as a distance ruler and its volume was set to 10.00 a.u.; the cross peak between  $H_d$  and  $H_e$  was measured 0.83 a.u. (corresponding to an interproton distance of 4.03 Å), in order to determine the absolute configuration.

<sup>&</sup>lt;sup>2</sup> See ref.40 in the **Chapter 2**.



Figure 4. Optimized geometries of obtained (R,R,R)-25 and of its possible diastereomer (R,R,S).

Calculated Coordinates:

Center Number	Atomic Number	Atomic Type	>	Coordinates	(Angstroms) Z
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	6 6 6 6 6 6 6 9 7 6 6 6 6 6 6 6 6 6 6 6		2. $344535$ 1. $942853$ 3. $086614$ 4. $337350$ 0. $684603$ 0. $966201$ 1. $518605$ 0. $096047$ -1. $070497$ -2. $286049$ -2. $679599$ -3. $797120$ -4. $547314$ -4. $166820$ -3. $045578$ -0. $155196$ 1. $829788$ -0. $163960$ -2. $775562$ -4. $739794$ -5. $418619$ -4. $084433$ -2. $087541$ -0. $797691$ 0. $820975$ 2. $964770$ 4. $858309$ 4. $997038$ 1. $474041$ 3. $095935$ -0. $585157$ -1. $656514$ 0. $062067$ -1. $299927$	$\begin{array}{c} 0. \ 480449\\ 0. \ 800232\\ 0. \ 743194\\ -0. \ 044564\\ 0. \ 009201\\ -1. \ 480156\\ -2. \ 084496\\ 0. \ 541655\\ 1. \ 440629\\ 0. \ 670209\\ -0. \ 499106\\ -1. \ 221543\\ -0. \ 792287\\ 0. \ 363776\\ 1. \ 089791\\ -2. \ 163222\\ -1. \ 668867\\ 0. \ 032050\\ 1. \ 990685\\ 0. \ 708062\\ -1. \ 355180\\ -2. \ 121256\\ -0. \ 843324\\ 2. \ 764820\\ 0. \ 972254\\ 1. \ 341347\\ 0. \ 394096\\ -0. \ 039321\\ 0. \ 571917\\ 1. \ 193728\\ 2. \ 620208\\ 3. \ 439101\\ 3. \ 266991\\ 1. \ 705807\\ \end{array}$	$\begin{array}{c} 2.184862\\ 0.736815\\ -0.2906588\\ 0.023824\\ 0.218786\\ -0.019376\\ 1.065269\\ -1.001704\\ -0.882846\\ -0.360558\\ -1.031769\\ -0.622346\\ 0.477278\\ 1.155381\\ 0.737902\\ -0.622346\\ 0.477278\\ 1.155381\\ 0.737902\\ -0.309526\\ -1.048802\\ 1.018203\\ 1.278480\\ 2.011724\\ 0.799360\\ -1.159236\\ -1.873351\\ -0.148884\\ -1.570260\\ -1.351838\\ 0.881788\\ 0.881788\\ 0.841410\\ 2.842134\\ 2.536793\\ 0.915712\\ -0.26594\\ -0.602235\\ -1.923667\\ \end{array}$
36 37	1 1	0 0	1.615239 4.084161	1.843051 -1.074091	0.708745 0.294140

(R,R,R)-25 obtained diastereomer

#### (R,R,S)

Center	Atomic	Atomic		Coordinates	(Angstroms)
Number	Number	Туре	X	Y	Ζ
1	1	0	-3.408971	-2.079919	1.591569

2 3 4 5 6 7 8 9 10 112 13 14 15 16 17 18 9 0 11 12 22 23 4 5 6 7 8 9 10 112 13 14 5 16 17 18 9 0 11 12 22 22 22 22 22 22 22 23 22 23 23	09 6 9 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6		$\begin{array}{c} -1.460800\\ -0.679765\\ 0.574479\\ -2.256478\\ -3.232134\\ -4.374564\\ -0.785533\\ -0.268273\\ 0.924780\\ 0.172723\\ 2.801353\\ 3.940944\\ 4.473103\\ 3.856873\\ 2.719554\\ -1.088166\\ -3.104837\\ 0.751070\\ -0.161709\\ 2.413833\\ 4.412182\\ 5.36104837\\ 0.751070\\ -0.161709\\ 2.413833\\ 4.412182\\ 5.36104837\\ 0.751070\\ -0.21679\\ 2.413833\\ 4.412182\\ 5.361008\\ -3.104837\\ -1.019322\\ -4.953923\\ -5.021247\\ 0.526288\\ 1.660222\\ -0.070392\\ 1.069154\\ -3.976143\\ -1.720880\\ -2.137252\\ -2.554959\end{array}$	$\begin{array}{c} 1.967745\\ 1.967745\\ 1.481862\\ 1.898513\\ -0.426248\\ -0.226168\\ 0.739268\\ -0.047729\\ -0.656401\\ -1.526402\\ -0.731461\\ -0.853864\\ -0.102135\\ 0.779173\\ 0.907445\\ 0.907445\\ 0.907445\\ 0.907445\\ 0.161000\\ 2.091580\\ -0.869018\\ -2.828372\\ -0.305504\\ -1.543891\\ -0.212826\\ 1.359204\\ -1.543891\\ -0.212826\\ 1.588271\\ 0.271935\\ -1.077434\\ 0.457411\\ 0.750572\\ -2.646806\\ -3.436431\\ -3.416685\\ -1.822990\\ 1.742520\\ -2.053169\\ -2.585291\\ 0.240150\end{array}$	-0.711449 0.288022 0.051212 0.769538 -0.401133 -0.200064 0.401086 -0.811994 -0.376654 0.87452 1.173469 0.234334 -1.014573 -1.311306 1.433177 -1.434173 0.039202 1.266022 1.610241 2.146061 0.468660 -1.755966 -2.278910 -1.349456 0.68699 -1.078268 1.078268 1.094413 -0.009064 -0.379514 -1.808486 -0.016514 2.117470 0.473356 -1.583569
---	---	--	---	--	---

As a consequence of the results obtained from the above reported procedure, the (*R*,*R*,*R*) absolute configuration can be assigned to the obtained *syn* isomer **25**. As a consequence, the (R,R,S) absolute configuration can be assigned to the starting  $\beta'$ -amino  $\beta$ -keto ester anti isomer **24**. The (*R*,*R*,*S*) absolute configuration can be assigned to all obtained  $\beta'$ -amino  $\beta$ -keto ester *anti*-isomer **19**, **20**, and **21**.



2D NMR spectra and optimized geometries of 19

Figure 5. 2D NOESY spectrum of 19.

The cross peak between the protons  $H_b$  and  $H_c$  was used as a distance ruler and its volume was set to 10.00 a.u.; the cross peak between  $H_b$  and  $H_a$  was measured 1.56 a.u. (corresponding to an interproton distance of 3.61 Å), in order to determine the absolute configuration.



Figure 6. Optimized geometries of obtained (R,R,S)-19 and of its possible diastereomer (R,S,R).

#### Calculated Coordinates:

Center Atomic Number Number	Atomic Type	······	Coordinates	(Angstroms) Z
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		$\begin{array}{c} -2.142829\\ -1.734012\\ -2.628199\\ -4.047223\\ -0.187537\\ 0.222576\\ 0.317187\\ 0.286530\\ 1.265387\\ 2.494556\\ 3.469702\\ 4.608582\\ 4.794697\\ 3.833867\\ 2.695192\\ 1.417430\\ -0.669000\\ 0.338558\\ 1.966713\\ 3.3967928\\ 5.682192\\ 5.352537\\ 3.326002\\ 0.662608\\ -0.405777\\ -2.215187\\ 3.326002\\ 0.662608\\ -0.405777\\ -2.215187\\ -3.5689968\\ -1.462086\\ -3.151872\\ 0.26669\\ -3.151872\\ 0.266998\\ -1.462086\\ -3.151872\\ 0.26659\\ -1.592864\\ -1.396787\\ -3.122793\\ -1.592864\\ -1.817224\\ -0.316505\\ \end{array}$	$\begin{array}{c} -0.801206\\ -0.468322\\ -1.243960\\ -1.580227\\ -0.703983\\ -2.118281\\ -2.159946\\ -0.509381\\ 0.515652\\ 0.501241\\ -0.489728\\ -0.544692\\ 0.393651\\ 1.382435\\ 1.436295\\ -2.498918\\ -3.080658\\ -0.022446\\ 2.222061\\ 2.118571\\ 0.354167\\ -1.317463\\ -1.226455\\ 1.91463\\ -0.732865\\ -1.553322\\ -0.693467\\ -1.317463\\ -1.317463\\ -1.226455\\ 1.914668\\ -0.732865\\ -1.553322\\ -0.693467\\ -1.315758\\ -0.440204\\ 2.325393\\ 2.613659\\ 1.858809\\ 0.183616\\ -1.875013\\ 1.016274\\ -2.329389\\ 1.405059\\ 1.811329\\ 3.1568281\\ 4.185731\\ 3.106276\\ 3.379382\\ 3.965445\\ 5.170646\\ 4.235519\end{array}$	$\begin{array}{c} -1.767907\\ -0.304854\\ 0.717752\\ 0.315303\\ -0.067084\\ -0.569691\\ -1.925040\\ 1.277207\\ 1.667517\\ 0.758756\\ 0.949495\\ 0.149161\\ -0.870333\\ -1.075001\\ -0.264596\\ -0.094626\\ -0.213814\\ -0.742604\\ -0.437376\\ -1.862589\\ -1.495190\\ 0.320676\\ 1.735023\\ 1.870415\\ 1.978013\\ 1.821299\\ -0.05736\\ 1.735023\\ 1.870415\\ 1.978013\\ 1.825177\\ -2.467164\\ -1.978788\\ 0.940803\\ 2.261618\\ 2.587043\\ 2.652371\\ -1.952893\\ -0.094934\\ -0.482785\\ 0.727379\\ -0.999156\\ -1.167659\\ -0.260586\\ -0.996042\\ -2.219627\\ 0.790638\\ -0.421855\\ \end{array}$

#### (*R*,*R*,*S*)-19 obtained diastereomer

#### (R,S,R)

Center	Atomic	Atomic		Coordinates	(Angstroms)
Number	Number	Type		X	Y Z
1 2 3 4 5 6 6 7 8 9	6 6 6 6 6 1 7 6 6 6 6	0 0 0 0 0 0 0 0 0 0 0	-2.949619 -1.898939 -2.164727 -0.440441 -0.653741 0.626570 1.513037 2.772322 3.452605	-1.491353 -0.718703 -1.223182 -1.226806 -2.281273 -1.240046 -0.152371 -0.028278 -1.196417	$\begin{array}{c} -0.228916\\ 0.637835\\ 2.076314\\ 0.205589\\ 0.001859\\ 1.179931\\ 1.641990\\ 0.764244\\ 0.388248\end{array}$
10	6	0	4.634845	-1.138827	-0.346250
11	6	0	5.165204	0.097047	-0.727804
12	6	0	4.498460	1.265802	-0.365085

13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	66111116181111688661111161		3.313849 0.038678 2.816438 4.895150 6.085614 5.142648 3.032847 0.842889 0.431437 -2.726175 0.506885 1.547267 -0.017243 1.878014 -2.156242 -2.374521 -2.164398 -2.465674 -3.184628 -2.937811 -0.769133 -1.452491 -0.463629 -4.274772 -4.636721	$\begin{array}{c} 1.202414\\ -0.720460\\ 2.128285\\ 2.233744\\ 0.145625\\ -2.058437\\ -2.158051\\ 1.190683\\ -1.905083\\ -1.905083\\ -2.642348\\ 1.701608\\ 1.850278\\ 1.047328\\ -0.538252\\ 0.793094\\ 1.473330\\ 1.272831\\ 2.683917\\ 3.531360\\ 2.991474\\ 2.723769\\ 3.531559\\ 4.564267\\ 3.157966\\ -0.835987\\ -0.220202\\ \end{array}$	0.375883 -1.158281 0.642540 -0.658773 -1.302553 -0.623929 0.666501 1.958193 1.911278 -0.556385 1.054344 2.473757 2.613270 2.602878 0.601840 1.586154 -0.652967 -0.797379 -0.797379 -0.797379 -0.797410 -1.824705 0.204257 -1.062687 -1.062687 -5.57388 -0.545835 0.282741
32 33 34	1 1 1	0 0 0	-3.184628 -2.937811 -0.769133	2.991474 2.723769 3.531559	-0.079410 -1.824705 0.204257
35 36 37 38	1 6 1	0 0 0	-1.452491 -0.463629 -4.274772 -4.636721	4.564267 3.157966 -0.835987 -0.220202	-1.06268/ -1.507388 -0.545835 0.282741
39 40 41	1 1 1	0 0 0	-5.004942 -4.147618 -3.193111	-1.608739 -0.178475 -1.011462	-0.788571 -1.411172 2.378343
42 43 44 45	⊥ 1 9 9	0 0 0	-1.503823 -2.006761 -0.948488 1.044907	-0.726963 -2.303540 -0.778700 -1.490010	2.786733 2.128497 -2.081975 -1.620675
46	9	Ŏ	0.494215	0.554577	-1.141594



#### 2D NMR spectra and optimized geometries of 20

The cross peak between the protons  $H_b$  and  $H_c$  was used as a distance ruler and its volume was set to 10.00 a.u.; the cross peak between  $H_b$  and  $H_a$  was measured 1.57 a.u. (corresponding to an interproton distance of 3.61 Å), in order to determine the absolute configuration.



Figure 8. Optimized geometries of obtained (R,R,S)-20 and of its possible diastereomer (R,S,R).

Calculated Coordinates:

#### (*R*,*R*,*S*)-**20** obtained diastereomer

(R,S,R)

9 10 112 13 14 156 17 18 9 22 23 24 56 78 9 01 22 23 24 56 78 9 01 23 33 4 56 7 8 9 0 12 23 24 56 78 9 01 22 23 45 67 89 01 23 33 45 67 89 01 22 23 45 67 89 01 22 23 45 67 89 01 22 23 45 67 89 01 22 23 45 67 89 01 22 23 45 67 89 01 22 23 45 67 89 01 22 23 45 67 89 01 22 23 45 67 89 01 22 23 45 67 89 01 22 23 24 56 78 90 12 23 24 56 78 90 12 23 24 56 78 90 12 23 24 56 78 90 12 23 24 56 78 90 12 23 24 56 78 90 12 23 24 56 78 90 12 23 24 56 78 90 12 23 24 56 78 90 12 23 24 56 78 90 12 23 24 56 78 90 12 23 24 56 78 90 12 23 24 56 78 890 12 23 24 56 78 90 12 23 24 56 78 90 12 23 24 56 78 90 12 23 24 56 78 90 12 23 44 56 78 90 12 23 44 56 78 90 12 23 44 56 78 90 12 23 44 56 78 90 12 23 44 56 78 90 12 34 44 56 78 90 12 34 44 56 78 90 12 34 44 56 78 90 12 34 44 56 78 90 12 34 4 4 56 78 90 12 34 44 56 78 90 12 34 44 56 78 90 12 34 44 56 78 90 12 34 4 4 56 78 90 12 34 4 56 78 90 12 34 4 4 56 78 90 12 34 4 4 56 78 90 12 34 4 4 56 77 890 12 34 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	9666687666666669911111111111111111111111	000000000000000000000000000000000000000	$\begin{array}{c} -0.705918\\ -2.376563\\ -1.983970\\ -1.559461\\ -0.993069\\ -0.317222\\ 0.662856\\ 2.129789\\ 2.526409\\ 2.754507\\ 2.862658\\ 3.437388\\ 3.918976\\ 3.815869\\ 3.236406\\ -1.658517\\ 0.464490\\ 0.338693\\ -2.297793\\ -2.813070\\ -1.144848\\ -2.431304\\ -0.839633\\ -2.297793\\ -2.813070\\ -1.144848\\ -2.431304\\ -0.839633\\ -2.970902\\ -1.360987\\ -3.349761\\ -2.981401\\ -1.730630\\ 0.273714\\ 3.168321\\ 4.187155\\ 3.512110\\ 2.484570\\ 2.520239\\ 2.173923\\ 3.614934\\ 2.101683\\ -3.413824\\ 4.371243\end{array}$	$\begin{array}{c} -1.259982\\ -1.827863\\ -2.997219\\ -2.320512\\ -0.969748\\ -0.235935\\ -1.615673\\ -1.558811\\ -1.790160\\ -0.325862\\ -0.276302\\ 0.821291\\ 1.895316\\ 1.860423\\ 0.758925\\ 0.602910\\ 0.602910\\ 0.420867\\ -2.095072\\ -3.695716\\ -3.564780\\ 0.2112997\\ -2.874954\\ 2.958955\\ 3.684526\\ 2.953367\\ 4.597371\\ 3.638039\\ -2.417169\\ 0.751784\\ 2.958955\\ 3.684526\\ 2.953367\\ 4.597371\\ 3.638039\\ -2.417169\\ 0.751784\\ 2.689702\\ 0.837443\\ -1.105524\\ -2.420094\\ -1.001774\\ -1.860583\\ -2.736724\\ -1.539206\end{array}$	2.656594 -0.037501 -0.973276 -2.280137 -1.874804 -2.558329 0.286938 0.286938 0.541650 2.009279 -0.102736 -1.500903 -2.1387789 0.004457 0.640638 2.074734 2.519293 0.066175 1.018218 -1.110778 -0.561336 -2.916883 -2.886967 -1.369773 -1.29875 1.129875 1.129875 1.367118 0.773935 1.367118 0.773935 1.362716 -2.9012588 0.551968 1.367118 0.773935 1.222176 -2.091258 -0.016867 -2.101764 2.595707 -0.222015 -1.879688



Figure 9. 2D NOESY spectrum of 21.

The cross peak between the protons  $H_b$  and  $H_c$  was used as a distance ruler and its volume was set to 10.00 a.u.; the cross peak between  $H_b$  and  $H_a$  was measured 1.56 a.u. (corresponding to an interproton distance of 3.61 Å), in order to determine the absolute configuration.





#### Calculated Coordinates:

( <i>R</i> , <i>R</i> , <i>S</i> )- <b>21</b> c	obtained	diastereomer
---	----------	--------------

Center	Atomic	Atomic	C	coordinates (	Angstroms)
Number	Number	Type	X	Y	Z
$\begin{array}{c} 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 20 \\ 21 \\ 22 \\ 23 \\ 24 \\ 25 \\ 27 \\ 28 \\ 29 \\ 30 \\ 31 \\ 32 \\ 33 \\ 34 \\ 35 \\ 36 \\ 37 \\ 38 \\ 39 \\ 40 \\ 41 \\ 42 \\ 43 \\ 44 \\ 45 \\ 46 \\ 47 \\ 48 \\ 49 \\ 50 \\ \ldots \\ $	6666668669686676666666689991111111111111		$\begin{array}{c} 1.477156\\ 1.947897\\ 3.210569\\ 3.084815\\ 2.774328\\ 1.506195\\ 1.325770\\ 0.049652\\ -0.425052\\ -1.518285\\ 2.490379\\ 3.135376\\ 4.108528\\ 3.444865\\ -0.919777\\ -2.213996\\ -2.111551\\ -3.349639\\ -4.387576\\ -5.452499\\ -5.46647\\ -4.47386\\ -4.374521\\ -6.243294\\ -5.26647\\ -4.493377\\ -2.604173\\ -2.606174\\ -2.606174\\ -2.60617$	$\begin{array}{c} -0.539713\\ -1.846825\\ -2.479387\\ -2.732384\\ -1.427048\\ -0.745579\\ -2.337111\\ -0.151379\\ 1.211751\\ 1.634389\\ 0.510424\\ 1.162016\\ 2.170007\\ 3.518991\\ -1.193787\\ -1.287592\\ -1.005100\\ -0.551174\\ 0.084320\\ 0.676680\\ 0.642618\\ 0.642618\\ 0.642618\\ 0.642618\\ 0.675669\\ 2.174016\\ 1.210203\\ 0.675269\\ 2.174016\\ 1.210203\\ 0.220595\\ 1.819811\\ 2.197795\\ 3.482960\\ 2.20595\\ 1.819811\\ 2.197795\\ 3.482960\\ 4.267756\\ 3.834078\\ 0.128372\\ 1.167143\\ 1.103078\\ -0.021984\\ -1.056475\\ -2.353468\\ 0.128372\\ 1.546384\\ -1.622886\\ -0.746407\\ -1.797059\\ -3.397575\\ -3.466114\\ -3.178319\\ -2.074042\\ -0.013778\\ -1.352982\\ -0.013778\\ -0.01378\\ -0.013778\\ -0.013$	0.013753 -0.703341 -0.158697 1.357325 2.093691 1.556793 -1.628262 -0.523639 -0.000192 -0.674223 -0.509716 0.463315 0.058245 -0.157671 -0.166584 -0.903414 -2.410637 -0.183778 -0.178639 -0.376954 -0.376954 -2.827071 -2.625104 -2.930375 -2.827071 -1.63000 2.004758 -0.341652 -0.721219 -1.536107 -1.728019 -0.340929 -1.606784 -1.810218
( <i>R</i> , <i>S</i> , <i>R</i> )					
Center	Atomic	Atomic	C	coordinates (	Angstroms)
Number	Number	Type	X	Y	Z
1	7	0	0.725579	1.110976	$\begin{array}{c} -1.264172\\ -1.326188\\ -0.712750\\ -1.760522\\ -1.083433\\ -0.465566\\ -1.761350\\ 1.648365\end{array}$
2	6	0	2.214487	1.149765	
3	6	0	-0.034435	0.005918	
4	6	0	-0.289675	-1.093547	
5	6	0	-2.271443	1.278030	
6	6	0	-3.369571	2.154830	
7	1	0	-2.717403	0.545906	
8	6	0	-2.031952	2.415855	

## Chapter 11

## <u>Synthesis of trifluoromethyl 2-imidazolines through Mannich-</u> type reactions with isocyano acetates

<u>General procedure for the synthesis of isocyano acetates (4-6).</u> The methyl ester HCl salt (100 mmol) was added to a semisaturated Na<sub>2</sub>CO<sub>3</sub> (aq) (100 mL) solution, and the mixture was extracted with DCM (4  $\times$  100 mL). The organic layers were combined and dried over MgSO<sub>4</sub>. Removal of the solvent under reduced pressure allowed isolation of the corresponding methyl ester. Acetic formic anhydride (prepared by stirring 1 equiv of acetic anhydride and 1.1 equiv of formic acid for 2 h at 55 °C; 15 mL, 16.8 g, 110 mmol) was added dropwise at 0 °C to a stirred solution of the appropriate methyl ester (50 mmol) in DCM (135 mL), and the mixture was stirred for 2 h at room temperature. All volatiles were evaporated under reduced pressure, and the corresponding formamides **7-9** were isolated (68-95%).

A solution of POCl<sub>3</sub> (2.9 mL, 4.8 g, 31 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added dropwise to a solution of a formamide (25 mmol) in Et<sub>3</sub>N (17 mL) and CH<sub>2</sub>Cl<sub>2</sub> (60 mL) at -25 °C. The reaction mixture was stirred for 5 h at the same temperature, and the resulting red mixture was added to cold H<sub>2</sub>O (60 mL) and extracted with Et<sub>2</sub>O (3 × 60 mL). The organic layers were combined, washed with H2O (2 × 50 mL), dried (MgSO<sub>4</sub>), filtered, and concentrated *in vacuo* to yield the desired (racemic) isocyano acetates **4-6** (64-93%), which was sufficiently pure for followup chemistry.

The formamides 7-9 and the isocyano acetates 4-6 are known in literature.<sup>1</sup>

<sup>&</sup>lt;sup>1</sup> Elders, N.; Schmitz, R. F.; Kanter, F. J. J.; Ruijter, E.; Groen, M. B.; Orru, R. V. A. J. Org. Chem. 2007, 72, 6135-6142

<u>Synthesis of trifluoromethyl imines (1a-f)</u>. The trifluoromethyl imines were synthesized following the procedures reported in the literature.<sup>2,3</sup> **1a-f** are known compounds.

#### *General procedure for the* Ag<sub>2</sub>O-Catalyzed Mannich-type reactions.

**Method A**: To a mixture of trifluoromethyl aldimines **1a-c** (0.18 mmol) and Ag<sub>2</sub>O (0.015 mmol), isocyano acetates **2** or **4** (0.15 mmol) was added. The reactions were performed under solvent-free conditions and stirred at room temperature (3-5 h, see **Tables 1,2, Chap. 6**). EtOAc was added to the mixture and the mixture filtered through a pad of celite. Then, the solvent was evaporated *in vacuo* and the residues purified by flash chromatography on silica gel (eluent hexane/ethyl acetate = 3:7).

**Method B**: To a mixture of trifluoromethyl aldimines **1a-c** (0.18 mmol) and Ag<sub>2</sub>O (0.018 mmol) in CH<sub>2</sub>Cb, isocyano acetates (0.18 mmol) was added. The reactions were stirred at room temperature (see **Tables 2,3**, **Chap.6**). EtOAc was added to the mixture and the mixture filtered through a pad of celite. Then, the solvent was evaporated *in vacuo* and the residues purified by flash chromatography on silica gel (eluent hexane/ethyl acetate = 3:7).

Bn∼N∕∕N ≻\_∕

## Methyl 1-benzyl-5-(trifluoromethyl)-4,5-dihydro-1*H*imidazole-4-carboxylate (*trans*-3a).

 $F_3C$  CO<sub>2</sub>Me Method A: colorless oil (44 mg, 85 %). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 3.77 (s, 3H), 4.25–4.39 (m, 2H), 4.77 (d, J = 15.1 Hz, 1H), 7.20–7.43 (m, 6H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -74.6 (d, J = 6.9 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 50.6, 52.9, 60.9 (q, J =31.9 Hz), 70.3, 124.8 (q, J = 280.3 Hz), 128.0 (2C), 128.4, 129.0 (2C), 134.5, 157.4, 169.1. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>13</sub>H<sub>14</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub> 287.1007, found 287.1068.

<sup>&</sup>lt;sup>2</sup> See ref.17 in the **Chapter 1**.

<sup>&</sup>lt;sup>3</sup> See ref.17 in the **Chapter 2**.


 Methyl
 1-(4-methoxyphenyl)-5-(trifluoromethyl) 

 4,5-dihydro-1*H*-imidazole-4-carboxylate
 (trans-3b).

 Method A:
 red oil (48 mg, 88 %). <sup>1</sup>H NMR (CDCl<sub>3</sub>):

 3.79 (s, 3H), 3.85 (s, 3H), 4.87–4.99 (m, 2H), 6.88 (d, J

= 9.0 Hz, 2H), 7.12 (d, J = 8.9 Hz, 2H), 7.20 (s, 1H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -74.8 (d, J = 6.1 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 53.2, 55.5, 63.1 (q, J = 31.7 Hz), 70.3, 114.9 (2C), 123.8 (2C), 124.4 (q, J = 281.2 Hz), 131.3, 155.5, 158.1, 170.0. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>13</sub>H<sub>14</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub> 303.0957, found 303.0905.

Methyl 1-benzyl-4-methyl-5-(trifluoromethyl)-4.5-Bn~N dihydro-1*H*-imidazole-4-carboxylate (*cis-*7a, trans-7'a). Method A: yellow oil (32 mg, 26 %). <sup>1</sup>H NMR (CDCl<sub>3</sub>): CO<sub>2</sub>Me 1.38 (s, 3H), 1.58 (s, 3H), 3.50 (q, J = 6.9 Hz, 1H), 3.70 (s, 3H), 3.73 (s, 3H), 4.19– 4.29 (m, 3H), 4.37 (d, J = 7.5 Hz, 1H), 4.56–4.64 (m, 1H), 6.93 (s, 1H), 7.09 (s, 1H), 7.19–7.39 (m, 10H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -69.3 (d, J = 7.3 Hz), -67.1 (d, J =8.5 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 19.7 (q, J = 3.0 Hz, 2C), 50.6 (2C), 52.2, 52.7, 52.8, 53.0, 62.8 (q, J = 30.4 Hz), 67.8 (q, J = 31.0 Hz), 124.3 (q, J = 282.0 Hz), 124.9 (q, J = 282.3 Hz), 128.1 (2C), 128.2 (2C), 128.3, 128.5, 128.9 (2C), 129.1 (2C), 134.5, 134.7, 155.5, 156.2, 170.8, 173.0. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>16</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub> 301.1164, found 301.1189.



Methyl 1-(4-methoxyphenyl)-4-methyl-5-(trifluoromethyl)-4,5 dihydro-1*H*-imidazole-4carboxylate (*cis*-7b).

 $F_3C$  CO<sub>2</sub>Me Method A: red oil (15 mg, 26 %). Separated by flash chromatography on silica gel (eluent: hexane/ethyl acetate = 30:70). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.71 (s, 3H), 3.80 (s, 3H), 3.84 (s, 3H), 5.08 (q, *J* = 7.3 Hz, 1H), 6.89 (d, *J* = 8.9 Hz, 2H), 7.01 (s, 1H), 7.13 (d, *J* = 8.8 Hz, 2H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -67.8 (d, *J* = 7.5 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 19.5 (q, *J* = 2.9 Hz), 53.3, 55.5, 60.3, 65.4 (q, *J* = 30.2 Hz), 114.8 (2C), 124.5 (q, *J* = 281.2 Hz), 124.9 (2C), 131.7, 154.1, 158.3, 173.2. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>16</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub> 317.1113, found 317.1154.

*trans*- 7'b: Method A: red oil (8 mg, 14 %). Separated by flash chromatography on silica gel (eluent: hexane/ethyl acetate = 30:70). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.68 (s, 3H), 3.81 (s, 6H), 4.23 (q, J = 6.9 Hz, 1H), 6.90 (d, J = 8.0 Hz, 2H), 7.09 (d, J = 8.9 Hz, 2H), 7.17 (s, 1H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -69.5 (d, J = 6.9 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 27.6, 53.0, 55.5, 70.8 (q, J = 30.4 Hz), 76.0, 114.9 (2C), 123.8 (q, J = 282.3 Hz), 124.1 (2C), 131.7, 153.9, 158.0, 170.7. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>16</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub> 317.1113, found 317.1137.



Methyl 1-benzyl-4-isobutyl-5-(trifluoromethyl)-4,5dihydro-1H-imidazole-4-carboxylate (*cis*-8a). Method B: colorless oil (12 mg, 19 %). Separated by HPLC (eluent: hexane/ethyl acetate = 70:30). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 0.86 (d, J = 6.6 Hz, 3H), 0.99 (d, J=6.6 Hz,

3H), 1.72 (dd, J = 5.2, 13.9 Hz, 1H), 1.83–1.92 (m, 1H), 2.02 (dd, J = 5.7, 13.5 Hz, 1H), 3.62 (s, 3H), 3.84 (q, J = 7.6 Hz, 1H), 4.21 (d, J = 15.2 Hz, 1H), 4.58 (d, J = 15.2 Hz, 1H), 7.06 (s, 1H), 7.15 (d, J = 6.6, 2H), 7.28–7.37 (m, 3H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -66.9 (d, J = 7.4 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 23.4, 24.5, 25.3, 41.3 (q, J = 2.5 Hz), 50.6 (q, J = 1.4 Hz), 52.6, 64.6 (q, J = 30.0 Hz), 80.2, 124.8 (q, J = 283.7 Hz), 128.0 (2C), 128.3, 128.9 (2C), 135.1, 155.7, 174.1. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>22</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub> 343.1633, found 343.1659.

(*trans-8'a*): Method B: colorless oil (10 mg, 16%). Separated by HPLC (eluent: hexane/ethyl acetate = 70:30). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 0.81 (d, J=6.7 Hz, 3H), 0.83 (d, J=6.7 Hz, 3H), 1.19 (dd, J = 5.3, 13.5 Hz, 1H), 1.66–1.70 (m, 1H), 1.93 (dd, J = 6.6, 13.6 Hz, 1H), 3.45 (q, J = 7.2 Hz, 1H), 3.74 (s, 3H), 4.21 (d, J = 15.1 Hz, 1H), 4.61 (d, J = 15.0 Hz, 1H), 7.09 (s, 1H), 7.21 (d, J = 6.6, 2H), 7.29–7.45 (m, 3H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -69.2 (d, J = 6.7 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 23.1, 24.2, 24.6, 49.8,

50.9, 52.6, 67.4 (q, J = 30.4 Hz), 79.7, 124.5 (q, J = 283.2 Hz), 128.5 (3C), 129.0 (2C), 134.6, 156.0, 170.8. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>22</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub> 343.1633, found 343.1602.



# Methyl 4-isobutyl-1-(4 methoxyphenyl)-5-(trifluoromethyl)-4,5-dihydro-1*H*-imidazole-4carboxylata (cic.8b) Mathod B: brown oil (15 mg

carboxylate (*cis*-8b). Method B: brown oil (15 mg, 23%). Separated by HPLC (eluent: hexane/ethyl acetate

= 70:30). <sup>1</sup>H NMR (CDCl<sub>3</sub>): <sup>1</sup>H NMR (CDCl<sub>3</sub>): 0.92 (d, *J*=6.5 Hz, 3H), 1.04 (d, *J*=6.5 Hz, 3H), 1.83–1.85 (m, 1H), 1.89–2.00 (m, 1H), 2.11 (dd, *J* = 5.1, 13.3 Hz, 1H), 3.80 (s, 3H), 3.82 (s, 3H), 4.67 (q, *J* = 7.1 Hz, 1H), 6.87 (d, *J* = 8.9 Hz, 2H), 7.06 (d, *J* = 8.9 Hz, 2H), 7.16 (s, 1H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -67.2 (d, *J* = 8.3 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 23.7, 24.5, 25.2, 41.5, 52.9, 55.5, 67.4 (q, *J* = 29.4 Hz), 80.3, 114.8 (2C), 124.2 (2C), 124.3 (q, *J* = 284.9 Hz), 131.9, 153.6, 157.9, 174.2. HR-MS (ESI Q-TOF) (*m*/*z*) [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>22</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub> 359.1583, found 359.1553.

(*trans*-8'b): Method B: brown oil (10 mg, 15%). Separated by HPLC (eluent: hexane/ethyl acetate = 70:30). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 0.94 (d, *J*=6.7 Hz, 3H), 1.00 (d, *J*=6.7 Hz, 3H), 1.67 (dd, *J* = 5.1, 13.3 Hz, 1H), 1.90–1.99 (m, 1H), 2.21 (dd, *J* = 13.4, 6.7 Hz, 1H), 3.81 (s, 6H), 4.20 (q, *J* = 7.3 Hz, 1H), 6.90 (d, *J* = 8.9 Hz, 2H), 7.07 (d, *J* = 8.9 Hz, 2H), 7.20 (s, 1H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -69.5 (d, *J* = 7.0 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 23.2, 24.5, 24.7, 50.2, 52.7, 55.5, 70.4 (q, *J* = 29.9 Hz), 79.6, 114.9 (2C), 123.4 (2C), 123.4 (q, *J* = 284.3 Hz), 132.1, 153.3, 157.7, 170.7. HR-MS (ESI Q-TOF) (*m*/*z*) [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>22</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub> 359.1583, found 359.1565



Methyl 1,4-dibenzyl-5-(trifluoromethyl) 4,5-dihydro-1*H*-imidazole-4-carboxylate (*cis*-9a). Method B: yellow oil (12 mg, 17%). Separated by HPLC (eluent: hexane/ethyl acetate = 70:30). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 3.13 (d, J=13.1 Hz,

1H), 3.34-3.37 (m, 4H), 4.13 (q, J = 7.5 Hz, 1H), 4.30 (d, J = 15.1 Hz, 1H), 4.75

(d, J = 15.2 Hz, 1H), 7.14–7.33 (m, 10H), 7.51 (s, 1H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): –67.3 (d, J = 9.9 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 39.2, 51.0, 52.5, 64.2 (q, J = 30.5 Hz), 80.2, 124.6 (q, J = 284.0 Hz), 127.1, 128.0 (2C), 128.1 (2C), 128.4, 129.0 (2C), 130.4 (2C), 134.6, 135.2, 156.6, 172.6. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>20</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub> 377.1477, found 377.1405.

*trans*-9'a: Method B: yellow oil (12 mg, 17%). Separated by HPLC (eluent: hexane/ethyl acetate = 70:30). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 3.09 (d, J = 13.7 Hz, 1H), 3.33 (d, J=13.4 Hz, 1H), 3.78 (s, 3H), 4.04 (q, J = 7.6 Hz, 1H), 4.32 (d, J = 15.0 Hz, 1H), 4.63 (d, J = 15.1 Hz, 1H), 6.91 (s, 1H), 7.13–7.39 (m, 10H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -68.5 (d, J = 9.9 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 38.8, 51.4, 52.9, 64.6 (q, J = 30.8 Hz), 78.8, 124.2 (q, J = 284.2 Hz), 127.4, 128.2 (2C), 128.4 (2C), 128.7, 129.1 (2C), 130.3 (2C), 133.9, 134.3, 157.7, 171.8. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>20</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub> 377.1477, found 377.1428.



# Methyl 4-benzyl-1-(4-methoxyphenyl)-5-(trifluoromethyl)-4,5-dihydro-1*H*-imidazole-4-

h carboxylate (*cis-9b*). Method B: brown oil (14 mg, 19%). Separated by HPLC (eluent: hexane/ethyl acetate =

70:30). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 3.26 (d, *J*=12.6 Hz, 1H), 3.45 (d, *J*=13.2 Hz, 1H), 3.52 (s, 3H), 3.80 (s, 3H), 4.93 (br, 1H), 6.89 (d, *J* = 8.7 Hz, 2H), 7.10 (d, *J* = 8.7 Hz, 2H), 7.22–7.35 (m, 6H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -67.4 (d, *J* = 7.5 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 39.5, 52.7, 55.5, 66.8 (br), 80.9, 114.8 (2C), 124.0 (2C), 124.3 (q, *J* = 286.0 Hz), 127.1, 128.2 (2C), 130.3 (2C), 131.5, 135.5, 153.7, 158.0 173.2. HR-MS (ESI Q-TOF) (*m*/*z*) [M + H]<sup>+</sup> calcd for  $C_{20}H_{20}F_{3}N_{2}O_{3}$  393.1426, found 393.1432.

(*trans-9'b*): Method B: brown oil (10 mg, 14%). Separated by HPLC (eluent: hexane/ethyl acetate = 70:30). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 3.34 (d, J=13.9 Hz, 1H), 3.46 (d, J=13.7 Hz, 1H), 3.73 (s, 3H), 3.85 (s, 3H), 4.39 (q, J=6.8 Hz, 1H), 6.40 (d, J=8.8

Hz, 2H), 6.69 (d, J = 8.9 Hz, 2H), 7.22–7.33(m, 6H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -68.7 (d, J = 7.0 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 44.2, 53.2, 55.4, 67.6 (q, J=30.8 Hz,), 79.1, 114.5 (2C), 123.8 (q, J = 287.7 Hz), 125.2 (2C), 127.5, 128.5 (2C), 131.3 (2C), 130.0, 134.4, 155.3, 158.4 170.2. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>20</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub> 393.1426, found 393.1468.



Methyl (4*S*,5*S*)-1-[(*R*)-1-phenylethyl]-5-(trifluoromethyl)-4,5-dihydro-1*H*-imidazole-4-carboxylate (10). Method A: colorless oil (17 mg, 38 %). Separated by HPLC (eluent: hexane/ethyl acetate = 70:30). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.62 (d, J =

6.9 Hz, 3H), 3.82 (s, 3H), 4.48–4.62 (m, 1H), 4.69 (q, J = 6.8 Hz, 1H), 4.78 (d, J = 5.6 Hz, 1H), 6.91 (s, 1H), 7.30–7.48 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): –75.0 (d, J = 7.7 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 18.4, 53.3, 56.2, 61.7 (q, J = 31.5 Hz), 68.9, 124.6 (q, J = 280.7 Hz), 127.2 (2C), 128.6, 129.1 (2C), 138.5, 156.4, 169.5. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>16</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub> 301.1164, found 301.1103.



# Methyl (4*R*,5*R*)-1-[(*R*)-1-phenylethyl]-5-(trifluoromethyl)-4,5-dihydro-1*H*-imidazole-4-

 $F_3C$  CO<sub>2</sub>Me carboxylate (10'). Method A: colorless oil (11 mg, 24 %). Separated by HPLC (eluent: hexane/ethyl acetate = 70:30). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.71 (d, *J* = 7.0 Hz, 3H), 3.72 (s, 3H), 4.03–4.16 (m, 1H), 4.57 (q, *J* = 6.8 Hz, 1H), 4.73 (d, *J* = 5.9 Hz, 1H), 7.15–7.39 (m, 6H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -75.1 (d, *J* = 7.5 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 22.1, 52.9, 56.8, 61.3 (q, *J* = 34.5 Hz), 69.8, 124.5 (q, *J* = 280.4 Hz), 126.2 (2C), 128.4, 129.1 (2C), 137.7, 154.5, 160.5. HR-MS (ESI Q-TOF) (*m/z*) [M + H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>16</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub> 301.1164, found 301.1153.

# 2D NMR spectra and optimized geometries to determine the absolute configuration of the new chiral centers.

 To determine the absolute configuration of the new chiral centers 2D NOESY NMR spectra and optimized geometries of the 2-imidazolines *trans*-10 and *trans*-10' were considered.



Figure 1. 2D NOESY spectrum of *trans*-10.



Figure 2. 2D NOESY spectrum of trans-10'

The cross peak between the protons  $H_b$  and  $H_c$  was used as a distance ruler and its volume was set to 10.00 a.u.; the cross peak between  $H_a$  and the protons  $H_c$  of the methyl group can be easily determinate for **10**, the value is 5.06 a.u. (corresponding to an interproton distance of 2.99 Å). The NOESY spectrum of **10'** did not show the correlation between  $H_a$ and  $H_c$ 



(*R*,S,S) possible diastereomer *trans*-10

 $H_c/H_a: 4.308 \text{ A}$ (*R*,*R*,*R*) possible diastereomer *trans*-10'

Figure 3. Optimize	d geometries of	(R,S,S)-10 and	(R,R,R)-10'.
--------------------	-----------------	----------------	--------------

(R,S,S)					
Center Number	Atomic Number	Atomic Type	C X	Coordinates Y	(Angstroms) Z
1	1	0	-1.140000	-4.367000	-3.224000
2	1	0	-2.572000	-1.001000	0.074000
3	6	0	-0.407000	-3.878000	-2.574000
4	1	0	0.589000	-4.027000	-3.00000
5	7	0	-4.081000	-0.060000	-1.064000
6	6	0	-4.240000	-0.082000	-2.336000
7	8	0	-2.743000	-2.906000	-1.636000
8	6	0	-1.880000	-2.137000	-2.046000
9	7	0	-3.176000	-0.322000	-3.029000
10	8	0	-0.656000	-2.470000	-2.510000
11	6	0	-2.652000	-0.234000	-0.703000
12	1	0	-0.428000	-4.313000	-1.571000
13	6	0	-5.155000	0.088000	-0.042000
14	6	0	-2.092000	-0.634000	-2.055000
15	9	0	-2.598000	1.440000	0.941000
16	6	0	-2.055000	1.073000	-0.239000
17	1	0	-1.165000	-0.116000	-2.322000
18	9	0	-0.726000	0.958000	-0.067000
19	9	0	-2.288000	2.063000	-1.122000
20	1	0	-4.660000	0.317000	0.909000
21	6	0	-5.836000	-1.272000	0.133000
22	6	0	-6.065000	1.237000	-0.386000
23	6	0	-5.613000	2.608000	-0.144000

24 25	6 6	0	-6.266000	3.738000 3.557000	-0.792000
26	6	Ő	-7.936000	2.228000	-1.718000
27	6	0	-7.326000	1.064000	-1.097000
28	1	0	-4.880000	2.827000	0.627000
29	1	0	-5.860000	4.733000	-0.629000
30	1	0	-7.881000	4.398000	-2.002000
31	1	0	-8.925000	2.141000	-2.159000
32	1	0	-7.937000	0.176000	-0.976000
33	1	0	-6.628000	-1.217000	0.888000
34	1	0	-6.279000	-1.641000	-0.799000
35	1	0	-5.115000	-2.028000	0.468000
36	1	0	-5.225000	0.101000	-2.794000

( <i>R</i> , <i>R</i> , <i>R</i> ) Center Number	Atomic Number	Atomic Type		Coordinates X	(Angstroms) Y Z
1	1	0	-1.140000	-4.367000	-3.224000
1	1	0	-2.258000	0.060000	-0.121000
2	6	0	-1.658000	0.071000	-2.673000
3	1	0	-5.293000	4.448000	-1.995000
4		0	-4.090000	2.621000	-0.8/1000
5	6	0	-2.730000	-0.816000	-0.579000
7	6	0	-2.274000	-2 007000	-1.990000
8	6	0	-5 864000	3 571000	-1 704000
9	6	õ	-5.168000	2.520000	-0.973000
10	1	0	-4.393000	0.655000	0.823000
11	7	0	-3.523000	-1.522000	-2.718000
12	7	0	-4.159000	-0.532000	-0.868000
13	1	0	-7.678000	4.210000	-2.597000
14	6	0	-7.160000	3.436000	-2.040000
15	6	0	-4.465000	-0.949000	-2.041000
16	6	0	-5.046000	0.182000	0.078000
10	6	0	-5.841000	1.275000	-0.601000
18	1	0	-5.505000	-0.896000	-2.397000
19	L 6	0	-5.294000	-1.553000	1.392000
20	6	0	-7.25/000	1 153000	-1.070000
22	6	Ő	-5.906000	-0.853000	0.816000
23	1	õ	-6.582000	-0.363000	1.526000
24	1	Õ	-6.511000	-1.456000	0.128000
25	1	0	-8.955000	2.184000	-1.891000
26	1	0	-7.881000	0.349000	-0.583000
27	9	0	-3.396000	-3.032000	-0.053000
28	9	0	-2.986000	-1.667000	1.585000
29	9	0	-1.338000	-2.466000	0.416000
30	8	0	-2.243000	1.166000	-2.457000
31	8	0	-0.515000	-0.243000	-3.382000
32	6	0	0.014000	0.852000	-4.128000
22 24	1	0	0.00000	1.001000	-3.403000
54 25	⊥ 1	0	0.892000	0.491000 1.215000	-4.672000
36	1	0	-1.570000	-1.986000	-2.013000



#### Methyl (4S,5S)-1-[(S)-1-methoxy-3-methyl-1-oxobutan-2-yl]-5-(trifluoromethyl)-4,5-dihydro-1H-imidazole-4-

carboxylate (18). Method B: colorless oil (22 mg, 39 %).  $[\alpha]_{\rm D} = 22.6$  (c = 1 g/100 mL, CHCl<sub>3</sub>). <sup>1</sup>H NMR (CDCl<sub>3</sub>):

1.00 (d, J = 6.6 Hz, 3H), 1.09 (d, J = 6.6 Hz, 3H), 2.20–2.29 (m, 1H), 3.52 (d, J =10.4 Hz, 1H), 3.75 (s, 3H), 3.81 (s, 3H), 4.29–4.35 (m, 1H), 4.70 (dd, J = 1.97, 6.5Hz, 1H), 7.14 (s, 1H) <sup>19</sup>F NMR (CDC<sub>b</sub>): -75.3 (d, J = 6.4 Hz). <sup>13</sup>C NMR (CDC<sub>b</sub>): 19.2, 19.6, 29.8, 52.4, 53.4, 62.7 (q, J = 31.8 Hz), 67.3, 69.9, 124.8 (q, J = 279.9Hz), 154.7, 169.9, 171.1. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>12</sub>H<sub>18</sub>F<sub>3</sub>N<sub>2</sub>O<sub>4</sub> 311.1219, found 311.1274.



(4*S*,5*S*)-1-[(*S*)-1-methoxy-4-methyl-1-Methyl oxopentan-2-yl]-5-(trifluoromethyl)-4,5-dihydro-1Himidazole-4-carboxylate (19). Method B: colorless oil (14 mg, 30 %).  $[\alpha]_D = 31.3$  (c = 2 g/100 mL, CHCl<sub>3</sub>).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): 0.96 (d, J = 6.1 Hz, 3H), 0.99 (d, J =

6.2 Hz, 3H), 1.74-1.88 (m, 3H), 3.73 (s, 3H), 3.84 (s, 3H), 4.03 (dd, J = 10.3, 5.0Hz, 1H), 4.38 (p, J = 6.6 Hz, 1H), 4.74 (dd, J = 6.9, 1.9 Hz, 1H), 7.07 (s, 1H) <sup>19</sup>F NMR (CDCl<sub>3</sub>): -75.2 (d, J = 6.7 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 21.0, 22.8, 24.5, 39.5, 52.8, 53.3, 58.5, 62.8 (q, J = 31.5 Hz), 68.8, 124.6 (q, J = 279.6 Hz), 155.3, 169.3, 171.6. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>13</sub>H<sub>20</sub>F<sub>3</sub>N<sub>2</sub>O<sub>4</sub> 325.1375, found 325.1342.



## (4S,5S)-1-[(S)-1-methoxy-1-oxo-3-Methyl phenylpropan-2-yl]-5-(trifluoromethyl)-4,5-dihydro-

oil (18 mg, 28 %).  $[\alpha]_D = 19.3$  (c = 1 g/100 mL, CHCb). <sup>1</sup>H NMR (CDC<sub>b</sub>): 3.10 (dd, J = 8.6, 14.2 Hz, 1H), 3.31 (d, J = 6.6, 14.2 Hz, 1H), 3.67 (s, 3H), 3.76 (s, 3H), 4.20 (dd, J = 6.7, 8.6 Hz, 1H), 4.33 (p, J = 6.5 Hz, 1H), 4.61 (dd, J = 2.0, 6.7 Hz, 1H), 6.98 (s, 1H), 7.12–7.28 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -75.6 (d, J = 7.5 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 37.2, 52.7, 53.1, 58.6, 62.6 (q, J = 31.6 Hz), 70.1, 124.6 (q, J = 279.9 Hz), 127.3, 128.7 (2C), 128.9 (2C), 135.5, 154.3, 169.9, 170.8. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>18</sub>F<sub>3</sub>N<sub>2</sub>O<sub>4</sub> 359.1219, found 359.1258.

# 2D NMR spectra and optimized geometries to determine the absolute configuration of the new chiral centers.

1. To determine the absolute configuration of the new chiral centers 2D NOESY NMR spectra and optimized geometries of the 2-imidazoline and **20** was considered. The cross peak between the protons  $H_b$  and  $H_c$  was used as a distance ruler and its volume was set to 10.00 a.u.; the cross peak between  $H_a$  and the protons  $H_b$  can be easily determinate for **20**, the value is 3.19 a.u. (corresponding to an interproton distance of 3.38 Å).



Figure 4. 2D NOESY spectrum of 20.





(S,R,R)					<i>,</i> ,
Center	Atomic	Atomic		Coordinates	(Angstroms)
1	1	o iype	_1 140000	-4 367000	-3 224000
1	7	0	-3 219000	1 078000	-0 121000
2	6	0	-3 408000	-0 277000	-0.690000
3	6	õ	-2.022000	0.978000	0.661000
4	7	0	-1.248000	-0.066000	0.343000
5	6	õ	-1.942000	-0.776000	-0.744000
6	6	õ	-1.868000	-2.293000	-0.623000
7	8	0	-2.870000	-3.008000	-0.576000
8	8	0	-0.643000	-2.887000	-0.668000
9	6	0	0.565000	-2.121000	-0.747000
10	6	0	-4.305000	1.813000	0.562000
11	6	0	-4.390000	3.289000	0.066000
12	6	0	-5.690000	1.138000	0.461000
13	8	0	-6.024000	0.133000	1.081000
14	8	0	-6.531000	1.801000	-0.390000
15	6	0	-7.809000	1.189000	-0.554000
16	6	0	-4.038000	-0.355000	-2.094000
17	1	0	-1.516000	-0.508000	-1.722000
18	1	0	0.517000	-1.352000	-1.522000
19	1	0	1.368000	-2.810000	-1.025000
20	1	0	0.816000	-1.706000	0.232000
21	1	0	-8.393000	1.810000	-1.239000
22	1	0	-8.339000	1.141000	0.402000
23	1	0	-7.707000	0.192000	-0.993000
24	9	0	-5.349000	-0.001000	-2.080000
25	9	0	-3.433000	0.466000	-2.991000
26	9	0	-3.995000	-1.600000	-2.629000
27	1	0	-3.985000	-0.902000	0.004000
28	6	0	-3.201000	4.191000	0.285000
29	6	0	-3.061000	4.958000	1.553000
30	6	0	-2.042000	4.123000	-0.655000
31	1	0	-4.122000	1.851000	1.647000
32	1	0	-4.623000	3.300000	-1.00/000
33	1	0	-5.252000	3.768000	0.551000
34	1	U	-4.028000	5.35/000	1.8//000
35	1	U	-2.38/000	5.811000	1.41/000
30 27	1	U	-2.660000	4.323000	2.348000
5/	T	U	-2.266000	3.505000	-1.229000

38 39 40 41	1 1 1 1	0 0 0 0	-1.161000 -1.794000 -3.713211 -1.778613	3.709000 5.126000 4.995265 1.651815	-0.156000 -1.016000 -0.200486 1.403805
39 40 41 ( <i>S</i> , <i>S</i> , <i>S</i> ) Center Number 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 3 24 5 26 27 28 9 30 31 32 33 4 35	1 1 1 Atomic Number 7 7 6 6 7 6 1 6 6 6 6 6 6 6 6 6 6 6 6 6	0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	-1.794000 -3.713211 -1.778613 -1.778613 -3.658000 -3.658000 -3.698000 -2.347000 -1.569000 -2.232000 -1.752000 -4.281000 -4.281000 -4.062000 -4.437000 -4.437000 -4.437000 -5.85000 -4.362000 -1.974000 -3.865000 -4.436000 -2.987000 -4.830000 -3.364000 -4.622000 -4.622000 -4.830000 -5.797000 -4.922000 -4.830000 -5.797000 -5.913000 -7.913000 -7.913000 -4.073000 -3.617000 -5.543000 -4.073000 -2.991000	S. 126000 4. 995265 1. 651815 Coordinates X 0.886210 1.157000 -0.336000 1.461000 0.396000 -0.774000 -0.917000 2.059000 3.568000 4.574000 6.005000 4.404000 1.840000 1.585000 1.248000 0.693000 1.585000 1.248000 0.693000 1.585000 1.248000 0.693000 3.782000 3.782000 3.782000 3.782000 3.782000 3.782000 3.782000 3.782000 3.782000 3.782000 3.782000 3.782000 3.782000 3.782000 3.782000 3.782000 0.956000 2.114000 0.956000 2.114000 0.956000 2.114000 0.956000 2.114000 0.956000 2.114000 0.956000 2.114000 0.956000 2.114000 0.692000 2.114000 0.956000 2.114000 0.721000 -2.298000 -2.298000	-1.016000 -0.200486 1.403805 (Angstroms) Y Z -1.132160 -0.838000 -0.644000 -1.3100000 0.0850000 0.143000 -0.167000 0.338000 2.246000 0.207000 1.233000 -1.016000 0.207000 1.233000 -1.016000 0.207000 -1.441000 -1.676000 1.132000 -1.441000 -0.173000 0.816000 0.323000 2.903000 2.903000 2.660000 -1.989000 0.676000 -0.676000 -0.671000 0.829000 0.671000 0.829000
36 37 38 39 40 41	8 6 1 1 1	0 0 0 0	-0.699000 0.249000 1.095000 0.637000 -0.145000 -2.022708	-2.627000 -1.902000 -2.570000 -1.052000 -1.582000 2.428644	-1.498000 -2.268000 -2.463000 -1.700000 -3.240000 -1.463375

# Chapter 12

# <u>Reactivity of trifluoromethyl aldimines in the aza-</u> <u>Reformatsky reaction</u>

All experiments were carried out under nitrogen atmosphere in flame-dried glassware using standard inert techniques for introducing reagents and solvents unless otherwise noted.

<u>Synthesis of trifluoromethyl imines (1a,c,g)</u>. The trifluoromethyl imines were synthesized following the procedures reported in the literature.<sup>1,2</sup> **1a,c** and **1g** are known compounds.

<u>Activation Zinc dust.</u> Zinc dust was activated by stirring with dilute HCl during 10-15 min, and then washed several times with distilled H<sub>2</sub>O, EtOH and absolute Et<sub>2</sub>O before rigorous drying. This procedure removes oxides from the surface of zinc, which form slowly upon standing in air.

<u>Preparation of the solution of Reformatsky reagent.</u> Under N<sub>2</sub> atmosphere, to a two-neck round bottom flask were added the above activated zinc (3 mmol) and dry THF (4 mL). The suspension was warmed to 40-50 °C, and methyl bromoacetate (**2a**, 3 mmol) in THF (1 mL) was added dropwise. After insoluble matter precipitated, the light yellow supernatant solution was decanted and used for subsequent experiments.

#### General procedure for the zinc promoted aza-Reformatsky reaction.

Method A (two-step protocol): to a solution of trifluoromethyl aldimines (1a,c 0.5 mmol) in THF (1 mL) warmed to 40 °C, the above methyl bromozincacetate/THF

<sup>&</sup>lt;sup>1</sup> See ref.17 in the **Chapter 1**.

<sup>&</sup>lt;sup>2</sup> See ref.54 in the **Chapter 2**.

solution was added. The resulting mixture was stirred at the same temperature for 18 h. The mixture was quenched with saturated aqueous NH<sub>4</sub>Cl, and then extracted with AcOEt. The organic layer was concentrated *in vacuo* to give the crude oil. The residues purified by flash chromatography on silica gel (eluent hexane/ethyl acetate = 80:20).

Method **B** (one-pot protocol): Under N<sub>2</sub> atmosphere, to a two-neck round bottom flask the above activated zinc (3 mmol), dry THF (4 mL), the trifluoromethyl aldimines **1a,c** or **1g** (0.5 mmol) and  $\alpha$ -bromo esters (**2b-c**) were added. The suspensions were warmed to 40-60 °C. The resulting mixtures were stirred at same temperature for the reaction time shown in **Table 2-3** and **8** (**Chap. 7**). The mixture was quenched with saturated aqueous NH<sub>4</sub>Cl, and then extracted with AcOEt. The organic layer was concentrated *in vacuo* to give the crude mixture. The residues purified by flash chromatography on silica gel (eluent hexane/ethyl acetate = 80:20).

#### 1-Benzyl-4-(trifluoromethyl)azetidin-2-one (3).

Bn N F<sub>3</sub>C

Ο

# **Method A**: colorless oil (90 mg, 79 %). IR: 1788, 1200. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 2.92–3.07 (m, 2H), 3.70–3.78 (m, 1H), 3.92 (d, J = 15.1

Hz, 1H), 4.75 (d, J = 15.1 Hz, 1H), 7.35–7.14 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -74.9 (d, J = 5.9 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 38.5 (q, J = 1.8 Hz), 45.7, 49.6 (q, J = 35.0 Hz), 124.4 (q, J = 279.3 Hz), 128.1, 128.4 (2C), 128.9 (2C), 134.5, 165.1. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>11</sub>H<sub>11</sub>F<sub>3</sub>NO 230.0793, found 230.0785.

Bn N **Hethod B**: colorless oil (85 mg, 70 %). IR: 1782. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.31 (d, J = 7.4 Hz, 3H), 3.30 (qd, J = 7.8, 1.9 Hz, 1H), 3.39 (qd, J = 6.0, 2.2 Hz, 1H), 3.95 (d, J = 15.1 Hz, 1H), 4.85 (d, J = 15.2 Hz, 1H), 7.24–7.42 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -74.1 (d, J = 5.8 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 12.3, 45.4, 46.9 (q, J = 1.8 Hz), 57.2 (q, J = 34.2 Hz), 124.4 (q, J = 279.3 Hz),

128.1, 128.4 (2C), 129.0 (2C), 134.8, 169.1. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>12</sub>H<sub>13</sub>F<sub>3</sub>NO 244.0949, found 244.0953.



**1-Benzyl-3-phenyl-4-(trifluoromethyl)azetidin-2-one** (*trans*-**5**). **Method B**: colorless oil (126 mg, 83 %). IR: 1780. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 3.80 (qd, J = 5.9, 2.4, 1H), 4.05 (d, J = 15.1 Hz, 1H), 4.46 (J = 2.1 Hz, 1H), 4.98 (d, J = 15.0 Hz, 1H), 7.14–

7.42 (m, 10H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -73.8 (d, J = 6.5 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 45.7, 56.3, 57.9 (q, J = 34.0 Hz), 124.3 (q, J = 279.9 Hz), 127.2 (2C), 128.3 (2C), 128.5 (2C), 129.0 (2C), 129.1 (2C), 132.6, 134.6, 166.5. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>15</sub>F<sub>3</sub>NO 306.1106, found 306.1153.



(*R*)-1-[(**R**)-1-Phenylethyl]-4-(trifluoromethyl)azetidin-2-one (7). Method A: colorless oil (38 mg, 31 %) Separated by HPLC (eluent: hexane/ethyl acetate = 90:10). IR: 1775.  $[\alpha]_D = 43.8$  (*c* = 4 g/100 mL, CHCl<sub>3</sub>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.82 (d, *J* = 7.2 Hz,

3H), 3.01 (m, 2H), 3.71–3.87 (m, 1H), 4.51 (q, J = 7.1 Hz, 1H), 7.28–7.39 (m, 5H). <sup>19</sup>F NMR (CDCb): –74.8 (d, J = 7.5 Hz). <sup>13</sup>C NMR (CDCb<sub>3</sub>): 19.7, 37.9, 49.4 (q, J = 34.9 Hz), 56.0, 124.5 (q, J = 279.6 Hz), 126.6 (2C), 128.0, 128.9 (2C), 135.8, 165.3. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>12</sub>H<sub>13</sub>F<sub>3</sub>NO 244.0949 found 244.0955.

(S) - 1 - [(R) - 1 - Phenylethyl] - 4 - (trifluoromethyl) azetidin - 2 - one



(7'). Method A: colorless oil (40 mg, 33 %) Separated by HPLC (eluent: hexane/ethyl acetate = 90:10). IR: 1778. [ $\alpha$ ]<sub>D</sub>: 28.2 (c =

4 g/100 mL, CHCl<sub>3</sub>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.62 (d, J = 7.3 Hz, 3H), 2.92–3.09 (m, 1H), 3.68–3.73 (m, 1H), 5.06 (q, J = 7.3 Hz, 1H), 7.31–7.41 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -74.8 (d, J = 5.4 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 18.0, 38.1, 49.7 (q, J = 35.7 Hz ), 52.1, 124.3 (q, J = 279.0 Hz), 127.2, 128.1 (2C), 128.9 (2C), 138.6, 165.3. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>12</sub>H<sub>13</sub>F<sub>3</sub>NO 244.0949, found 244.0951.



#### (3*S*,4*R*)-3-Methyl-1-[(*R*)-1-phenylethyl]-4-

(trifluoromethyl)azetidin-2-one (*trans-8*). Method B: colorless oil (43 mg, 33 %). Separated by HPLC (eluent: hexane/ethyl acetate = 90:10). IR: 1780.  $[\alpha]_D = 30.1$  (c = 3 g/100 mL, CHCl<sub>3</sub>).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.30 (d, J = 7.4 Hz, 3H), 1.82 (d, J = 7.2 Hz, 3H), 3.20 (qd, J=7.4, 2.1 Hz, 1H), 3.36 (qd, J=6.0, 2.2 Hz, 1H), 4.48 (q, J=7.2 Hz, 1H), 7.27–7.41 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -74.1 (d, J= 6.4 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 12.4, 19.9, 46.0, 55.8, 57.0 (q, J=34.0 Hz ), 124.4 (q, J=279.4 Hz), 126.5 (2C), 127.9, 128.9 (2C), 140.9, 169.3. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>13</sub>H<sub>15</sub>F<sub>3</sub>NO 258.1106, found 258.1115.

#### (3R,4S)-3-Methyl-1-[(R)-1-phenylethyl]-4

#### (trifluoromethyl)azetidin-2-one (trans-8').

Ph Method B: colorless oil (40 mg, 31 %). Separated by HPLC (eluent: hexane/ethyl acetate = 90:10). IR: 1779. [α]<sub>D</sub> = 38.3 (c = 3 g/100 mL, CHCl<sub>3</sub>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.25 (d, J = 7.3 Hz, 3H), 1.60 (d, J = 7.4 Hz, 3H), 3.16–3.28 (m, 2H), 5.10 (q, J = 7.4 Hz, 1H), 7.30–7.41 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -74.1 (d, J = 6.0 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 12.2, 17.6, 46.3, 51.3, 57.2 (q, J = 34.7 Hz ), 124.3 (q, J = 279.1 Hz), 127.2 (2C), 128.1, 128.9 (2C), 138.5, 169.3 HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>13</sub>H<sub>15</sub>F<sub>3</sub>NO 258.1106, found 258.1130.

#### (3*S*,4*R*)-3-Phenyl-1-[(*R*)-1-phenylethyl]-4-



Ο

(trifluoromethyl)azetidin-2-one (*trans-9*). Method B colorless oil (40 mg, 25 %). Separated by HPLC (eluent: hexane/ethyl acetate = 90:10). IR: 1779, 1500. [ $\alpha$ ]<sub>D</sub>: 38.3 (c =

3 g/100 mL, CHCl<sub>3</sub>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.89 (d, *J* = 7.2 Hz, 3H), 3.77 (qd, *J* = 5.9,

2.4 Hz, 1H), 4.36 (d, J = 2.4 Hz, 1H), 4.59 (q, J = 7.1 Hz, 1H), 7.15–7.52 (m, 10H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -73.7 (d, J = 5.9 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 19.8, 55.5 (q, J = 1.7Hz), 56.1, 57.7 (q, J = 33.9 Hz), 124.3 (q, J = 280.01 Hz), 126.7 (2C), 127.3 (2C), 128.1, 128.2, 128.9 (2C), 129.1 (2C), 132.9, 140.7, 166.6. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>NO 320.1262, found 320.1280.

#### (3*R*,4*S*)-3-Phenyl-1-[(*R*)-1-phenylethyl]-4-

(trifluoromethyl)azetidin-2-one (*trans-9'*). Method B: colorless oil (59 mg, 37 %). Separated by HPLC (eluent: hexane/ethyl acetate = 90:10). IR: 1779, 1500.  $[\alpha]_D = 19.5$  (c =

3 g/100 mL, CHCl<sub>3</sub>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.68 (d, J = 7.2 Hz, 3H), 3.69 (qd, J = 5.8, 2.4 Hz, 1H), 4.33 (d, J = 2.4 Hz, 1H), 5.20 (q, J = 7.2 Hz, 1H), 7.15–7.39 (m, 10H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -73.7 (d, J = 5.9 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 17.8, 52.0, 55.8 (q, J = 1.77 Hz), 58.0 (q, J = 34.5 Hz), 124.2 (q, J = 279.4 Hz), 127.3 (4C), 128.2 (2C), 128.9 (2C), 129.1 (2C), 132.8, 138.5, 166.6. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>NO 320.1262, found 320.1235. 2D NMR spectra and optimized geometries to determine the absolute configuration of the new chiral centers.

1. To determine the absolute configuration of the new chiral centers 2D NOESY NMR spectra and optimized geometries of the  $\beta$ -lactams 8 and 8' were considered.



Figure 1. 2D NOESY NMR spectrum of 8.



Figure 2. 2D NOESY NMR spectrum of 8'.

The cross peak between the protons  $H_b$  and  $H_c$  was used as a distance ruler and its volume was set to 10.00 a.u.; the cross peak between  $H_a$  and the protons  $H_c$  of the methyl group can be easily determinate for **8**, the value is 1.33 a.u. (corresponding to an interproton distance of 3.73 Å). The NOESY spectrum of **8'** did not show the correlation between  $H_a$ and  $H_c$ . The same correlation value (5.99 a.u. corresponding to an interproton distance of 2.90 Å) was found for the cross peak between  $H_a$  and the protons  $H_d$  of the methyl group in the NOESY spectra of **8** and **8'**.<sup>3</sup>

$$\frac{V_X}{V_R} = \left(\frac{d_R}{d_X}\right)^6$$

<sup>&</sup>lt;sup>3</sup> The 2D NOESY <sup>1</sup>H NMR analysis permit to determinate the relative interproton distances and thus molecular geometry, by the following equation:

in which  $V_R$  is the volume of the reference cross peak,  $d_R$  is the corresponding interproton distance and  $V_X$  is the volume relative to the unknown distance  $d_X$ . As suggested by the equation, if the protons are too far apart do not generate a NOESY correlation.



Figure 3. Optimized geometries.

By NOESY analysis coupled with computational studies, the (R,R,S) absolute configurations can be assigned to *trans*-**8**, and the (R,S,R) to *trans*-**8'**.

( <i>R,R,R</i> ) Center Number	Atomic Number	Atom Type	ic ,	Coordinates	(Angstroms) ( Z
1	6	0	-0.030770	0.044215	0.016045
2	7	0	0.050861	-0.112647	1.480246
3	6	0	1.414475	0.115317	1.535185
4	6	0	1.492488	0.417950	0.033493
5	8	0	2.206231	0.014185	2.449538
6	6	0	1.952799	1.822866	-0.358470
7	1	0	2.080738	-0.336511	-0.493770
8	1	0	-0.238063	-0.878839	-0.537118
9	6	0	-1.016806	1.083784	-0.492209
10	6	0	-0.727092	-0.888853	2.471065
11	6	0	-1.023381	-0.032013	3.696199
12	6	0	-0.747454	-0.520739	4.975982
13	1	0	-0.283746	-1.497887	5.086563
14	6	0	-1.060909	0.234255	6.108360
15	1	0	-0.838996	-0.158893	7.096141
16	6	0	-1.649838	1.491348	5.969295
17	1	0	-1.891049	2.081565	6.848118

Calculated Coordinates:

18	6	0	-1.919493	1.991736	4.691728
19	1	0	-2.368084	2.974164	4.575472
20	6	0	-1.608736	1.235263	3.563105
21	1	0	-1.793014	1.639930	2.572501
22	1	0	-0.079694	-1.715513	2.787095
23	6	0	-1.998635	-1.478539	1.852358
24	1	0	-2.693364	-0.697718	1.540980
25	1	0	-2.495171	-2.101700	2.600967
26	1	0	-1.764710	-2.107832	0.989057
27	9	0	-2.281525	0.599509	-0.515700
28	9	0	-0.706061	1.427025	-1.763571
29	9	0	-1.033302	2.207830	0.255023
30	1	0	1.396566	2.592325	0.180243
31	1	0	1.824333	1.987713	-1.430422
32	1	0	3.014291	1.931289	-0.118777

(R,S,S)

Center Number	Atomic Number	Atomic Type	X	Coordinates	(Angstroms) (    Z
			0 009754	0 172624	0 040759
1 2	7	0	-0.098734	-0.173034 -0.373175	1 504604
2	6	0	1 206967	-0.373175	1 502654
7	6	0	1 330596	0.099243	0 103792
5	8	0	2 070444	0.173283	2 526327
6	1	0	1 225414	1 568660	0 001578
7	6	Õ	2 505259	-0.007080	-0 734670
8	6	0	-0 207741	-1 439734	-0 793839
9	1	õ	-0.902477	0.496261	-0.270421
10	6	Ő	-0.887377	-0.827922	2.583427
11	ő	õ	-0.945260	0.194939	3.715779
12	6	õ	-0.782006	-0.223409	5.039791
13	1	Ō	-0.555983	-1.266156	5.247888
14	6	0	-0.899504	0.684452	6.094454
15	1	Ō	-0.765125	0.343100	7.116695
16	6	0	-1.178304	2.026637	5.834310
17	1	0	-1.264905	2.735665	6.652296
18	6	0	-1.339770	2.454427	4.513859
19	1	0	-1.553742	3.498124	4.302345
20	6	0	-1.225623	1.544354	3.463570
21	1	0	-1.347995	1.886840	2.439669
22	1	0	-0.459983	-1.753232	2.989608
23	6	0	-2.297135	-1.139284	2.062791
24	1	0	-2.764700	-0.250109	1.629027
25	1	0	-2.915432	-1.463216	2.903179
26	1	0	-2.288662	-1.932992	1.315667
27	1	0	2.388798	0.271013	-1.784867
28	1	0	2.629737	-1.089707	-0.674365
29	1	0	3.419683	0.459984	-0.357816
30	9	0	-1.463966	-1.945910	-0.806072
31	9	0	0.609672	-2.420651	-0.360995
32	9	0	0.107587	-1.166687	2.079470

(R,R,S)

Center Number	Atomic Number	Atomic Type	C X	coordinates ( Y	(Angstroms) 7
				·	
1	6	0	-0.069121	0.098485	0.093862
2	7	0	0.251663	-0.144559	1.510361
3	6	0	1.609352	0.023121	1.333152
4	6	0	1.436182	0.440595	-0.140369
5	8	0	2.545265	-0.175393	2.079123
6	1	0	1.600662	1.512482	-0.282614

7	6	0	2.200665	-0.379192	-1.171220
8	1	0	-0.411679	-0.788633	-0.448298
9	6	0	-1.052235	1.218094	-0.195151
10	6	0	-0.427576	-0.880433	2.583959
11	6	0	-0.933109	0.011217	3.718325
12	6	0	-1.222973	-0.586203	4.953905
13	1	0	-1.056533	-1.652739	5.086940
14	6	0	-1.713185	0.169737	6.017506
15	1	0	-1.927733	-0.311359	6.967425
16	6	0	-1.917998	1.543298	5.863545
17	1	0	-2.296512	2.136180	6.690935
18	6	0	-1.623070	2.147353	4.641699
19	1	0	-1.770408	3.215928	4.513236
20	6	0	-1.132915	1.387434	3.575965
21	1	0	-0.892711	1.874249	2.638820
22	1	0	0.346815	-1.532772	3.006829
23	6	0	-1.543812	-1.768510	2.011373
24	1	0	-2.321188	-1.163263	1.538974
25	1	0	-2.005538	-2.342669	2.817459
26	1	0	-1.145574	-2.474820	1.276492
27	9	0	-2.291597	0.947588	0.274300
28	9	0	-1.152809	1.400747	-1.529142
29	9	0	-0.670836	2.396768	0.348081
30	1	0	1.901018	-0.104949	-2.186754
31	1	0	2.026518	-1.451602	-1.038253
32	1	0	3.274044	-0.196349	1.070399

(R,S,R) Center Number	Atomic Number	Atomic Type	c x	coordinates ( Y	(Angstroms) Z
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 20 21 22 23 24 25 26 27 28 29 30 31 20 21 22 23 24 25 26 27 27 28 29 30 31 20 21 22 23 24 25 26 27 27 28 29 30 31 20 21 22 23 24 25 26 27 27 27 27 27 27 27 27 27 27	67668616166661616161119999111		$\begin{array}{c} -0.021747\\ 0.014262\\ 1.331175\\ 1.455429\\ 2.072158\\ 1.734319\\ 2.151161\\ -0.169826\\ -0.745172\\ -0.881625\\ -0.974406\\ -0.673779\\ -0.333318\\ -0.801265\\ -0.974406\\ -0.673779\\ -0.333318\\ -0.801265\\ -0.560930\\ -1.227133\\ -1.322043\\ -1.322043\\ -1.524342\\ -1.851937\\ -1.400154\\ -1.626302\\ -0.417792\\ -2.268322\\ -2.213678\\ -1.459051\\ 0.511016\\ 0.309988\\ 1.024296\\ 1.660305\\ -0.40055\\ -0.40055\\ -0.40055\\ -0.40055\\ -0.40055\\ -0.40055\\ -0.40055\\ -0.40055\\ -0.40055\\ -0.40055\\ -0.40055\\ -0.40055\\ -0.40055\\ -0.40055\\ -0.4005\\ -0.40$	$\begin{array}{c} -0.051731\\ -0.203351\\ 0.172964\\ 0.441039\\ 0.231045\\ 1.883501\\ -0.248511\\ -1.318382\\ 0.684344\\ -0.732212\\ 0.260767\\ -0.146090\\ -1.163065\\ 0.742141\\ 0.412046\\ 2.050873\\ 2.744565\\ 2.468513\\ 3.488180\\ 1.578998\\ 1.914081\\ -1.650818\\ -1.080240\\ 0.204791\\ -1.425420\\ -1.871168\\ -1.702618\\ -2.358855\\ -1.094877\\ 2.570717\\ 1.995882\\ -1.995882\\ -1.16102\\ -1.1$	$\begin{array}{c} 0.036410\\ 1.500542\\ 1.623394\\ 0.117030\\ 2.582172\\ -0.291653\\ -0.370060\\ -0.802772\\ -0.330035\\ 2.548785\\ 3.699293\\ 5.003085\\ 5.182805\\ 6.073074\\ 7.079611\\ 5.847927\\ 6.677950\\ 4.548055\\ 4.366127\\ 3.481726\\ 2.472882\\ 2.927123\\ 2.002013\\ 1.255628\\ -0.949362\\ -0.277842\\ -2.048280\\ 0.178949\\ -1.376781\\ \end{array}$
52	±	U	2.742980	2.1/3103	0.014930

As a consequence of the reported procedure the following absolute configurations can be assigned: (R,R)-7, (R,S)-7', (R,R,S)-9, (R,R,S)-9'.



2D NMR spectra and optimized geometries of 7 and 7'

The cross peak between the protons  $H_b$  and  $H_c$  was used as a distance ruler and its volume was set to 10.00 a.u. The cross peak between  $H_a$  and the protons  $H_c$  of the methyl group can be easily determinate for **7**, the value is 1.22 a.u. (corresponding to an interproton

distance of 3.791 Å). The NOESY spectrum of 7' did not show the correlation between  $H_a$  and  $H_c$ .



Figure 6. Optimized geometries of obtained (R,R)-7 and of (R,R)-7'.

Calculated Coordinates:

(R,R)Center Atomic Atomic Coordinates (Angstroms) Number Number туре Х Υ Ζ 0.319294 0.300927 6 0 2.028801 1 2 3 7 0 0.715638 0.981742 0.322350 6 1.992429 -0.533913 0 1.085742 4 6 0 2.486676 1.388023 -0.732120 5 0.493405 8 0 2.982503 -0.910293 6 1 0 2.683296 1.012710 -1.7378747 1 2.024038 0 3.308552 -0.400594 1 8 0 2.566211 0.341955 1.253854 9 6 0 2.050834 -1.110589 -0.210281 10 6 0 -0.482403 0.894058 1.174012 6 0 11 -1.6510470.215583 0.461519 6 0 12 -2.7208130.999103 0.012164 13 1 0 2.074350 -2.6966490.168955 14 6 0 -3.811076 0.419241 -0.639666 15 1 0 -4.631410 1.044585 -0.979708 16 6 0 -3.842915 -0.958895 -0.853860 17 1 0 -4.688681 -1.414516-1.360364 18 6 0 -1.749468 -0.414323 -2.778233 19 1 0 -2.793979 -2.822955 -0.579476 20 6 0 -1.690923 -1.168176 0.238356 21 1 0 -0.871723-1.7984320.565975 1 0 -0.772685 22 1.938067 1.336354 23 6 0 -0.1399630.276548 2.534084 24 1 0 0.223514 -0.749042 2.435687 25 1 -1.0337710.260546 0 3.162295 26 1 0 0.626988 0.867485 3.043609 27 9 0 -1.254345 1.372789 -1.363371

28 29	9 9	0 0	1.514919 3.325132	-1.978148 -1.502386	0.686917 -0.424013
( <i>R</i> , <i>S</i> ) Center Number	Atomic Number	Atomic Type	C X	Coordinates ( Y	(Angstroms) Z
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28	6 7 6 8 1 1 6 1 6 1 6 1 6 1 6 1 6 1 6 1 1 6 1 9 9		-1.928509 -0.519464 -0.423043 -1.854828 0.458896 -1.908099 -2.532966 -2.900352 -2.131445 0.347349 1.810751 2.542097 2.044071 3.903126 4.455810 4.546714 5.603858 3.822768 4.316132 2.466418 1.911553 0.054284 0.135999 0.405012 0.771771 -0.900912 -2.751097 -2.734356	$\begin{array}{c} 0.385909\\ 0.296556\\ 1.632777\\ 1.912608\\ 2.297556\\ 2.529374\\ 2.299026\\ -0.348107\\ 0.082407\\ -0.881456\\ -0.482483\\ -0.875347\\ -1.416417\\ -0.578857\\ -0.890893\\ 0.119776\\ 0.354989\\ 0.518522\\ 1.066416\\ 0.216755\\ 0.536711\\ -1.389881\\ -1.859275\\ -1.395141\\ -2.736164\\ -2.198203\\ -1.692433\\ -1.692433\\ -0.006220\\ \end{array}$	$\begin{array}{c} 0.700578\\ 0.292456\\ -0.057770\\ 0.434081\\ -0.554536\\ 1.332515\\ -0.327996\\ -0.210706\\ 1.731244\\ 0.126494\\ -0.000373\\ -1.125476\\ -1.925870\\ -1.231292\\ -2.112594\\ -0.210198\\ -0.290747\\ 0.917111\\ 1.714650\\ 1.022110\\ 1.899511\\ -0.801556\\ 1.294956\\ 2.247981\\ 1.148954\\ 1.346883\\ -0.131841\\ -1504928 \end{array}$
29	9	õ	-4.173983	-0.063958	0.133326



2D NMR spectra and optimized geometries of 9 and 9'

The cross peak between the protons  $H_b$  and  $H_c$  was used as a distance ruler and its volume was set to 10.00 a.u.; the cross peak between  $H_a$  and the protons  $H_c$  of the methyl group can be easily determinate for **9**, the value is 2.84 a.u. (corresponding to an interproton distance of 3.041 Å). The NOESY spectrum of **9'** did not show the correlation between  $H_a$ and  $H_c$ 



Figure 9. Optimized geometries of obtained (R,R,S)-9 and of (R,S,S)-9'.

Calculated Coordinates:

(R,R,S)				
Center Number	Atomic Number	Atomic Type	Coordinates ( X Y	Angstroms) Z
1	6	0	1.696227 -0.562460	0.347369
2	7	0	0.531688 0.240467	-0.091987
3	6	0	1.255292 0.968340	-0.992088
4	6	0	2.442949 -0.031342	-0.913761
5	8	0	1.002826 2.009651	-1.550193
6	1	0	2.439984 -0.716517	-1.773065
7	6	0	3.865988 0.639264	-0.708583
8	1	0	2.108799 -0.198162	1.296351
9	6	0	1.498/8/ -2.062538	0.34/213
10	6	0		0.701029
11	6	0		0.121153
12	6 1	0	-2.932336 1.406022	0.109780
14	L 6	0	-2.749052 2.412074	0.401002
14	0	0		-0.374661
16	1	0	-4.987005 1.840705 -4.466607 $-0.191975$	
17	1	0	-4.400007 -0.191973	-0.033070
18	6	0	-3 461777 $-1$ 155939	-0.849394
19	1	Õ	-3 664895 -2 155451	-1 225246
20	6	0	-2.192564 -0.841878	-0.358726
21	1	õ	-1.431066 -1.616982	-0.357301
22	1	Õ	-0.431355 1.896336	0.646291
23	6	0	-0.498861 0.416927	2.180474
24	1	Ō	-0.612593 -0.661842	2.325031
25	1	0	-1.304044 0.908062	2.739048
26	1	0	0.448531 0.721882	2.636932
27	9	0	0.685154 -2.443929	1.356831
28	9	0	2.687486 -2.686126	0.518116
29	9	0	0.961577 -2.501512	-0.813244
30	6	0	4.879939 -0.023623	0.018427
31	6	0	4.220591 1.889060	-1.255376
32	1	0	3.496886 2.446494	-1.850175
33	6	0	5.486687 2.453535	-1.066980
34	6	0	6.449864 1.775892	-0.329560
35	1	0	5.716084 3.422594	-1.503295
36	6	0	6.148166 0.532742	0.211364
37	1	0	7.434495 2.211995	-0.184820
38	1	0	6.899523 -0.010551	0.778906
39	1	0	4.684970 -1.007935	0.442339

## (R,R,S)

Center	Atomic	Atomic	Coordinates (Angstroms)			
Number	Number	Туре	X Y Z			
1	6	0	1.690260 0.248200 -0.559510			
2	7	0	0.334370 0.173480 0.034880			
3	6	0	0.544110 1.207990 0.896600			
4	6	0	1.854740 1.609410 0.182300			
5	8	0	-0.048530 1.554390 1.891600			
6	6	0	1.793260 2.834660 -0.657400			
7	6	0	2.730360 -0.761510 -0.116680			
8	1	0	1.632030 0.322400 -1.652150			
9	6	0	-0.551560 -0.938470 0.303950			
10	6	0	-1.993180 -0.515910 0.045030			
11	6	0	-2.916470 -0.473690 1.100830			
12	1	0	-2.606200 -0.719680 2.114280			
13	6	0	-4.242610 -0.102010 0.871260			
14	1	0	-4.946850 -0.070370 1.698480			
15	6	0	-4.661720 0.236260 -0.413610			
16	1	0	-5.693450 0.528580 -0.589360			
17	6	0	-3.754060 0.211610 -1.469860			
18	1	0	-4.077770 0.485340 -2.470460			
19	6	0	-2.427550 -0.158770 -1.242930			
20	1	0	-1.731480 -0.161810 -2.078390			
21	1	0	-0.443400 -1.179130 1.369820			
22	6	0	-0.243630 -2.206930 -0.492370			
23	1	0	-0.107890 -2.002050 -1.559780			
24	1	0	-1.046100 -2.946350 -0.387670			
25	1	0	0.667360 -2.683080 -0.120920			
26	9	0	2.657280 -1.889810 -0.856570			
27	9	0	2.584990 -1.093310 1.185090			
28	9	0	3.973600 -0.251540 -0.282500			
29	6	0	2.817560 3.017670 -1.690690			
30	6	0	2.884480 4.261960 -2.443960			
31	1	0	3.641830 2.318090 -1.780320			
32	6	0	0.937890 3.964660 -0.297720			
33	1	0	2.697200 1.653410 0.885540			
34	6	0	1.016000 5.210390 -1.048040			
35	1	0	0.336970 3.946090 0.606310			
36	6	0	1.997050 5.364620 -2.110230			
37	1	0	0.465140 6.076050 -0.699400			
38	1	0	3.720260 4.437780 -3.111000			
39	1	0	2.181620 6.347350 -2.528900			



Methyl 3-[2-oxo-4-(trifluoromethyl)azetidin-1yl]propanoate (18).

Method B: colorless oil (38 mg, 34 %). purified by flash chromatography on silica gel (eluent CH2Cl2 with 2% of

MeOH). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 2.59–2.74 (m, 2H), 2.95–3.17 (m, 1H), 3.34–3.42 (m, 1H), 3.67–3.75 (m, 4H), 4.07–4.15 (m, 1H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -75.3 (d, J = 7.1 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 32.3, 37.9, 38.5, 51.2 (q, J = 34.9 Hz), 52.0, 124.5 (q, J = 279.4 Hz), 165.3, 171.4. (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>8</sub>H<sub>11</sub>F<sub>3</sub>NO<sub>3</sub> 226.0691, found 226.0635.



Methyl 3-[3-methyl-2-oxo-4-(trifluoromethyl)azetidin-1yl]propanoate (*trans*-19).

**Method B**: colorless oil (48 mg, 40 %). The residue purified by flash chromatography on silica gel (eluent CH<sub>2</sub>Cl<sub>2</sub> with 2% of MeOH). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.35 (d, J = 7.4 Hz, 3H),

2.6 (dt, J = 16.3, 6.6 Hz, 1H), 2.68–2.78 (m, 1H), 3.22 (qd, J = 7.2, 1.7 Hz, 1H), 3.29–3.43 (m, 1H), 3.63–3.77 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -74.7 (d, J=6.5 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 12.4, 32.3, 37.8, 46.9, 51.9, 58.8 (q, J = 34.1 Hz), 124.5 (q, J = 279.2 Hz), 169.1, 171.4. (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>9</sub>H<sub>13</sub>F<sub>3</sub>NO<sub>3</sub> 240.0848, found 240.0865.



Methyl 3-[2-oxo-3-phenyl-4-(trifluoromethyl)azetidin-1-vllpropanoate (*trans*-20).

**Method B**: colorless oil (63 mg, 42 %). The residue purified by flash chromatography on silica gel (eluent hexane/ethyl acetate = 80:20). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 2.63 (dt,

J = 16.2, 6.3 Hz, 1H), 2.73–2.87 (m, 1H), 3.37–3.51 (m, 1H), 3.67 (s, 3H), 4.07–4.13 (m, 1H), 4.39 (s, 1H), 7.23–7.40 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -74.3 (d, *J*=6.3 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 32.3, 37.9, 51.9, 56.2, 59.3 (q, *J* = 33.9 Hz), 124.3 (q, *J* =

279.7 Hz), 127.2 (2C), 128.2, 129.0, 132.6, 166.3, 171.2. (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>15</sub>F<sub>3</sub>NO<sub>3</sub> 302.1004, found 302.1052.

General procedure of the racemic Et<sub>2</sub>Zn-promoted aza-Reformatsky reaction  $\alpha$ -Bromo ester **2a-c** (1.0 mmol) was added to a solution of the corresponding imine **1a,c** or **1g** (0.5 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) at ambient temperature. Then, 1.0 M Et<sub>2</sub>Zn in hexane (1.0 mL, 1.0 mmol) was slowly added to the mixture at the appropriate temperature (reported in **Table 4,5,7** and **9 Chap. 7**, pp. 80, 81, 85, 89). The whole mixture was stirred at the same temperature for the appropriate time. The mixture was quenched with saturated aqueous NaHCO<sub>3</sub>, and was extracted with AcOEt. Then the extract was washed with brine and dried over MgSO<sub>4</sub>. The solvent was removed *in vacuo* and the residue was purified by column chromatography (AcOEt: hexane = 5:95) to afford the corresponding  $\beta$ -amino esters.

# General procedure of the Et<sub>2</sub>Zn-promoted asymmetric aza-Reformatsky <u>reaction</u>

α-Bromo ester **2a-c** (1.0 mmol) was added to a solution of the corresponding imine **1a,c** or **1g** (0.5 mmol) and (1*R*,2*S*)-1-phenyl-2-(1-pyrrolidinyl)propan-1-ol **6** (0.38 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) at ambient temperature. Then the mixture was cooled to -20 °C, and 1.0 M Et<sub>2</sub>Zn in hexane (1.2 mL, 1.2 mmol) was slowly added to the mixture at the same temperature. The whole mixture was stirred at the same temperature for the appropriate time (reported in **Table 6**, **Chap 7**, p. 83). The mixture was quenched with saturated aqueous NaHCO<sub>3</sub>, and extracted with AcOEt. Then the extract was washed with brine and dried over MgSO<sub>4</sub>. The solvent was removed *in vacuo* and the residue was purified by column chromatography (AcOEt: hexane: 5:95) to afford the corresponding β-amino esters. Bn NH O  $F_3C$  (10'). Colorless oil (65 mg, 50%). IR: 1745. [ $\alpha$ ]<sub>D</sub> = -15.8 (c = 2.7 g/100 mL, CHCl<sub>3</sub>). The ee was determined to be 98% by HPLC (Column Lux 5u Amylose-2), hexane/EtOH = 95:5, 0.7 ml/min, 206 nm, major 7.77 min and minor 6.91 min). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.65 (br, 1H), 2.50 (dd, J= 15.6, 9.7 Hz, 1H), 2.70 (dd, J = 15.5, 4.0 Hz, 1H), 3.56–3.68 (m, 1H), 3.69 (s, 3H), 3.87 (d, J = 13.0 Hz, 1H), 4.01 (d, J = 13.0 Hz, 1H), 7.21–7.38 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -74.8 (d, J = 7.5 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 34.7, 51.8, 52.1, 55.9 (q, J = 28.7 Hz), 126.2 (q, J = 284.4 Hz), 127.4, 128.4 (4C), 138.8, 170.4. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>12</sub>H<sub>15</sub>F<sub>3</sub>NO<sub>2</sub> 262.1055, found 262.1068.

Methyl (2*S*,3*S*)-3-(benzylamino)-4,4,4-trifluoro-2methylbutanoate (*syn*-12'). Colorless oil (71 mg, 52%). IR: 1758. [ $\alpha$ ]<sub>D</sub> = -20.0 (*c* = 2.4 g/100 mL, CHCl<sub>3</sub>) The ee was determined to be 98% by HPLC (Column Lux 5u Amylose-2), hexane/EtOH = 95:5, 0.7 mL/min, 206 nm, major 9.12 min and minor 9.62 min). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.24 (d, *J* = 7.1 Hz, 3H), 1.76 (br, 1H), 2.86 (qd, *J* = 7.1, 4.5 Hz, 1H), 3.63 (s, 3H), 3.64–3.73 (m, 1H), 3.84 (d, *J* = 13.1 Hz, 1H), 4.03 (d, *J* = 13.0 Hz, 1H), 7.23–7.40 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -71.1 (d, *J* = 7.3 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 10.8, 39.5, 52.0, 52.3, 59.4 (q, *J* = 27.0 Hz), 126.6 (q, *J* = 286.1 Hz), 127.3, 128.3 (2C), 128.4 (2C), 139.3, 173.7. HR-MS (ESI Q-TOF) (*m*/*z*) [M + H]<sup>+</sup> calcd for C<sub>13</sub>H<sub>17</sub>F<sub>3</sub>NO<sub>2</sub> 276.1211, found 276.1258.



Methyl (2*R*,3*S*)-3-(benzylamino)-4,4,4-trifluoro-2phenylbutanoate (*anti*-13'). Colorless oil (98 mg, 58%). IR: 1779.  $[\alpha]_D = 18.3$  (*c* = 1.5 g/100 mL, CHCb). The ee was determined to be 91% by HPLC of *trans*-5, obtained after cyclization of *anti*-13' (Column Lux 5u Amylose-2).

hexane/EtOH = 95:5, 1.0 mL/min, 206 nm, major 5.24 min and minor 5.91 min). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.64 (br, 1H), 3.63 (d, J = 12.9 Hz, 1H), 3.68 (s, 3H), 3.81 (d, J = 12.9 Hz, 1H), 3.88 (d, J = 9.1 Hz, 1H), 3.93–4.03 (m, 1H), 6.97–7.35 (m, 10H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -73.0 (d, J = 6.5 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 51.4z, 52.5, 52.8, 60.1 (q, J = 27.3 Hz), 126.3 (q, J = 284.6 Hz), 127.3, 128.3 (4C), 128.4, 128.9 (2C), 129.3 (2C), 133.6, 138.8, 171.6. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>19</sub>F<sub>3</sub>NO<sub>2</sub> 338.1368, found 338.1397.

## HPLC trace of racemic 10



# HPLC traces of 10'



	Reten. Time [min]	Area [mV.s]	Height [mV]	Area [%]	Height [%]	W05 [min]	Compound Name
1	6,907	517,332	59,125	0,9	1,1	0,15	
2	7,767	56070,923	5345,700	99,1	98,9	0,17	
	Total	56588,255	5404,824	100,0	100,0		

## HPLC trace of racemic syn-12



HPLC trace of syn-12'



	Reten. Time [min]	Area [mV.s]	Height [mV]	Area [%]	Height [%]	W05 [min]	Compound Name
1	9,108	137665,648	9500,182	99,0	98,9	0,23	
2	9,607	1390,206	108,624	1,0	1,1	0,19	
	Total	139055,854	9608,806	100,0	100,0		
#### HPLC trace of racemic trans-5



	Reten. Time [min]	Area [mV.s]	Height [mV]	Area [%]	Height [%]	W05 [min]	Compound Name
1	5,368	176622,428	11271,893	49,5	49,9	0,26	
2	5,804	180545,968	11296,712	50,5	50,1	0,24	
	Total	357168,396	22568,606	100,0	100,0		

HPLC trace of enantioriched trans-5<sup>4</sup>



	Reten. Time [min]	Area [mV.s]	Height [mV]	Area [%]	Height [%]	W05 [min]	Compound Name
1	5,244	20998,183	2492,955	95,5	94,9	0,14	
2	5,908	997,719	133,942	4,5	5,1	0,13	
	Total	21995,902	2626,897	100,0	100,0		

<sup>&</sup>lt;sup>4</sup> Obtained from the cyclization of *anti*-13'

#### 4,4,4-trifluoro-2-methyl-3-{[(R)-1-Methyl phenylethyl]amino}butanoate (syn-16, 16'). Colorless oil NH O (98 mg, 68%). IR: 1780, 1785. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.15 (d, J Hz, 3H), 1.21 (d, J = 7.1 Hz, 3H), 1.27 (d, J = 6.6 Hz,

3H), 1.30 (d, J = 6.6 Hz, 3H), 1.80 (br, 2H), 2.67–2.75 (m, 1H), 2.81–2.89 (m, 1H), 3.38-3.44 (m, 4H), 3.61-3.68 (m, 4H), 3.92 (q, J = 6.3 Hz, 1H), 4.03 (d, J = 6.2Hz, 1H), 7.20–7.30 (m, 10H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -70.0 (d, J = 10.0 Hz), -72.1 (d, J = 6.2 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 10.3, 10.7, 23.5, 24.8, 39.0, 39.3, 51.8, 52.1, 55.6, 55.9, 57.2 (q, J = 26.4 Hz), 57.4 (q, J = 27.1 Hz), 126.2 (q, J = 284.8 Hz), 126.7 (q, J = 287.6 Hz), 126.8 (2C), 127.3 (2C), 127.4 (2C), 128.3 (2C), 128.5 (2C), 143.7, 144.6, 173.3, 173.9. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>19</sub>F<sub>3</sub>NO<sub>2</sub> 290.1368, found 290.1394.



# Methyl (2*S*,3*S*)-4,4,4-trifluoro-2-methyl-3-{[(*R*)-1-1.31 (d, J = 6.4 Hz, 3H), 1.81 (br, 1H), 2.86–2.94 (m, 1H),

3.67-3.73 (m, 4H), 3.98 (q, J = 6.2 Hz, 1H), 7.26-7.39 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -72.2 (d, J = 7.9 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 10.7, 23.5, 39.1, 52.0, 55.5, 57.4 (q, J =27.1 Hz), 126.3 (q, J = 284.8 Hz), 126.7 (2C), 127.4, 128.5 (2C), 144.8, 173.9. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>19</sub>F<sub>3</sub>NO<sub>2</sub> 290.1368, found 290.1385.



Colorless oil (64 mg, 50%).  $[\alpha]_D = 23.2$  (c = 3 g/100 mL. CHCl<sub>3</sub>). The ee was determined to be 74% by HPLC (Column Lux 5u Amylose-2), hexane/EtOAc = 95:5, 1.0 mL/min, 203 nm, major 7.82 min and minor 8.77 min). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 2.47–2.55 (m, 4H), 2.7 (dd, J = 15.8, 3.9 Hz, 1H), 2.93–3.01

(m, 1H) , 3.0.9-3.17 (m 1H), 3.58-3.64 (m, 1H), 3.68 (s, 3H), 3.73 (s, 3H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -75.5 (d, *J*=7.9 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 34.1, 43.4, 51.7, 52.2, 56.7 (q, *J* = 29.4 Hz), 125.6 (q, *J* = 283.7 Hz), 170.2, 172.6. HR-MS (ESI Q-TOF) (*m*/*z*) [M + H]<sup>+</sup> calcd for C<sub>9</sub>H<sub>15</sub>F<sub>3</sub>NO<sub>4</sub> 258.0953 found 258.0908.





	Reten. Time [min]	Area [mV.s]	Height [mV]	Area [%]	Height [%]	W 05 [min]	Compound Name
1	8,096	697,357	53,849	49,5	50,6	0,18	
2	8,844	712,594	52,545	50,5	49,4	0,20	
	Total	1409,951	106,394	100,0	100,0		



	Reten. Time [min]	Area [mV.s]	Height [mV]	Area [%]	Height [%]	W05 [min]	Compound Name
1	7,824	12182,682	680,149	87,1	82,1	0,28	
2	8,768	1809,883	148,318	12,9	17,9	0,19	
	Total	13992,565	828,467	100,0	100,0		

#### 4,4,4-trifluoro-3-[(3-methoxy-3-Methyl



oxopropyl)amino]-2-methylbutanoate (syn-22). Colorless oil (65 mg, 48%). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.21 (d, J = 7.1 Hz, 3H), 1.65 (br, 1H), 2.45 (t, J = 6.3 Hz, 2H),

2.77-2.94 (m, 2H), 3.08-3.16 (m, 1H), 3.56-3.71 (m, 4H), 3.75 (s, 3H). <sup>19</sup>F NMR  $(CDCl_3)$ : -72.1 (d, J = 8.1 Hz). <sup>13</sup>C NMR  $(CDCl_3)$ : 11.2, 34.8, 39.4, 44.3, 51.6. 52.2, 60.7 (q, J = 27.1 Hz), 126.2 (q, J = 217.9 Hz), 172.8, 173.6. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>10</sub>H<sub>17</sub>F<sub>3</sub>NO<sub>4</sub> 272.1110 found 272.1118.



# Methyl 4,4,4-trifluoro-3-(3-methoxy-3-

 

 NH
 O

  $F_3C$  O

<tr 3.55 (s, 3H), 3.68 (s, 3H), 3.77-3.92 (m, 2H), 7.26

-7.48 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -73.6 (d, J = 6.6 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 35.0, 44.5, 51.4, 51.5, 52.4, 61.1 (q, J = 27.3 Hz), 126.2 (q, J = 284.1 Hz), 128.3, 128.8 (2C), 129.3 (2C), 133.6, 171.6, 172.4. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>19</sub>F<sub>3</sub>NO<sub>4</sub> 334.1266 found 334.1208.

#### General procedure for the benzyl group hydrogenolysis reaction

To a solution of  $\beta$ -amino esters syn-12' or 16' (0.5 mmol) in MeOH (15 mL), 10 mol % Pd(OH)<sub>2</sub> on carbon (0.05 mmol) was added while being exposed to H<sub>2</sub>. After 12 hours, the reaction mixture was filtered through celite pad and concentrated in vacuo. The corresponding amines were used in the next experiments without further purification.



HPLC (Column Lux 5u Amylose-2), hexane/EtOH = 95:5, 1.0 mL/min, 203 nm, major 5.74 min and minor 6.25 min). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.26 (d, J = 7.1 Hz, 3H), 1.65 (br, 2H), 2.85 (qd, J = 7.2, 4.6 Hz, 1H), 3.58–3.87 (m, 4H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -75.8 (d, J = 7.9 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 12.3, 37.55, 53.0, 54.1 (q, J = 29.7 Hz), 123.8 (q, J = 283.3 Hz), 172.1. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>6</sub>H<sub>11</sub>F<sub>3</sub>NO<sub>2</sub> 186.0742, found 186.0758.



HPLC trace of racemic syn-14

HPLC trace of syn-14', obtained starting from syn-12'



	Reten. Time [min]	Area [mV.s]	Height [mV]	Area [%]	Height [%]	W05 [min]	Compound Name
1	5,736	29,838	4,264	0,9	1,3	0,06	
2	6,252	3172,984	327,225	99,1	98,7	0,17	
	Total	3202,823	331,489	100,0	100,0		

HPLC trace of syn-14', obtained starting from 16'



Coupling reactions: general procedure. To a solution of syn-14' (0.25 mmol) in 7 mL of CH<sub>2</sub>Ch<sub>2</sub> equimolar of N-Boc-L-Val, N.N'amounts dicyclohexylcarbodiimide (DCC) and catalytic of 4amounts dimethylaminopyridine (DMAP, 10 mol %) were added. After 24 h of stirring at room temperature, the crude mixture was filtered off to remove the formed N,N'dicyclohexylurea (DCU) and the solvent was evaporated under vacuum. Purified by flash chromatography on silica gel (eluent: hexane/ethyl acetate = 8:2)



Methyl (2*S*,3*S*)-3-{(*S*)-2-[(*tert*butoxycarbonyl)amino]-3methylbutanamido}-4,4,4-trifluoro-2methylbutanoate (15'). White viscous oil. (80

mg 56%). IR: 3440, 3342, 1708, 1670. [ $\alpha$ ]<sub>D</sub>= 21.2 (*c* =1 g/100 mL, CHCl<sub>3</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) 0.93–0.97 (m, 6H), 1.24 (d, *J* = 7.2 Hz, 3H), 1.44 (s, 9H), 2.09–2.23 (m, 1H), 2.82–2.91 (m, 1H), 3.71 (s, 3H), 3.83 (t, *J* = 7.6 Hz, 1H), 4.98–5.13 (m, 2H), 6.60 (d, *J* = 7.2 Hz, 1H). <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>) –73.3 (br). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) 12.4, 19.1 (2C), 28.2 (3C), 30.0, 38.8, 51.6 (q, *J* = 30,3 Hz), 52.3, 60.7, 80.5, 124.6 (q, *J* = 282.2 Hz), 156.0, 171.8, 172.6. HRMS: *m/z* [M + H]<sup>+</sup> caked for C<sub>16</sub>H<sub>28</sub>F<sub>3</sub>N<sub>2</sub>O<sub>5</sub> [M+H]<sup>+</sup> 385.1950, found 385.1934.

# Synthesis of the cis-14 and trans-5 by Et<sub>2</sub>Zn promoted aza-Reformatsky reaction

 $\alpha$ -Bromo ester **2b-c** (1.0 mmol) was added to a solution of the corresponding imine **1a** (0.5 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) at ambient temperature. Then the mixture was cooled to -20 °C, and 1.0 M Et<sub>2</sub>Zn in hexane (1.0 mL, 1.0 mmol) was slowly added to the mixture at same temperature. The whole mixture was stirred at the same temperature for appropriate time (reported in **Table 5**, **Chap 7**, p. 83). The temperature was allowed to rise to room temperature and quenched with saturated aqueous NaHCO<sub>3</sub> after 14 days. The mixture was extracted with AcOEt and then

the extract was washed with brine and dried over MgSO<sub>4</sub>. The solvent was removed *in vacuo* and the residue was purified by column chromatography (AcOEt: hexane: 5:95) to afford the corresponding  $\beta$ -lactams *cis*-14 and *trans*-5.

Bn N Colorless oil (52 mg, 43 %). IR: 1788. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.35 (d, J = 7.7 Hz, 3H), 3.40–3.52 (m, 1H), 3.77–3.88 (m, 1H), 3.97 (d, J = 15.1 Hz, 1H), 4.85 (d, J = 15. Hz, 1H), 7.22–7.41 (m, 5H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): -68.8 (d, J = 9.2 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 8.9, 45.3, 47.3, 53.9 (q, J = 32.8 Hz), 124.4 (q, J = 280.3 Hz), 128.1, 128.5 (2C), 128.9 (2C), 134.7, 169.3. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>12</sub>H<sub>13</sub>F<sub>3</sub>NO 244.0949, found 244.0965.

# Synthesis of the cis-17 by asymmetric Et<sub>2</sub>Zn promoted aza-Reformatsky <u>reaction</u>

α-Bromo ester **2b** (1.0 mmol) was added to a solution of the corresponding imine **1c**(0.5 mmol) and (1*R*,2*S*)-1-phenyl-2-(1-pyrrolidinyl)propan-1-ol **6** (0.38 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) at ambient temperature. Then the mixture was cooled to -20 °C, and 1.0 M Et<sub>2</sub>Zn in hexane (1.2 mL, 1.2 mmol) was slowly added to the mixture at the same temperature. The whole mixture was stirred at the same temperature for 5 days. The temperature was allowed to rise to room temperature and quenched with saturated aqueous NaHCO<sub>3</sub> after 14 days. The mixture was extracted with AcOEt and then the extract was washed with brine and dried over MgSO<sub>4</sub>. The solvent was removed *in vacuo* and the residue was purified by column chromatography (AcOEt: hexane: 1:9) to afford the corresponding β-lactam *cis*-**17**.

(3S,4S)-3-methyl-1-[(R)-1-phenylethyl]-4-(trifluoromethyl)azetidin-



**2-one** (*cis*-17). White solid (55 mg, 43 %). IR: 1769.  $[\alpha]_D = 12.3$  (*c* = 3 g/100 mL, CHCl<sub>3</sub>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.32 (dq, J = 7.6, 3.4 Hz, 3H), 1.62 (d, J = 7.3 Hz, 3H), 3.33–3.40 (m, 1H), 3.64–3.74

(m, 1H), 5.07 (q, J = 7.4 Hz, 1H), 7.27–7.39 (m, 5H). <sup>19</sup>F NMR (CDCb): -68.5 (d,

J = 6.9 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 9.0, 17.9, 46.6, 51.6, 53.7 (q, J=34.7 Hz), 124.4 (q, J=279.8 Hz), 127.2 (2C), 128.0, 128.8 (2C), 138.6, 169.4. HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>13</sub>H<sub>15</sub>F<sub>3</sub>NO 258.1106, found 258.1167.

# 2D NMR spectra and optimized geometries to determine the absolute configuration of the new chiral centers of *cis*-17.

1. To determine the absolute configuration of the new chiral centers 2D NOESY NMR spectra and optimized geometries of the  $\beta$ -lactam *cis*-17 were considered.



Figure 10. 2D NOESY spectrum of *cis*-17.

The cross peak between the protons  $H_b$  and  $H_c$  was used as a distance ruler and its volume was set to 10.00 a.u.; the cross peak between  $H_a$  and the protons  $H_c$  of the methyl group can be easily determinate for *cis*-**17**, the value is 0.88 a.u. (corresponding to an interproton distance of 4.034 Å). The correlation between  $H_a$  and  $H_d$  shows a value equal to 2.89 a.u., corresponding to an interproton distance of 3.27 Å, that confirms the *cis* configuration (compared to the distance determinate for the *trans*-**8** and **8**').

The optimized geometries of all possible diastereomers (see pp.166-168) coupled with NOESY analysis permits to assign the (R,S,S) to *cis*-16

## Chapter 13

# Work towards the discovery of selective and potent PCAF inhibitors

**Synthesis of 6-chloro-3-methyl**[1,2,4]**triazolo**[3,4-a]**phthalazine** (2). Multistep procedure for the synthesis of 2 was followed.<sup>1</sup>

Synthesis of amines 5-8

Synthesis of 3-methyl-2-phenylbutan-1-amine (4). The amine 5 was synthesized starting from (*E*)-(2-nitrovinyl)benzene which, following a reported procedure of Michael addition reaction with Grignard reagent,<sup>2</sup> gave the corresponding adduct. The reported procedure of reduction of the nitro group<sup>3</sup> lead to the amine 4. The Michael adduct<sup>4</sup> and 4 are known.<sup>5</sup>

Synthesis of  $N^1$ -methyl-1-phenylethane-1,2-diamine (5). Procedure: To a stirred suspension of LiAIH<sub>4</sub>, (237.2 mg, 6.30 mmol) in Et<sub>2</sub>O (10 mL) under N<sub>2</sub> was added dropwise, over 0.5 h, a solution of 2-(methylamino)-2-phenylacetonitrile (230.0 mg, 1.57 mmol) in Et<sub>2</sub>O (500 mL) at 0 °C. The mixture was stirred at this temperature for 5 h and then at room temperature overnight. H<sub>2</sub>O was then added, followed by 15% NaOH (2 mL), and finally another 10 mL of H<sub>2</sub>O. Inorganic material was removed by filtration. The solution was extracted with EtOAc, dried over MgSO<sub>4</sub>, filtered and the solvent was evaporated to give the product as yellow

<sup>&</sup>lt;sup>1</sup> See ref. 19 in the **Chapter 7**.

<sup>&</sup>lt;sup>2</sup> Yao, C.; Kao, K.; Liu, J.; Wang, Y.; Chen, W.; Lin, Y.; Yan, M.; *Tetrahedron* 1998, 54, 791-822.

<sup>&</sup>lt;sup>3</sup> Martinelli, E.; Vicini, A. C.; Mancinelli, M.; Mazzanti, A.; Zania, P.; Bernardi, L.; Fochi, M. *Chem. Commun.* **2015**, *51*, 658-660.

<sup>&</sup>lt;sup>4</sup> Yao, C.; Kao, K.; Liu, J.; Wang, Y.; Chen, W.; Lin, Y.; Yan, M.; Tetrahedron 1998, 54, 791-822.

<sup>&</sup>lt;sup>5</sup> Brenna, E.; Fuganti, C.; Gatti, F. G.; Passoni, M.; Serra, S. Tetrahedron Asymmetry 2003, 14, 2401 -2406

oil. The crude product (52% yield) was used in the next step without further purification. **5** is a known compound.<sup>6</sup>



Synthesisof2-(dimethylamino)-2-phenylpropanenitrileProcedure:LDA was prepared by adding BuLi (0.69 mL, 1.1mmol, 1.6 M in hexanes) to a solution of diisopropylamine (0.17mL, 1.2 mmol) in 2.5 mL of THF, at 0 °C under N2. The solution

was stirred 15 min at 0 °C and then cooled to -78 °C. A solution of 2-(dimethylamino)-2-phenylacetonitrile (160 mg, 1 mmol) in THF (2.5 mL) was added to the LDA solution and the mixture was stirred for 30 min at -78 °C. CH<sub>3</sub>I (0.07 mL, 1.1 mmol) was then added to the solution. The reaction mixture was stirred for 16 hours, while the temperature was allowed to rise to 0 °C and quenched with saturated aqueous NH<sub>4</sub>Cl solution. The aqueous phase was extracted with ethyl ether (3x20 mL), the combined organic phases were dried (MgSO<sub>4</sub>) and concentrated. The crude product (72% yield) was used in the next step without further purification.

**2-(Dimethylamino)-2-phenylpropanenitrile.** Colorless oil. IR: 2230. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.60 (s, 3H), 2.17 (s, 6H), 7.19–7.28 (m, 3H), 7.46–7.48 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 29.3, 40.7 (2C), 67.2, 117.6, 125.4 (2C), 141.0, 128.3, 128.7 (2C). HR-MS (ESI Q-TOF) (m/z) [M + H]<sup>+</sup> calcd for C<sub>11</sub>H<sub>15</sub>N<sub>2</sub> 175.1235, found 175.1242.

Synthesis of  $N_2, N_2$ -dimethyl-2-phenylpropane-1,2-diamine (6)



**Procedure:** To a stirred suspension of LiAIH<sub>4</sub>, (90.4 mg, 2.4 mmol) in Et<sub>2</sub>O (5 mL) under N<sub>2</sub> was added dropwise, over 0.5 h, a solution of 2-(dimethylamino)-2-phenylpropanenitrile (105 mg, 0.6

mmol) in Et2O (5 mL) at 0 °C. The mixture was stirred at this temperature for 5 h

<sup>&</sup>lt;sup>6</sup> Malkov, A.V.; Stewart-Liddon, A. J. P.; McGeoch, G. D.; Ramirez-Lopez, P.; Kocovsky, P. Org. Biomol. Chem. 2012, 10, 4864-4877

and at room temperature overnight.  $H_2O$  (1 mL) was then added, followed by 15% NaOH (1 mL), and finally another 2 mL of  $H_2O$ . Inorganic material was removed by filtration. The solution was extracted with Et<sub>2</sub>O, dried over MgSO<sub>4</sub>, filtered and the solvent was evaporated to give the product (44%) as yellow oil. Purification by FCC (MeOH 10%/ EtOAc) yielded **6** (44%) as colorless oil.

*N*<sub>2</sub>,*N*<sub>2</sub>-Dimethyl-2-phenylpropane-1,2-diamine.Colorless oil. IR: 3335. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.29 (s, 3H), 2.18 (s, 6H), 2.58 (d, *J* = 13.4 Hz, 1H), 2.99 (d, *J* = 13.4 Hz, 1H), 7.23 (t, *J* = 7.3 Hz, 1H), 7.33 (t, *J* = 7.6 Hz, 2H), 7.48 (dd, *J* = 8.2, 0.8 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 12.6, 38.8 (2C), 52.2, 63.8, 126.5, 127.1 (2C), 128.0 (2C), 144.7. HR-MS (ESI Q-TOF) (*m*/*z*) [M + H]<sup>+</sup> calcd for C<sub>11</sub>H<sub>19</sub>N<sub>2</sub> 179.15428, found 179.15434.

Synthesis of  $N_1,N_1$ -dimethyl-2-phenylethane-1,2-diamine (7). Procedure: Ammonium acetate (1.5 g, 20 mmol) and 2-(dimethylamino)-1-phenylethan-1-one (0.163 g, 1 mmol) were mixed in methanol (20 mL) and then treated with sodium cyanoborohydride (0.314 g, 5 mmol). The mixture was stirred at room tempearture under a N<sub>2</sub> atmosphere for 4 days. The reaction mixture was quenched by adding 1N NaOH, and the product was extracted with EtOAc (3 x 50 mL). The organic extract was dried (MgSO<sub>4</sub>) and the solvent was evaporated to give the crude free base. Purification by FCC (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). 49% yield. **7** is a known compound.<sup>7</sup>

Synthesis of 3-methyl-6-(4-methylpiperazin-1-yl)-[1,2,4]triazolo[3,4a]phthalazine (11). Procedure: 3-Methyl-6-(piperazin-1-yl)-[1,2,4]triazolo[3,4a]phthalazine (11) (87.6 mg, 0.32 mmol) was added to CHCl<sub>3</sub> followed by a formaldehyde solution 37 % (0.15 ml. 1.92 mmol) and formic acid (0.07 ml, 1.92 mmol). The mixture was heated at 70 °C for 3h. The mixture was charged with aqueous 1N NaOH (50 mL), and the layers were separated. The aqueous layer was

<sup>&</sup>lt;sup>7</sup> Ooka, H.; Arai, N.; Azuma, K.; Kurono, N.; Ohkuma, T. J. Org. Chem., **2008**, 73, 9084–9093.

extracted with CHCl<sub>3</sub> (2 x 50 mL). The combined organic layers were dried over  $Na_2SO_4$  and concentrated under reduced pressure. Purification by FCC (MeOH-NH<sub>3</sub> 10%/EtOAc) yielded **11** (43%) as a white solid.



White solid. Mpt: 210-212 °C; IR: 3400, 2938, 2847, 2800, 2360, 2341, 1510, 708. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 8.58 (d, J = 7.6 Hz, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.81 (t, J = 7.2, 1H), 7.69 (t, J = 7.2, 1H), 3.43 (s, 4H), 2.72 (s, 3H), 2.70 (s, 4H), 2.41 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>): 157.5, 147.7, 142.4, 132.7, 129.8, 126.3, 125.0, 123.7, 120.0, 54.7 (2C), 51.1 (2C), 46.1, 9.7. LR-ESI-

MS:  $C_{15}H_{19}N_6$  (*m/z*) [M + H]<sup>+</sup>found 283.1 calcd 283.2. HR-ESI-MS:  $C_{15}H_{19}N_6$  (*m/z*) [M + H]<sup>+</sup> found 283.16656 calcd 283.16657.

#### General procedure for the coupling reactions of 2 with amines 4-7

In a pressure tube, 6-chloro-3-methyl[1,2,4]triazolo[3,4-a]phthalazine (2) (20 mg, 0.092 mmol) was dissolved in EtOH (0.2 mL), amine 4-7 (0.21 mmol), KI (1.5 mg, 0.009 mmol) and concentrated HCl (2  $\mu$ L, 0.002 mmol) were added, the tube was sealed and the reaction was stirred at 100 °C, until the complete disappearance of reactants was observed by TLC. The reaction mixture was concentrated, 1M NaOH (aq) (20 mL) was added and the aqueous phase was extracted with CHCl<sub>3</sub>-MeOH (10%) (3 × 20 mL). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The compound **9** is known.<sup>8</sup>



#### 3-Methyl-*N*-(3-methyl-2-phenylbutyl)[1,2,4]triazolo[3,4a]phthalazin-6-amine (12).

Brown oil (22 %). IR: 3292, 2957, 2928, 2800, 2360, 2341, 1514, 701. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 0.82 (d, J = 6.7 Hz, 3H), 1.17 (d, J = 6.6 Hz, 3H), 2.04 (ddt, J = 13.3, 8.5, 6.7 Hz, 1H),

<sup>&</sup>lt;sup>8</sup> See ref. 18 in the **Chapter 7**.

2.72–2.80 (m, 1H2.73 (s, 3H), 3.49 (ddd, J = 14.0, 10.7, 3.5 Hz, 1H), 4.21 (ddd, J = 13.0, 7.3, 4.5 Hz, 1H), 4.78 (d, J = 3.8 Hz, 1H), 7.20–7.38 (m, 6H), 7.53–7.61 (m, 1H), 7.74–7.78 (m, 1H), 8.55 (dd, J = 7.9, 0.6 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 9.8, 21.0, 21.1, 31.6, 44.9, 52.2, 118.2, 121.7, 123.8, 124.2, 127.0, 128.4 (2C), 128.8 (2C), 150.7, 147.3, 142.0, 141.9, 132.4, 129.9. LR-ESI-MS: C<sub>21</sub>H<sub>24</sub>N<sub>5</sub> (m/z) [M + H]<sup>+</sup> found 346.2 calcd 346.2. HR-ESI-MS: C<sub>21</sub>H<sub>24</sub>N<sub>5</sub> (m/z) [M + H]<sup>+</sup> found 346.20216.

N-N N N NH NH  $N^1$ -Methyl- $N^2$ -(3-methyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)-1-phenylethane-1,2-diamine (13).

White solid (30%). IR: 3275, 2926, 2853, 2360, 2343, 1518, 701. <sup>1</sup>H-NMR (CDCl<sub>3</sub>): 2.43 (s, 3H), 2.65 (s, 3H), 3.52–3.65 (m, 1H), 3.81 (dt, *J* = 13.2, 5.3 Hz, 1H), 4.01 (dd, *J* = 8.2, 4.9 Hz, 1H), 6.06 (br, 1H), 7.31–7.48 (m, 5H), 7.66–7.71 (m, 1H),

7.75 (d, J = 8.0 Hz, 1H), 7.80 (t, J = 7.5 Hz, 1H), 8.56 (d, J = 7.8 Hz, 1H). <sup>13</sup>C-NMR (CDCl<sub>3</sub>): 9.7, 33.8, 47.0, 62.9, 118.3, 122.5, 123.7, 123.9, 127.2 (2C), 128.2, 129.0 (2C), 130.0, 132.5, 140.1, 141.9, 147.2, 151.0. LR-ESI-MS: C<sub>19</sub>H<sub>21</sub>N<sub>6</sub> (*m/z*) [M + H]<sup>+</sup> found 333.1 calcd 333.2. HR-ESI-MS: C<sub>19</sub>H<sub>21</sub>N<sub>6</sub> (*m/z*) [M + H]<sup>+</sup> found 333.18205 calcd 333.18222.

N<sup>2</sup>,N<sup>2</sup>-Dimethyl-N<sup>1</sup>-(3-methyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)-1 phenylethane-1,2-diamine 14).



Yellow oil (21%). IR: 3334, 2926, 2856, 2360, 2342, 1510, 701. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 2.39–2.40 (m, 9H), 2.54 (dd, J = 12.5, 4.5 Hz, 1H), 2.90 (t, J = 11.7 Hz, 1H), 4.85 (dd, J = 11.4, 3.7 Hz, 1H), 6.77 (br, 1H), 7.21–7.26 (m, 1H), 7.31 (t, J = 7.5 Hz, 2H), 7.40–

7.49 (m, 2H), 7.70–7.78 (m, 1H), 7.78–7.85 (m, 1H), 7.99 (d, J = 8.0 Hz, 1H), 8.56 (dd, J = 7.9, 0.7 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 9.5, 45.1 (2C), 54.2, 64.9, 118.8, 122.8, 123.7, 124.2, 126.7 (2C), 127.3, 128.3 (2C), 130.0, 132.5, 141.5, 141.8,

147.3, 150.6. LR-ESI-MS:  $C_{20}H_{23}N_6 (m/z) [M + H]^+$  found 347.2 calcd 347.2. HR-ESI-MS:  $C_{20}H_{23}N_6 (m/z) [M + H]^+$  found 347.19788 calcd 347.19787 error = 0.01 ppm.

#### $N^2, N^2$ -Dimethyl- $N^1$ -(3-methyl[1,2,4]triazolo[3,4-

a]phthalazin-6-yl)-2-phenylpropane-1,2-diamine (15).



Brown oil (17 %). IR: 3368, 2941, 2829, 2784, 2360, 2341, 1513, 701. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.53 (s, 3H), 2.31 (s, 6H), 2.66 (s, 3H), 3.64 (s, 2H), 5.70 (br, 1H), 7.27 (d, *J* = 7.4 Hz, 1H), 7.39 (dd, *J* = 10.6, 5.0 Hz, 2H), 7.59 (d, *J* = 8.0 Hz, 1H), 7.63 (dd, *J* 

= 8.3, 1.0 Hz, 2H), 7.67–7.72 (m, 1H), 7.78–7.83 (m, 1H), 8.56 (dd, J = 7.9, 0.7 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 9.8, 14.9, 38.9 (2C), 50.6, 60.4, 118.4, 121.9, 123.8, 124.2, 126.6 (2C), 127.2, 128.4 (2C), 129.9, 132.4, 141.9, 143.9, 147.2, 150.8. LR-ESI-MS: C<sub>21</sub>H<sub>25</sub>N<sub>6</sub> (m/z) [M + H]<sup>+</sup> found 361.2 calcd 361.2. HR-ESI-MS: C<sub>21</sub>H<sub>25</sub>N<sub>6</sub> (m/z) [M + H]<sup>+</sup> found 361.21352 error = 0.28 ppm.

2-{(3-methyl[1,2,4]triazolo[3,4-α]phthalazin-6-yl)amino}-1-**Synthesis** of phenylethan-1-ol (17). **Procedure**: In a pressure tube. 6-chloro-3methyl[1,2,4]triazolo[3,4-a]phthalazine (1) (601 mg, 2.76 mmol) was dissolved in EtOH (2 mL), 2-amino-1-phenylethan-1-ol (862 mg, 6.29 mmol), KI (45.3 mg, 0.27 mmol) and concentrated HCl (0.055ml) were added, the tube was sealed and the reaction was stirred at 100 °C for 4d. The reaction mixture was cooled to room temperature and filtered through a buchner funnel. The filter cake was washed with DCM and dried in vacuum. 23 (505mg, 57%) was obtained as a white solid.



### 2-{(3-Methyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)amino}-1phenylethan-1-ol (17).

White solid (57 %). IR: 3400, 2938, 2801, 2360, 1511, 701. Mpt: 218-220 °C. <sup>1</sup>H NMR (DMSO): 2.61 (s, 3H), 3.39 (ddd, *J* = 13.5, 8.5, 5.1 Hz, 1H), 3.71 (ddd, *J* = 13.4, 5.9, 3.9 Hz, 1H), 5.12 (dt, J = 8.3, 4.0 Hz, 1H), 5.55 (d, J = 4.4 Hz, 1H), 8.36–8.40 (m, 2H), 7.25 (dd, J = 10.4, 4.3 Hz, 1H), 7.36 (t, J = 7.6 Hz, 2H), 7.46 (d, J = 7.2 Hz, 2H), 7.81–7.87 (m, 2H), 7.91–7.97 (m, 1H). <sup>13</sup>C NMR (DMSO): 9.4, 50.0, 69.4, 118.3, 122.5, 123.4, 124.3, 125.8 (2C), 127.0, 128.1 (2C), 130.2, 132.8, 141.1, 144.1, 146.0, 151.2; LR-ESI-MS: C<sub>18</sub>H<sub>18</sub>N<sub>5</sub>O (m/z) [M + H]<sup>+</sup> found 320.2 calcd 320.2. HR-ESI-MS: C<sub>18</sub>H<sub>18</sub>N<sub>5</sub>O (m/z) [M + H]<sup>+</sup> found 320.15059.

Synthesis of 3-methyl-6-phenyl-6,7-dihydroimidazo[2,1-a][1,2,4]triazolo[4,3-c]phthalazine (18). Procedure: To a solution of 17 (0.123 mmol) in pyridine (3.7 mL) was added methanesulfonyl chloride (5.5 mmol) and the mixture was stirred at room temperature for 1 h. Then, water (0.6 mL) was added to the solution. The mixture was concentrated to a small volume and the residue was partitioned between CHCl<sub>3</sub> (20 mL) and water (20 mL). The organic layer was dried over MgSO<sub>4</sub> and evaporated to give 18.



# 3-Methyl-6-phenyl-6,7-dihydroimidazo[2,1

a][1,2,4]triazolo[4,3-c]phthalazine (18).

White solid (68 %). <sup>1</sup>H-NMR (CHCl<sub>3</sub>): 2.42 (s, 3H), 4.09 (dd, J = 14.5, 2.6 Hz, 1H), 4.44 (dd, J = 14.5, 8.9 Hz, 1H), 5.62

(dd, J = 8.8, 2.6 Hz, 1H), 7.03–7.29 (m, 5H), 7.64 (td, J = 7.8, 1.1 Hz, 1H), 7.76 (td, J = 7.8, 1.1 Hz, 1H), 8.23 (d, J = 7.8 Hz, 1H), 8.38 (d, J = 7.9 Hz, 1H). <sup>13</sup>C NMR (DMSO): 12.3, 61.8, 68.6, 121.6, 123.6, 123.8, 125.3 (2C), 127.1, 129.0, 129.6 (2C), 130.9, 133.2, 137.5, 144.7, 144.9, 156.6; LR-ESI-MS: C<sub>18</sub>H<sub>16</sub>N<sub>5</sub> [(m/z) [M + H]<sup>+</sup> found 320.1 calcd 320.2.

Synthesis of 2-{(3-methyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)amino}-1phenylethan-1-one (19). Procedure: To a solution of 23 (700 mg, 2.2 mmol) in DMF (11ml) was added pyridinium dichromate (5.640 g, 15 mmol). The mixture was stirred at room temperature for 14 hours. The mixture was poured into water (60 mL), and then filtered through a buchner funnel. The filter cake was washed with EtOAc and filtered through the silica gel (CHCl<sub>3</sub>-MeOH). 25 was obtained (75% yield) as a beige solid.



**2-{(3-Methyl[1,2,4]triazolo[3,4-\alpha]phthalazin-6-yl)amino}-1phenylethan-1-one (19).** Beige solid (75 %). IR: 3268, 2929, 2360, 1698, 1516, 700. Mpt: 240-242 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>): 2.63 (s, 3H), 4.90 (d, J = 4.1 Hz, 2H), 6.51 (br, 1H), 7.51 (t, J = 7.7 Hz, 2H), 7.59–7.63 (m, 1H), 7.66 (dd, J = 11.3, 4.1 Hz, 1H), 7.77 (t, J = 7.6 Hz, 1H), 7.89 (d, J = 8.1 Hz, 1H), 8.02–8.05 (m,

2H), 8.53 (d, J = 7.8 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 9.8, 48.0, 118.1, 122.5, 123.8, 124.2 (2C), 128.0, 129.0 (2C), 130.1, 132.8, 134.4 (2C), 142.0, 147.2, 150.3, 194.5. LR-ESI-MS: C<sub>18</sub>H<sub>15</sub>N<sub>5</sub>O (*m*/*z*) [M + H]<sup>+</sup> found 318.1 calcd 318.1. HR-ESI-MS: C<sub>18</sub>H<sub>15</sub>N<sub>5</sub>O (*m*/*z*) [M + H]<sup>+</sup> found 318.13459 calcd 318.13603.

#### General procedure for the reductive amination reaction

To a solution of ketone **19** (0.1mmmol) in 0.5 mL of a mixture CHCl<sub>3</sub>/MeOH (2:1), the amine (0.88 mmol) was added. AcOH was added until the pH is 5, then NaBH<sub>3</sub>CN (0.12 mmol), and stirred to 50 °C until the reactants are consumed. The reaction mixture was quenched by adding 1N NaOH, and the product was extracted with CHCl<sub>3</sub>/MeOH (10%) (3  $\times$  50 mL). The organic extract was dried (MgSO<sub>4</sub>) and the solvent was evaporated to give the crude free base. Purification by FCC (CHCl<sub>3</sub>-iPrOH 5%).



### $N^1$ -Ethyl- $N^2$ -(3-methyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)-1-phenylethane-1,2-diamine (20)

White solid (43 %). IR: 3232, 3068, 2963, 2361, 1515, 669. Mpt: 228-230 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.20 (t, *J* = 7.0 Hz, 3H), 2.73–2.62 (m, 4H), 3.58–3.68 (m, 1H), 3.75–3.83 (m, 1H), 4.20 (br, 1H), 6.23 (br, 1H), 7.31–7.51 (m, 5H), 7.61–7.73 (m, 1H),

7.77 (d, J = 7.2 Hz, 2H), 8.52 (d, J = 7.3 Hz, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>): 9.7, 15.0,

41.6, 47.1, 61.0, 118.3, 122.5, 123.7, 124.0, 127.1 (2C), 128.1, 129.0 (2C), 130.1, 132.5, 141.9 (2C), 147.2, 151.0. LR-ESI-MS:  $C_{20}H_{24}N_6 (m/z) [M + H]^+$  found 347.2 calcd 347.2. HR-ESI-MS:  $C_{20}H_{24}N_6 (m/z) [M + H]^+$  found 347.19784 calcd 347.19787.



#### $N^1$ -Isopropyl- $N^2$ -(3-methyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)-1-phenylethane-1,2-diamine (21)

White solid (69 %). IR: 3228, 2968, 2360, 1517, 701. Mpt: 258-260 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.13 (d, J = 6.1 Hz, 6H), 2.64 (s, 3H), 2.89– 2.80 (m, 1H), 3.50 (t, J = 10.2 Hz, 1H), 3.79 (dt, J = 13.1, 5.6 Hz, 1H), 4.22 (br, 1H), 6.25 (br, 1H), 7.47–7.32

(m, 5H), 7.71–7.65 (m, 2H), 7.79 (t, J = 7.4 Hz, 1H), 8.53 (d, J = 7.9 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 9.8, 22.1, 23.9, 45.8, 47.5, 58.4, 118.4, 122.2, 123.7, 124.1, 126.9 (2C), 127.9, 128.9 (2C), 130.0, 132.5, 141.9 (2C), 147.2, 151.0. LR-ESI-MS: C<sub>21</sub>H<sub>25</sub>N<sub>6</sub> (*m*/*z*) [M + H]<sup>+</sup> found 409.2 calcd 409.2. HR-ESI-MS: C<sub>21</sub>H<sub>25</sub>N<sub>6</sub> (*m*/*z*) [M + H]<sup>+</sup> found 361.21348 calcd 361.21352.

#### $N^2$ -(3-Methyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)-1-phenyl- $N^1$ -propylethane-1,2-diamine (22)



White solid (28 %). IR: 3067, 2900, 2854, 2359, 2341, 1515, 700. Mpt: 216-218 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 0.94 (t, J = 7.4 Hz, 3H), 1.55 (dq, J = 21.8, 7.2 Hz, 2H), 2.56 (ddd, J = 25.4, 14.7,

7.6 Hz, 2H), 2.66 (s, 3H), 3.49–3.58 (m, 1H), 3.75– 3.84 (m, 1H), 4.06 (dd, J = 7.7, 5.0 Hz, 1H), 6.10 (br, 1H), 7.47–7.30 (m, 5H), 7.71 (s, J = 14.0 Hz, 2H), 7.81 (d, J = 7.7 Hz, 1H), 8.58 (d, J = 7.9 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 151.0, 147.3, 142.0, 141.6, 132.5, 130.0, 128.9 (2C), 127.8, 126.9 (2C), 124.2, 123.8, 122.2, 118.4, 61.2, 49.1, 47.3, 23.3, 11.8, 9.8. LR-ESI-MS: C<sub>21</sub>H<sub>25</sub>N<sub>6</sub> (m/z) [M + H]<sup>+</sup> 361.2 calcd 361.2. HR-ESI-MS: C<sub>21</sub>H<sub>25</sub>N<sub>6</sub> (m/z) [M + H]<sup>+</sup> 361.21341 calcd 361.21352.



#### $N^1$ -Isobutyl- $N^2$ -(3-methyl[1,2,4]triazolo[3,4-a]phthalazin-6yl)-1-phenylethane-1,2-diamine (23)

White solid (68 %). IR: 3228, 3068, 2952, 2813, 1514, 700. Mpt: 218-220 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 0.95 (dd, *J* = 6.6, 5.5 Hz, 6H), 1.76 (tt, *J* = 13.3, 6.7 Hz, 1H), 2.41 (ddd, *J* = 42.4, 11.5, 6.7 Hz, 2H), 2.66 (s, 3H), 3.51 (ddd, *J* = 8.4, 6.0, 3.0 Hz, 1H).

0.7 HI, 210, 2.00 (s, 511, 5.51 (ddd, J = 0.4, 0.0, 5.0 HI, 111), 3.82–3.77 (m, 1H), 4.02 (dd, J = 8.2, 5.0 Hz, 1H), 6.14 (s, 1H), 7.31–7.44 (m, 5H), 7.70 (d, J = 3.8 Hz, 2H), 7.79–7.85 (m, 1H), 8.60 (d, J = 7.9 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 9.8, 20.6, 20.8, 28.7, 47.3, 55.2, 61.4, 118.5, 122.1, 123.9, 124.3, 126.8 (2C), 127.8, 128.8 (2C), 130.0, 132.5, 141.8, 142.0, 147.3, 151.0. LR-ESI-MS: C<sub>22</sub>H<sub>27</sub>N<sub>6</sub> (*m/z*) [M + H]<sup>+</sup> found 375.2 calcd 375.2. HR-ESI-MS: C<sub>22</sub>H<sub>27</sub>N<sub>6</sub> (*m/z*) [M + H]<sup>+</sup> found 375.22882 calcd 375.22917.

#### N<sup>1</sup>-Benzyl-N<sup>2</sup>-(3-methyl[1,2,4]triazolo[3,4-a]phthalazin-6yl)-1-phenylethane-1,2-diamine (24)



White solid (34%). IR: 3230, 2970, 2360, 1515, 700. Mpt: 258-260 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>): 2.64 (s, 3H), 3.58–3.51 (m, 1H), 3.66 (d, *J* = 13.2 Hz, 1H), 3.76–3.83 (m, 1H), 3.85 (d, *J* = 13.2 Hz, 1H), 4.10 (dd, *J* = 8.4, 4.8 Hz, 1H), 5.90 (br, 1H), 7.48 –

7.26 (m, 10H), 7.66 (d, J = 8.0 Hz, 1H), 7.69–7.74 (m, 1H), 7.83 (t, J = 7.7 Hz, 1H), 8.59 (d, J = 7.8 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 9.8, 47.5, 51.1, 60.2, 118.4, 122.1, 123.9, 124.3, 127.1 (2C), 127.3, 128.0, 128.3 (2C), 128.5 (2C), 129.0 (2C), 130.0, 132.6, 140.0, 141.3, 142.0, 147.3, 150.9. LR-ESI-MS: C<sub>25</sub>H<sub>25</sub>N<sub>6</sub> (*m/z*) [M + H]<sup>+</sup> found 409.2 calcd 409.2. HR-ESI-MS: C<sub>25</sub>H<sub>25</sub>N<sub>6</sub> (*m/z*) [M + H]<sup>+</sup> found 409.21341 calcd 409.21352.

## $N^1$ -(2-(Dimethylamino)ethyl)- $N^2$ -(3-



methyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)-1-

#### phenylethane-1,2-diamine (25)

White solid (72 %). IR: 3230, 2970, 2360, 1514, 751, 700. Mpt: 218-220 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 2.23 (s, 6H), 2.47–2.37

(m, 1H), 2.58–2.65 (m, 2H), 2.66 (s, 3H), 2.67–2.74 (m, 1H), 3.52 (ddd, J = 13.1, 8.9, 4.0 Hz, 1H), 3.85 (ddd, J = 13.3, 6.0, 4.7 Hz, 1H), 8.56 (d, J = 7.9 Hz, 1H), 6.48 (br, 1H), 4.08 (dd, J = 8.9, 4.5 Hz, 1H), 7.29–7.45 (m, 5H), 7.64–7.73 (m, 1H), 7.80 (t, J = 7.6 Hz, 1H), 7.90 (d, J = 8.1 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 9.8, 44.0, 44.9 (2C), 47.6, 58.5, 61.2, 118.6, 122.8, 123.6, 124.1, 126.9 (2C), 127.8, 128.8 (2C), 129.9, 132.4, 141.5, 142.0, 147.2, 151.1. LR-ESI-MS: C<sub>22</sub>H<sub>28</sub>N<sub>7</sub> (m/z) [M + H]<sup>+</sup> found 390.3 calcd 390.2. HR-ESI-MS: C<sub>22</sub>H<sub>28</sub>N<sub>7</sub> (m/z) [M + H]<sup>+</sup> found 390.23943 calcd 390.24007.

# $N^1$ -Allyl- $N^2$ -(3-methyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)-1phenylethane-1,2-diamine (26)



White solid (54 %). IR: 3228, 3069, 2927, 2361, 2341, 1515, 700. Mpt: 246-247 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 2.66 (s, 3H), 3.18 (dd, *J* = 14.1, 6.2 Hz, 1H), 3.30 (dd, *J* = 14.1, 5.6 Hz, 1H), 3.53–3.66 (m, 1H), 3.81 (dt, *J* = 13.2, 5.4 Hz, 1H), 4.13 (t, *J* = 7.1 Hz,

1H), 5.09–5.27 (m, 2H), 5.93 (ddd, J = 16.3, 11.0, 5.9 Hz, 1H), 6.02 (s, 1H), 7.28–7.48 (m, 5H), 7.65–7.76 (m, 2H), 7.76–7.87 (m, 1H), 8.58 (d, J = 7.9 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 9.8, 47.3, 49.6, 60.4, 116.5, 118.4, 122.2, 123.8, 124.2, 127.0 (2C), 128.0, 128.9 (2C), 130.0, 132.5, 136.2, 141.1, 142.0, 147.3, 150.9. LR-ESI-MS: C<sub>21</sub>H<sub>23</sub>N<sub>6</sub> (m/z) [M + H]<sup>+</sup> found 359.2 calcd 359.2; HR-ESI-MS: C<sub>21</sub>H<sub>23</sub>N<sub>6</sub> (m/z) [M + H]<sup>+</sup> found 359.19787.



### N<sup>1</sup>-Cyclohexyl-N<sup>2</sup>-(3-methyl[1,2,4]triazolo[3,4a]phthalazin-6-yl)-1-phenylethane-1,2-diamine (27).

White solid (5 %). IR: 3235, 2970, 2930, 950, 816. Mpt: 208-210 °C. <sup>1</sup>H NMR (CDCb): 1.14–1.27 (m, 6H), 1.53–1.83 (m, 6H), 2.48 (s, 1H), 2.65 (s, 3H), 3.43–3.53 (m, 1H), 3.74–3.82 (m, 1H), 4.24 (dd, *J* = 8.5, 4.7 Hz, 1H), 6.30 (s, 1H), 7.30–7.47

(m, 5H), 7.65–7.77 (m, 2H), 7.81 (dd, J = 11.6, 4.6 Hz, 1H), 8.57 (d, J = 7.9 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 9.8, 24.5 (2C), 24.9, 25.9 (2C), 47.6, 53.5, 57.9, 118.5, 122.3, 123.8, 124.1, 126.9 (2C), 127.8, 128.9 (2C), 130.1, 132.5, 141.6, 142.0, 147.2, 151.0. LR-ESI-MS: C<sub>24</sub>H<sub>29</sub>N<sub>6</sub> (m/z) [M + H]<sup>+</sup> found 401.3 calcd 401.2; HR-ESI-MS: C<sub>24</sub>H<sub>29</sub>N<sub>6</sub> (m/z) [M + H]<sup>+</sup> found 401.24482.

Synthesis of  $N^{1}$ -(3-methyl[1,2,4]triazolo[3,4- $\alpha$ ]phthalazin-6-yl)-2phenylethane-1,2-diamine (28). Procedure: To a solution of ketone 19 (10 mg, 0.03 mmol) in 0.5 mL of a mixture CHCl<sub>3</sub>/MeOH (2:1) a solution of MeOH/NH<sub>3</sub> (0.5 ml) was added. Then, AcOH was added until the pH is 5, followed by adding NaBH<sub>3</sub>CN (2.25 mg, 0.036 mmol) and stirring to 50 °C for 18h. The reaction mixture was quenched with 1N NaOH, and the organic layer was extracted with CHCl<sub>3</sub>/ MeOH (10%) (3 × 50 mL). The organic extract was dried (MgSO<sub>4</sub>) and the solvent was evaporated to give the crude free base. Purification by FCC (CHCl<sub>3</sub>iPrOH 5%).

# N<sup>1</sup>-(3-Methyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)-2phenylethane-1,2-diamine (28).



Yellow solid (52 %). IR: 3277, 3065, 2925, 2854, 2359, 2341, 1515, 700. Mpt: 210-212 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>): 2.69 (s, 3H), 3.52 (ddd, *J* = 13.0, 8.7, 4.2 Hz, 1H), 3.87 (ddd, *J* = 13.2, 6.0, 4.8

Hz, 1H), 4.38 (dd, J = 8.7, 4.7 Hz, 1H), 5.91 (br, 1H), 7.31–7.45 (m, 5H), 7.71 (ddd, J = 12.3, 9.3, 4.4 Hz, 2H), 7.79–7.85 (m, 1H), 8.60 (d, J = 7.6 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 9.8, 48.9, 54.4, 118.4, 122.2, 123.9, 124.3, 126.1 (2C), 127.8, 128.9

(2C), 130.1, 132.6, 142.0, 143.8, 147.3, 151.0. LR-ESI-MS:  $C_{18}H_{19}N_6 (m/z) [M + H]^+$  found 319.1 calcd 319.2. HR-ESI-MS:  $C_{18}H_{19}N_6 (m/z) [M + H]^+$  found 319.16652 calcd 319.16657.

#### Synthesis of N-(2-((3-methyl[1,2,4]triazolo[3,4-a]phthalazin-6 yl)amino)-1phenylethyl)acetamide (29).

**Procedure:** Triethylamine (0.015 mL, 0.11 mmol) was added to a solution of **28** (31.8 mg, 0.1 mmol) in CHCl<sub>3</sub>/MeOH (2:1, 0.5 mL), the mixture was cooled to 0  $^{\circ}$ C, and acetyl chloride (7 µL, 0.104 mmol) was slowly added. The reaction mixture was stirred for 3h, warmed to room temperature and stirred overnight. The mixture was quenched with saturated sodium bicarbonate solution (20 mL). The phases were separated and the aqueous layer was washed with CHCl<sub>3</sub>/MeOH (2:1, 20 mL). The combined organic layers were dried over magnesium sulfate and concentrated. The crude product was purified by washing with EtOAc and CHCl<sub>3</sub>.



### *N*-(2-{(3-Methyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)amino}-1-phenylethyl)acetamide (29).

White solid (42 %). IR: 3270, 3065, 2925, 2853, 1625, 1517, 701. Mpt: 216-218 °C. <sup>1</sup>H-NMR (MeOD): 1.99 (s, 3H) 2.71 (s, 3H), 3.75 (dd, *J* = 13.6, 8.6 Hz, 1H), 3.91 (dd, *J* = 13.6, 5.6 Hz, 1H), 3.91 (dd, J = 13.6, 5.6 Hz

1H), 5.58 (dd, J = 8.6, 5.6 Hz, 1H), 7.27 (ddd, J = 7.3, 3.9, 1.2 Hz, 1H), 7.35 (dd, J = 10.4, 4.8 Hz, 2H), 7.42–7.46 (m, 2H), 7.82 (dt, J = 8.4, 3.7 Hz, 1H), 7.92 (dd, J = 11.5, 4.4 Hz, 1H), 8.10 (d, J = 8.1 Hz, 1H), 8.43 (d, J = 7.4 Hz, 1H). <sup>13</sup>C-NMR (MeOD): 9.5, 22.7, 48.3, 53.1, 120.4, 124.2, 124.3, 124.9, 128.0 (2C), 128.6, 126.6 (2C), 132.2, 134.1, 141.7, 143.3, 148.6, 153.4, 173.2. LR-ESI-MS: C<sub>20</sub>H<sub>21</sub>N<sub>6</sub>O (m/z) [M + H]<sup>+</sup> found 361.2 calcd 361.2, HR-ESI-MS: C<sub>20</sub>H<sub>21</sub>N<sub>6</sub>O (m/z) [M + H]<sup>+</sup> found 361.17714.

Synthesis of methyl (2-{(3-methyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)amino}-1-phenylethyl)carbamate (30). Procedure: Into a well stirred solution of 28 (10.0 mg, 0.03 mmol) in CHCl<sub>3</sub>/MeOH (2:1, 0.3 mL), cooled in a water-bath, was added dropwise a solution of methyl chloroformate (3  $\mu$ L, 0.035mmol). The mixture was stirred for 1 h to 0 °C, warmed to room temperature, and stirred overnight. The mixture was concentrated. Purification by FCC (DCM/ MeOH: 98/2) yielded 29 (62%) as a white solid.

White solid (62 %). IR: 3270, 3065, 2929, 2858, 1628, 1517, 701. Mpt: 240-242 °C. <sup>1</sup>H NMR (DMSO): 2.61 (s, 3H), 3.48 (s, 3H), 3.60 (ddd, *J* = 13.2, 8.1, 4.9 Hz, 1H), 3.73 (dd, *J* = 12.4, 6.1 Hz, 1H), 5.19 (dd, *J* = 13.8, 8.1 Hz, 1H), 7.22 (t, *J* = 7.3 Hz, 1H), 7.32 (t, *J* = 7.6 Hz, 2H), 7.42 (d, *J* = 7.4 Hz, 2H), 7.75–7.80 (m, 2H),

7.80–7.86 (m, 1H), 7.90–7.94 (m, 1H), 8.26 (d, J = 8.3 Hz, 1H), 8.38 (dd, J = 7.9, 0.9 Hz, 1H). <sup>13</sup>C NMR (DMSO): 9.4, 47.1, 51.3, 53.0, 118.1, 122.5, 123.4, 124.2, 126.6 (2C), 127.0, 128.2 (2C), 130.2, 133.0, 141.1, 141.9, 146.1, 151.1, 156.4. LR-ESI-MS: C<sub>20</sub>H<sub>21</sub>N<sub>6</sub>O<sub>2</sub> (m/z) [M + H]<sup>+</sup> found 377.2 calcd 377.2. HR-ESI-MS: C<sub>20</sub>H<sub>21</sub>N<sub>6</sub>O<sub>2</sub> (m/z) [M + H]<sup>+</sup> found 377.17214 calcd 377.17205.

## 1-Methyl-3-(2-{(3-methyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)amino}-1phenylethyl)thiourea (31)

**Procedure**: Into a well stirred solution of **29** (10.0 mg, 0.03 mmol) in CHCl<sub>3</sub>/MeOH (2:1, 0.3 mL), was added methyl isothiocyanate (10.9 mg, 0.15 mmol). The mixture was stirred for 16 h to room temperature. The mixture was concentrated. Purification by washing with CHCl<sub>3</sub> yielded **31** (79%) as a white solid.



White solid (79 %). IR: 3031, 2952, 1516, 1018, 797. Mpt: 262-264 °C. <sup>1</sup>H NMR (DMSO): 2.63 (s, 3H), 2.79 (d, J = 4.2 Hz, 3H), 3.68–3.84 (m, 2H), 7.21 (t, J = 7.3 Hz, 1H), 7.32 (t, J = 7.6 Hz, 2H), 7.41 (d, J = 7.3 Hz, 2H), 7.81 (t, J = 7.5 Hz, 1H), 7.70 (br, 1H), 8.37 (d, J = 7.6 Hz, 1H), 7.88–7.95 (m, 2H), 8.29 (d, J = 8.1Hz, 1H). <sup>13</sup>C NMR (DMSO): 9.5, 30.9, 46.9, 55.6, 118.2, 122.5,

123.3, 124.3, 126.8 (2C), 126.9, 128.1 (2C), 130.2, 132.9, 141.1,

141.6, 146.1, 151.1, 175.8. LR-ESI-MS:  $C_{20}H_{22}N_7S$  (*m/z*) [M + H]<sup>+</sup> found 392.2 calcd 392.2. HR-ESI-MS:  $C_{20}H_{22}N_7S$  (*m/z*) [M + H]<sup>+</sup> found 392.16518 calcd 392.16519.

#### 1-Ethyl-3-(2-{(3-methyl[1,2,4]triazolo[3,4-a]phthalazin-6-yl)amino}-1-

**phenylethyl)urea (32)**. **Procedure:** Into a well stirred solution of **29** (10.0 mg, 0.03 mmol) in CHCl<sub>3</sub>/MeOH (2:1, 0.3 mL), was added ethyl isocyanate (0.01 mL, 0.15mmol). The mixture was stirred for 16 h to r.t. The mixture was concentrated. Purification by washing with CHCl<sub>3</sub> yielded **32** (51%) as a beige solid.



Beige solid (51 %). IR: 3035, 2958, 1519, 1018, 797. Mpt: 240-242 °C. <sup>1</sup>H NMR (MeOD): 1.02 (t, *J* = 7.2 Hz, 3H), 2.90 (s, 3H), 3.09 (q, *J* = 7.2 Hz, 2H), 3.69–3.76 (m, 1H), 3.90 (dd, *J* = 13.7, 4.6 Hz, 1H), 5.42 (dd, *J* = 8.9, 4.6 Hz, 1H), 7.28 (t, *J* = 7.3 Hz, 1H), 7.37 (t, *J* = 7.5 Hz, 2H), 7.45 (d, *J* = 7.3 Hz, 2H), 8.00–8.08 (m, 2H), 8.34 (d, *J* = 7.9 Hz, 1H), 8.46 (dd, *J* = 7.6, 1.0 Hz, 1H).

<sup>13</sup>C NMR (MeOD): 9.2, 15.7, 35.8, 49.4, 53.3, 121.6, 121.7, 125.2, 125.5, 127.7 (2C), 128.6, 129.7 (2C), 134.7, 134.9, 142.4, 142.5, 148.1, 155.1, 160.9. LR-ESI-MS:  $C_{21}H_{24}N_7O$  (*m/z*) [M + H]<sup>+</sup> found 390.2 calcd 390.2. HR-ESI-MS:  $C_{20}H_{22}N_7S$  (*m/z*) [M + H]<sup>+</sup> found 390.20500 calcd 390.20368.